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ABSTRACT 
Recent studies have indicated that inhioition of apoptosis may play an important role 
m both multistep carcinogenesis and multidrug resistance (.MDR). Apoptosis is 
controlled through many cellular genes. The pattern of these apoptosis-regulating proteins 
varied in different cell types. The molecular mechanism of apoptosis in the multistep 
carcinogenesis and multidrug resistance of cervical cells is still poorly understood. 
To examine the role of apoptosis in tumorigenesis and chemoresistance of human 
endocervical cells, a cisplatin-resistant endocervical cell line (HEN-16-2/CDDP) was 
established by treating an HPV16-immortalized human endocervical cell line previously 
established in this lab, HEN-16-2, with cisplatin. A phenotype ofMDR was identified for 
HEN-16-2/CDDP by clonogenic survival efficiency assay using two structurally and 
functionally distinct anticancer drugs: cisplatin and paclitaxel. 
The thresholds to undergo apoptosis of HEN-16-2/CDDP cells in response to various 
apoptotic stimuli was compared with that of its parental HEN-16-2 cells. HEN-16-
2/CDDP cells were found to be significantly more resistant to cell death induced by 
several chemotherapeutic drugs, UV irradiation, anti-Fas antibody and heat shock. 
Moreover, the dysregulation of apoptosis in HEN-16-2/CDDP cells was found to confer 
tumorigenicity. Further characterization of HEN-16-2/CDDP cells indicated the 
following: 1) they displayed distinct morphologies in monolayer; 2) they had an 
increased rate of proliferation in medium containing physiological calcium levels; 3) they 
demonstrated anchorage-independent growth in vitro; 4) they expressed similar levels of 
pro-apoptotic genes, including p53, Bak, Bax and the anti-apoptotic gene Bcl-2, 
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compared to the drug-sensitive cell line, HEN-16-2; and 5) they expressed significantly 
higher levels of the anti-apoptotic gene Bcl-XL as well as the p50 and p33 isoforms of 
BAG-1. Overexpression of BAG-1 in cervical carcinoma C33A cell line confers 
resistance to cisplatin, etoposide and doxorubicin, but not to actinomycin D and 
paclitaxeL BAG-1 also protects C33A cells from apoptosis induced by heat shock and UV 
irradiation. 
The yeast two-hybrid system was established to screen BAG-1 interacting proteins 
from a human keratinocyte eDNA library. Eighteen positives were obtained from 2.5 
x 106 clones. Further analysis of the interacting clones identified four genes: Hsp 70, 
Hsp70-2, Hsc70 pseudogene and a putative novel Hsp70Y. Carboxyl-terminal amino 
acids of BAG-1 were found to be important in the mediation of the interactions. 
Overexpression of Hsp70 or Hsp70-2 in C33A cells conferred the resistance to 
various apoptotic stimuli, including cisplatin, doxorubicin, etoposide, paclitaxel, 
actinomycin D, heat shock and UV irradiation. 
In summary, this study provided the first in vitro evidence that inhibition of apoptosis 
conferred MDR and tumorigenesis in endocervical cells. Increased levels of Bcl-XL and 
BAG-1 p50 and p33 isoforms were found to be associated with this phenotype. Hsp70s 
were identified as BAG-1-interacting proteins from a eDNA library using the yeast two-
hybrid system, and further studies indicated that they may also contribute to the 
regulation of apoptosis. 
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CHAPTER I 
INTRODUCTION 
1.1. Apoptosis, carcinogenesis and cancer therapy 
1.1.1. General information on apoptosis 
The term, apoptosis, is derived from the Greek word used to descn'be the shedding 
of leaves from a tree during autumn. Apoptosis, as seen for example in the developing 
embryo and during tissue turnover in the adult, is a highly regulated cell suicide process. 
Developmentally regulated cell death, which has been studied in both invertebrates 
and vertebrates, has been referred to as programmed cell death (PCD) since the middle of 
the 19th century (Vogt, 1842). With the finding that regulated forms of cell death also 
occur in adult multicellular organisms, the term PCD was adopted to describe all forms of 
cell death that are mediated by an intracellular program. However, not until 1972 did a 
report formalize the existence of a form of cell death called apoptosis by describing its 
distinct morphological characteristics (Kerr et al., 1972). 
1.1.2. Morphological characteristics of apoptosis 
The earliest recognized morphologic apoptotic changes are: compaction and 
segregation of the nuclear chromatin; formation of sharply delineated, uniform, fine 
granular masses that become marginated against the nuclear envelope; condensation of 
the nucleus and cytoplasm; and the loss of surface cellular protuberances called microvilli 
(see review Kerr et al., 1994; Liepins and Bustamante, 1994). Progression of the 
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condensation is accompanied by convolution of the nuclear and cell outlines. This is 
followed by the breaking up of the nucleus into discrete fragments that are surrounded by 
double-layered envelopes and by budding or blebbing of the cell as a whole to produce 
plasma membrane-bound vesicles called apoptotic bodies. The extent of the nuclear and 
cellular budding varies with cell type. The cytoplasmic organelles within newly formed 
apoptotic bodies remain well preserved. 
Apoptotic bodies arising in tissues are quickly phagocytosed by neighbouring cells 
or macrophages and degraded within their lysosomes. There is no inflammation 
associated with the invasion of specialized phagocytes into the tissue, such as occurs with 
necrosis, and various types of resident cells, including epithelial cells, participate in the 
removal of apoptotic bodies. 
Similar morphologic events occur in vitro. However, most apoptotic cultured cells 
are in the floating population and apoptotic bodies formed in cell culture mostly escape 
phagocytosis and eventually degenerate. 
In addition to apoptosis, cell death can also occur by necrosis and senescence. 
Necrosis is believed to occur in response to more intense cell injury, resulting in a loss of 
osmotic balance. The distinction between apoptosis and necrosis is obvious by electron 
microscopy. Condensation of nuclear chromatin occurs in the early stages of necrosis, 
but the chromatin is not radically redistributed, as it is in apoptosis, and edges of the 
chromatin clumps tend to be irregular and poorly defined. The cytoplasm of the necrotic 
cell becomes grossly swollen, and plasma and organelle membranes progressively 
disintegrate. Most important, necrosis, unlike apoptosis, is not under biological control. 
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Senescence also causes little tissue damage, but is less well regulated, possibly 
representing a housekeeping form of cell death, as occurs during normal epithelial 
differentiation. 
1.1.3. Biochemical mechanism of apoptosis 
Along with the obvious morphological changes, distinct biochemical alterations are 
also associated with apoptosis. The most prominent is the random cleavage of the 
genome at intranucleosomal sites, which is detected in agarose gel electrophoresis as a 
DNA "ladder" composed of fragments in multiples of 180-200 base pairs (bp) (Wyllie, 
1987). However, this type of DNA fragmentation does not occur in some experimental 
systems (Ucker et al., 1992; Oberhammer et al., 1993; Schulze-Osthoff et al., 1994; 
Sakahira et al., 1998; Janicke et al., 1998). 
Apoptosis triggered by various stimuli has in common the ability to induce 
activation of a family of cysteine proteases called caspases, such as caspase-3, which 
cleave a variety of specific protein substrates (for review, see Cryns and Yuan, 1997; 
Nunez et al., 1998). Caspases implement cell death and "act"as the execution arm for 
apoptosis (Alnemri et al., 1996; Nunez et al., 1998). Caspases are crucial components of 
cell death pathways. They are normally present in the cell as zymogens that require 
proteolysis for activation of enzymatic activity. The mammalian caspases have been 
divided into upstream initiator caspases and downstream effector caspases, based on their 
sites of action in the proteolytic caspase cascade. Binding of initiator caspase precursors 
to activator molecules appears to promote procaspase oligomerization and autoactivation 
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by enzymatic cleavage of the procaspase into fragments. Enzymatic activation of 
initiator caspases leads to proteolytic activation of downstream effector caspases and then 
cleavage of a number of vital proteins, including poly(ADP-ribose) polymerase (P ARP), 
gesolin, MEKK-1, and Iamin (for review see Cryns and Yuan, 1997). PARP cleavage is 
observed in most forms of apoptosis (Kaufinann 1989; Kaufinann et al., 1993), and is 
often used as a marker of apoptosis. 
Among the downstream caspases identified, caspase-3 stands out because it is often 
activated by various cell death signals and cleaves many important cellular proteins, 
including PARP. It has been recently demonstrated that caspase-3 activates the 
endonuclease called caspase-activated DNase (CAD), which is responsible for the 
fragmentation of DNA, by specifically cleaving and inactivating the inhibitor of CAD 
(ICAD/DFF45) (Liu eta/., 1997; Enari eta/., 1998; Sakahira eta/., 1998). 
1.1.4. Regulation of apoptosis 
The regulation of apoptosis is summarized in Figure 1.1. Apoptosis can be 
triggered by a wide variety of stimuli, including chemotherapeutic drugs, ultraviolet light 
irradiation (UV), heat shock, cytokines, oxidative stress, growth factor deprivation, viral 
infections, genetic abnormalities, as well as normal differentiation and development. 
Moreover, the initiation of apoptosis involves biochemical changes that might be unique 
to each apoptotic stimulus (Ucker, 1997). 
The p53 tumor suppressor gene, the "guardian of the genome", has been clearly 
linked to apoptosis induced by various stimuli (Levine, 1997). Two alternative cellular 
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Figure 1.1. Apoptosis pathways (adapted from Reed, 1998b). Apoptosis can be triggered 
by a wide variety of stimuli (examples on the left), all of which have in common the 
ability to eventually induce activation of downstream caspases that cleave a variety of 
specific protein substrates, leading to apoptosis. The p53 tumor suppressor gene plays an 
important role in apoptosis, although p53-independent pathways leading to apoptosis also 
exist. The complexity of the p53 response may depend on the cellular context. At least 
two pathways leading to activation of downstream effector caspases have been identified: 
a mitochondria-dependent pathway clearly governed by the Bcl-2 family of proteins and 
a parallel pathway involving activation of upstream caspases, such as those involved in 
Fas signaling. Extensive cross-talk probably exists between these two pathways 
(bidirectional arrow). Several members of a family of apoptosis-suppressing proteins 
called inhibitor of apoptosis proteins (lAPs) have been shown to bind directly to the 
active forms of the downstream effector caspases, but not the upstream initiator caspases. 
Some of the lAP family can bind to and inhibit effector caspases. FLIP/FLAME family 
of proteins bind to the inactive zymogens of certain upstream caspases and prevent their 
activation under some circumstances. 
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responses occur as a result of p53 induction: growth arrest in the G 1 phase of the cell 
cycle or apoptosis. p53 was recognized as a regulator of apoptosis following the 
observation that transfection or activation of wild-type p53 in tumor cells can result in 
rapid apoptotic cell death (Yonish-Rouach et al., 1991; Levy et al., 1993). Studies 
demonstrated that cell death induced by serum deprivation in Myc-overexpressing cells 
or in interleukin-3 (ll ... -3) -dependent thymocytes required functional p53 to induce 
apoptosis (Wagner eta!., 1994; Hermeking and Eiclc, 1994; Canman eta!., 1995). DNA 
strand breaks induce rapid p53 upregulation, but exactly how remains unknown. The 
upregulation of p53 is mostly post-transcriptional, involving both an increase in 
translation and a prolonged protein half-life (Dragovich eta!., 1998). 
p53 is a sequence-specific DNA-binding protein, and known targets of p53 include 
genes associated with growth control, cell cycle checkpoints and DNA repair (e.g., 
W AF1/CIP1, WIP1, MDM2, EGFR, PCNA, cyclin D1, cyclinG, TGF-a, 14-3-3 a-, and 
GADD45), and apoptosis (Bax, Bcl-XL, FasL, IGF-BP3, PAG608 and DRS) (reviewed 
by Amundson et al., 1998). Activation of p53 results in a cascade of downstream events, 
depending on the cellular environment. Although most studies have focused on the 
involvement of p53 in regulating apoptosis, p53-independent apoptosis pathways were 
found to exist (Strasser et al., 1994). 
At least two apoptotic pathways leading to the execution of apoptosis have been 
identified (Figure 1.1 ): a mitochondria-dependent pathway that is clearly governed by 
Bcl-2 family proteins and a parallel pathway involving activation of upstream caspase-8, 
such as those involved in Fas and TNF receptor signaling. 
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Some cytokines, such as FasL and TNF-a, can bind to their receptors on the plasma 
membrane, causing trimerization of their receptors and thereby activation of an initiator 
caspase such as caspase-8 through interaction of the receptor with death adaptor proteins 
such as F ADD or TRADD (Baker and Reddy, 1998; Nuiiez et al., 1998). In addition, 
other apoptotic stimuli, such as the anticancer therapeutic agent using cis-
diamrninedichloroplatinum (II) ( cisplatin, CDDP), can cause mitochondria dysfunction. 
Mitochodrial dysfunction includes a reduction in the mitochondrial membrane potential 
(~'tflll), production of reactive oxygen species (ROS), opening of the permeability 
transition pore (PTP), and the release of the intermembrane space protein, cytochrome c 
(see review Gross et al., 1999). In response to cytochrome c binding, the apoptotic 
proteinase activating factor-! (Apaf-1) can form a complex with and then activate 
initiator caspase-9 (Li et al., 1997; Zou et al., 1997). Cross-talk probably exists between 
these two pathways within the cell. For example, Bid, a pro-apoptotic Bcl-2 family 
protein, is cleaved into two fragments by caspase-8 in response to signaling by Fas or 
TNF receptor. The C-terminal fragment of Bid then binds to mitochondria, thus initiates 
the mitochondria-dependent pathway to apoptosis (Li et al., 1998; Luo et al., 1998). 
Several members of a family of apoptosis-suppressing proteins called inhibitor of 
apoptosis proteins (lAPs) have been shown to bind directly to the active forms of the 
downstream effector caspases, such as caspase-3, and to potently inhibit their enzymatic 
activities (Deveraux et al., 1997; Roy et al., 1997). FLIP family proteins bind to the 
pro forms of certain upstream caspases, such as procaspase-8 and procaspase-1 0, and 
prevent their activation under some circumstances (Imler et al., 1997; Srinivasula et al., 
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1997). 
Different pathways involved in regulating cell proliferation and apoptosis may have 
different significance in various cells or within the same cell at different stages of 
development or differentiation. Extensive cross-talk probably also exists between 
proliferation and apoptosis within the cell. For example, Akt, a growth factor-dependent 
serine/threonine kinase, will phosphorylate Bad when the growth factor binds to the 
receptor. Bad is a Bcl-2 family protein and executes its pro-apoptotic function by 
binding to anti-apoptotic Bcl-2 and Bcl-XL Phosphorylated Bad is sequestered by 
cytosolic 14-3-3 protein, thus releasing and increasing the levels of free Bcl-2 and Bcl-
XL. Therefore, this growth factor-initiated signal pathway interferes with the Bcl-2- and 
Bcl-XL -dependent regulation of the cellular apoptotic threshold through Bad 
phosphorylation (Zha eta/., 1996; Gajewski and Thompson, 1996). 
1.1.5. Apoptosis in carcinogenesis 
1.1.5.1. Cellular basis 
Normal tissue has carefully balanced proliferation and apoptosis. Rates of 
proliferation are paired with rates of apoptosis so that cell numbers remain constant and 
tissue homeostasis is maintained (Figure 1.2A). However, given the critical role of 
apoptosis, it is not surprising that dysregulation of apoptosis occurs frequently during 
pathological disturbances. Neoplasia is a good example in which apoptosis is 
dysregulated. Carcinogenesis is characterized by the abnormal accumulation of cells. 
This accumulation of cells is generally accepted to be the result of enhanced cellular 
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Figure 1.2. The effect of relative rates of proliferation and apoptosis on homeostasis and 
carcinogenesis (adapted from Thompson, 1995). The rates of cell proliferation and 
apoptosis are indicated by the yellow and blue bars, respectively. In mature organisms, 
cell number is controlled by the net effects of cell proliferation and apoptosis, which are 
normally balanced and lead to homeostasis (A). In the absence of compensatory changes 
in the rates, increased cell proliferation (B), or decreased apoptosis (C), can result in cell 
accumulation, as seen in hyperproliferation, premalignancy and cancer. 
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proliferation (Figure 1.2B). However, recent mounting evidence suggests that the 
downregulation of apoptosis is also of critical importance resulting in an abnormal 
accumulation of cells during the initiation, promotion and transformation of some 
neoplasms (Figure 1.2C) (Reed, 1994; Reed et al., 1995; Thompson, 1995). 
In addition, apoptosis is important for metastasis. Apoptosis induced in the absence 
of native or the presence of foreign environment-specific factors in foreign sites may 
serve to prevent the survival of cancer cells that migrate from their native tissues 
(Williams et al., 1990; Neiman eta/., 1991; Raff et al., 1993; Cyster et al., 1994; Frisch 
and Francis, 1994; Boudreau et al., 1995). However, metastatic tumor cells have 
circumvented this homeostatic mechanism and can survive at sites distinct from the tissue 
in which they arose. For instance, epithelial cells that detach from the extracellular matrix 
in the process of metastasis rely on inhibition of apoptosis for survival in the absence of 
integrin-mediated signaling (Rabinovitz and Mercurio, 1996). Inactivation of the 
apoptosis pathway is thus a central event in the development of cancers. 
1.1.5.2. Molecular basis 
Recent advances are beginning to shed some light on the molecular basis for the 
role of apoptosis in carcinogenesis. Mutations or dysregulated expression of apoptosis-
related genes, often in synergy with other genetic lesions that result in a high rate of 
proliferation, can be shown to result in tumor development. The relationship between the 
acquisition of these genetic lesions and the development of cancer is complex and highly 
tissue-specific. 
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Several types of genes that can be critical in the regulation of apoptosis have been 
defined. Bcl-2 production at abnormally high levels or in aberrant patterns is found in 
approximately half of all human cancers, suggesting that deregulated expression of this 
proto-oncogene represents one of the most common events associated with human 
malignancy (Reed, 1995a). Recently, it has been demonstrated that Bcl-2 is only one 
member of a gene family that can control the cellular apoptotic threshold (Boise et al., 
1993; Kozopas et al., 1993; Lin et al., 1993; Oltvai et al., 1993). 
The wild-type p53 gene product influences several essential processes that prevent 
potentially oncogenic mutant cell propagation. It appears to have a direct role in DNA 
repair and also plays a role in regulating DNA repair enzymes, arresting cellular growth 
and inducing apoptosis following exposure to genotoxic stress. Loss of p53 function is 
strongly associated with the development and progression of many tumor types (Hollstein 
et al., 1994). Moreover, studies in transgenic mice have confirmed the notion that the 
tumor suppressor role of p53 in vivo is closely linked to its ability to induce apoptosis 
(Symonds eta/., 1994; Donehower et al., 1995). 
A number of viral oncoproteins have been shown to play roles in regulating 
apoptosis. Examples are the E1B of adenovirus and E6 of human papillomavirus (HPV). 
ElB and E6 disable the p53 pathway in apoptosis, canceling the pRB-mediated cell death 
response to E1A or E7, respectively (Rao eta/., 1992; Debbas and White, 1993; White et 
al., 1994). 
lAPs can block downstream effector caspase and therefore inhibit apoptosis. An 
example is survivin, one member of the lAP family. Survivin is not detectable in adult 
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differentiated tissue; however, it is expressed in most cancers tested, including lung, 
colon, breast, prostate, pancreatic cancers, high grade lymphomas, neuroblastomas and 
gastric carcinoma (Ambrosini et al., 1997; Adida et al., 1998; Kawasaki et al., 1998; Lu 
et al., 1998). Overexpression of FLIPs (the inhibitors of upstream initiator caspases) is 
also detected in some human cancers (Irmler et al., 1997). 
1.1.6. Apoptosis in cancer chemo- and radiotherapies 
Cancer chemo- and radiotherapies kill targeted malignant cells by causing 
irreversible cellular damage. The mechanism of this action was previously thought to be 
due to cell necrosis. However, recent studies have indicated that induction of apoptosis is 
the primary cytotoxic mechanism of action of most radio- and chemotherapeutic agents 
(Kerr et al., 1994). Immunohistochemical assays specific for apoptotic cell death have 
revealed that cell death by apoptosis, not necrosis, often follows radiotherapy or 
chemotherapy (Eastman, 1990; Hickman, 1992). Consistent with this notion, clinical 
data has suggested that there are prognostic links between treatment outcome and distinct 
molecular genetic alterations that are known to regulate apoptosis (Fung and Fisher, 
1995). Overexpression of Bcl-2 or related genes can result in a multidrug resistance 
~R) phenotype in vitro (Reed, 1995b; Thompson, 1995). 
1.2. Drug resistance of cancer ceUs 
1.2.1. General information 
The response of tumors to chemotherapy varies. Failure to respond is frequent and 
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is due usually to the emergence of drug resistance. Drug resistance is one of tlue major 
obstacles hindering the success of conventional antineoplastic agents. In Canada, drug 
resistance is the principal explanation for the high mortality rate (approximately 65 %) 
from many cancers found in men and/or women (NCIC, Canadian Cancer Sttatistics, 
1999). The significance of this is exemplified by the fact that cancer causes a greater loss 
of potential years of life than any other disease, including heart disease. 
Patterns of drug resistance are divided into two groups: intrinsic and acquired. 
Intrinsic drug resistance is seen when previously untreated cancers are resistant to 
chemotherapeutic agents and is observed in patients with malignant melanomaas, non-
small cell lung cancers, pancreatic cancers, renal cancers, and colon cancers. -rumors 
with acquired drug-resistance, including breast carcinomas, small cell lung cancers, acute 
leukemias, ovarian carcinomas, and cervical carcinomas, are responsive to• initial 
treatments, but often become refractory to further therapy. Relapse of tumors, particularly 
during or shortly after the completion of therapy, generally heralds the emerg-ence of 
tumor cells that are resistant to the antineoplastic agents used initially and often 11o other 
drugs to which the patient was never previously exposed. 
The phenomenon of clinical drug resistance has prompted studies to idenrtify the 
mechanisms involved. Using in vitro (tissue culture) and in vivo (animal and xenograft) 
models, a number of physical and biochemical mechanisms of drug resistance hawe been 
identified (Table 1.1 ). Physiological resistance to chemotherapy implies the host-drug-
tumor interactions or anatomic drug barriers. Some physiological and biochemical 
mechanisms can overlap. Traditionally, the term "drug resistance" in basic scienc-e refers 
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to biochemical resistance that is seen in the targeted tumor cells, as opposed to changes 
such as the detoxification of drugs by the non-malignant liver. 
Table 1.1. General mechanisms contributing to drug resistance 
Physiological Mechanisms 
Anatomic drug barriers 
Host-drug-tumor interactions 
Biochemical Mechanisms 
Decreased intracellular drug accumulation 
Decreased influx 
Increased effi.ux 
Altered intracellular drug metabolism 
Increased inactivation 
Decreased pro-drug activation 
Increased drug detoxification 
Altered drug targets 
Changes in molecules involved in repair of cellular damage 
Cellular oncogene and tumor suppressor genes in drug resistance 
Apoptosis regulation in drug resistance 
1.2.2. Biochemical mechanisms 
To understand the complexity of the biochemical mechanisms of drug resistance, it 
is essential to realize that cell killing by each cytotoxic drug is a complex process (Figure 
1.3). While some drugs can enter the cell by passive diffusion through the plasma 
membrane lipid bilayer, other agents require the presence of special membrane carriers 
and/or pores for entry. Some drugs are inactive in the form in which they enter the cell 
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Figure 1.3. Drug resistance pathways (adapted from Roninson, 1997). The potential 
biochemical changes are indicated as black arrows. The dashed line separates two types of 
MDR mechanisms. Above the dashed line, are the mechanisms that limit the extent of drug-
indured cellular damage; below the dashed line, are the mechanisms that alter the cellular 
response to the damage. ~influx transport machinery. ETM, effiux transport machinery. 
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and need to be activated through chemical modification by appropriate cellular enzymes. 
An active drug inside the cell needs to reach and bind to its specific target, such as DNA 
or microtubules, and interfere with its normal function. These events could trigger cell 
growth arrest or apoptosis. 
The alteration of any step between drug uptake and cellular damage response genes 
could result in drug resistance. Generally, the mechanisms of drug resistance can be 
described as those which limit the extent of drug-induced damage or alter the cellular 
response, and can be categorized into the following six areas. 
1.2.2.1. Altered intracellular drug influx or emux 
Decreased intracellular accumulation of cytotoxic agents due to decreased influx or 
increased efflux is one of the most common mechanisms of drug resistance. This may 
result from decreased drug influx due to a defective carrier-mediated transport system. 
Decreased influx via a reduction in high affinity folate-binding protein transport as well 
as via a reduced folate carrier has been identified in methotrexate resistant cells (Hill et 
al., 1979; Sirotnak et al., 1981; Antony et al., 1985; Dixon et al., 1994). Similarly, a 
deficient membrane influx transport system has been identified in cells resistant to 
nitrogen mustard (Goldenberg et al., 1970). 
Enhanced drug efflux may also lower intracellular steady state levels of drugs. 
Classical MDR is frequently associated with overexpression of P-glycoprotein (Pgp ), a 
transmembrane transport protein capable of expelling and maintaining tolerable 
intracellular levels of certain cytotoxic drugs (Juliano and Ling, 1976; Endicott and Ling, 
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1989). Pgp belongs to the ATP binding cassette (ABC) family of transporter molecules, 
directly binds cytotoxic compounds and expels them from the cell through an energy-
dependent efflux mechanism (Hyde eta!., 1990; Beck and Qian, 1992; Germann et al., 
1993; Breuninger eta/., 1995; Bosch and Croop, 1996). Transducing the eDNA ofmdr-1 
(the gene encoding Pgp) into tissue culture cells resulted in an :rviDR phenotype, even 
before stable cell lines were selected (Gros et aL, 1986; Croop et al., 1987). In addition., 
the incorporation of purified Pgp into liposomal membranes has demonstrated th~t Pgp is 
able to hydrolyze ATP and transport drugs (Saeki et a!., 1992; Thierry et aL, 1992; 
Sharom et al., 1993; Naito and Tsuruo, 1995; Shapiro and Ling, 1995; Dong et al., 1996; 
Eytan et al., 1997). lVIDR-related protein (MRP) family members, MR.P1, MRP2, MRP3, 
MRP4, MRP5, and cMOAT, are other members ofthe ABC family oftransporters (Cole 
et al., 1992; Krishnamachary and Center, 1993; Zaman et al., 1994; Lautier et al., 1996; 
Kool et al., 1997). 
Lung-related protein (LRP) is also associated with an MDR phenotype (Scheper et 
al., 1993). It has been identified as the major component of certain nucleoprotein 
particles (vaults), which possibly translocate cytotoxic drugs from nuclei to cytoplasmic 
vesicles, which in tum release their contents at the cell surface (Scheper et al., 1993; 
Izquierdo eta/., 1996). 
1.2.2.2. Altered intracellular drug metabolism 
The cytotoxicity of many chemotherapeutic agents is determined by the enzymatic 
conversion of the drugs into their active metabolites. For example, 5-:tluorouracil (5-FU) 
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is a pro-drug, and must be activated to its cytotoxic form by the targeted tumor. 
Resistance to such nucleic acid base and nucleoside drugs has been associated with 
decreased conversion of these analogues to their cytotoxic nucleoside and nucleotide 
derivatives by phosphorylases, ki.nases and the phosphoribosyltransferase salvage 
pathway (Drahovsky and Kreis, 1970). 
Furthermore, cellular factors involved in detoxifying chemotherapeutic agents 
could impact on the cytotoxicity of drugs that have gained access to the intracellular 
compartment of tumor cells. A number of mechanisms may permit detoxification. For 
example, glutathione (GSH), is an important intracellular antioxidant. When a compound 
is conjugated with GSH, the compound becomes more hydrophilic, more readily 
excreted, and usually less toxic (O'Brien and Tew, 1996). A group of cytosolic enzymes 
termed GSH-S-transferases (GSTs) conjugate certain drugs with GSH. This 
detoxification mechanism may require vesicle-mediated transport of GSH-drug 
conjugates by a poorly understood ATP-dependent GS-X pump. Overexpression of 
GST -1t leads to resistance to alkylating drugs and to platinum compounds through their 
conjugation with GSH (Ozols et al., 1990). Further study indicates that many drug-
resistant cell lines have increased expression or activity of GSH and/or related enzymes 
(O'Brien and Tew, 1996). 
Metallothioneins (MTs) are low molecular weight intracellular proteins 
characterized by high cysteine content and affinity for binding heavy metals. These 
proteins are located mainly in parenchymal tissues such as the liver, gut and kidneys, 
where they play a role in the detoxification of cadmium, platinum and certain other heavy 
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metals and in the regulation of normal zinc and copper metabolism. Overexpression of 
MTs has been correlated with acquired resistance of cancers to cytotoxic alkylating 
agents and to cisplatin through an unknown mechanism (Mousseau eta!., 1993; Kelley et 
al., 1988; Lohrer and Robson, 1989; Kaina eta/., 1990). 
In addition, enhanced inactivation of pyrimidine and purine analogues by elevated 
deaminases and oxidases has been linked to resistance toward these agents (Steuart and 
Burke, 1971; Hunt and Hoffee, 1983). 
1.2.2.3. Altered drug targets 
The mechanisms of cytotoxicity of several antineoplastic drugs involve interactions 
between the drugs and essential intracellular enzymes that consequently alter or inhibit 
normal functions. Quantitative or qualitative changes in these enzyme targets of 
antineoplastic drugs can compromise drug efficacy. 
Topoisomerase (Topo) II is a nuclear enzyme that modifies the topologic state of 
DNA to facilitate strand relaxation, controlled cleavage, and religation of the DNA helix 
during replication and repair. It also serves a role during chromosome segregation in 
mitosis. Topo II is an important target of several antineoplastics, including etoposide and 
doxorubicin, which bind to and inhibit Topo II enzymatic religation, thereby stabilizing 
the enzyme-DNA cleavage complex. Qualitative changes affecting Topo II activity in 
selected cell lines result in an MDR phenotype similar to that described for Pgp, with the 
characteristic exception of preserved sensitivity to microtubule-targeting agents, such as 
Taxol (Potmesil et al., 1987). Alterations of several other enzymes, including the 
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methotrexate-targeted d.ihydrofolate reductase, are associated with drug-resistance (Haber 
et al., 1981). 
1.2.2.4. Changes in molecules involved in repair of cellular damage 
Cells contain multiple complex systems involved in damage repair, especially in 
their membranes and DNA. Because such damage may occur as a direct or secondary 
consequence of cytotoxic drug action, altered repair mechanisms can influence drug 
sensitivity of tumor cells. 
For instance, alkylating agents induce lethal DNA damage by forming covalent 
bonds with nucleophilic sites in DNA. The N7 and 06 atoms of guanine are probably the 
main targets for alkylation of DNA. Repair of DNA adducts represents one of the main 
mechanisms o.f cellular protectio~ and one important DNA repair enzyme is 06-
methylguanine-DNA methyltransferase (MGMT), which removes alkyl adducts from the 
06 atom of the guanine base (Gerson et al., 1995). A striking correlation between 
MGMT activity and resistance to nitrosourea and cisplatin has been demonstrated both in 
vitro and in xenograft models (Pegg eta!., 1984; Gerson et al., 1994). 
Correlation between mutations in DNA mismatch repair genes, such as hMLHI, 
and resistance to N-methyl-N-nitro-N-nitrosoguanidine (MNNG) and cisplatin has been 
reported (Kat et al., 1993). Introduction of wild-type hMLffi gene-carrying chromosome 
3 into hMLH1 mismatch repair-deficient HCT-116 human colon cancer cells restored 
mismatch repair efficiency and conferred increased sensitivity to MNNG (Koi et al., 
1994). 
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1.2.2.5. Cellular oncogenes and tumor suppressor genes in drug resistance 
It has recently been appreciated that changes in the level or activity of cellular 
oncogene and tumor suppressor gene products may be responsible for resistance to a 
broad range of drugs. There are a number of such cellular genes whose upregulatio~ 
downregulation or mutation contributes to drug resistance. 
For example, c-fos and c-jun proto-oncogene levels can be elevated in 
chemoresistant cells (Bhushan eta/., 1992; Yamazaki eta/., 1994; Moffat eta/., 1996). 
Also, a relationship between cisplatin resistance and overexpression of the c-myc gene 
has been observed in an erythroleukemia cell line (Sklar and Prochownik, 1991). 
Transfection of c-myc enhanced cisplatin resistance of Nlli 3T3 cells, and antisense 
oligonucleotide to c-myc RNA enhanced cisplatin sensitivity of urinary bladder cancer 
cells (Niimi eta/., 1991; Mizutani eta/., 1994; Sanchez-Prieta et al., 1995;). Serially 
transplanted tumors that survived treatment with cisplatin displayed elevation in c-myc 
expression, and their growth could be inhibited by c-myc antisense RNA (Walker eta/., 
1996). In additio~ blocking Ras oncogene product function by famesyltransferase 
inhibitors caused increased radiosensitivity and chemosensitivity (Bernhard eta/., 1996; 
Danesi et a/., 1996). Furthermore, studies have correlated Her-2/neu oncogene 
expression with intrinsic MDR of human non-small cell lung cancer cells (Tsai eta/., 
1993), and transfection of Her-2/neu conferred chemoresistance on these cells (Tsai et 
a/., 1995). Blocking Her-2/neu receptor function by emodin and tyrphostin, inhibitors of 
tyrosine kinase activity, sensitized Her-2/neu-overexpressing lung cancer cells to in vitro 
killing by cisplatin, doxorubicin, or etoposide (Tsai eta!., 1996; Zhang and Hung, 1996). 
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One of the roles of p53 is to regulate the cell cycle. Functional p53 is required for 
G 1 cell cycle arrest in response to DNA damage. The loss or mutation of p53 can affect 
drug sensitivity or resistance (Ruley, 1996; Velculescu and El-Deiry, 1996; Gallagher et 
a/., 1997; Coukos and Rubin, 1998). pRB is another cell cycle regulator/tumor 
suppressor gene that is involved in drug resistance (Wang eta!., 1998; Yamamoto et al., 
1998; Yoo eta!., 1998). Studies have shown that cells null for the p21 WAFliCIPl cell cycle 
regulator display defective repair of in vitro damaged DNA and are more sensitive to the 
cytotoxic effects of a variety of cytotoxic drugs, as well as to UV (McDonald et al., 1996; 
Waldman eta!., 1996). Recently, p27KIP1 has been also demonstrated to play a role in 
drug resistance in some neoplasia (for review, see Lloyd eta/., 1999). 
1.2.2.6.. Apoptosis regulation in drug resistance 
In addition to the role of apoptotic inhibition in oncogenesis (section 1.1.5), it is 
becoming clear that the same process is involved in the drug resistance of many cancers. 
This is because essentially all chemotherapeutic drugs available to date, as well as 
radiation, ultimately act on tumor cells through apoptosis. The Bcl-2 family proteins 
have been implicated not only in the pathogenesis of cancer, but also in resistance to 
chemotherapy. Anti-apoptotic Bcl-2 expression correlates with poor response to 
chemotherapy and shorter survival for patients with some types of lymphomas, acute 
myelogenous leukemias, and prostate cancers (Lotem et al., 1993; Campos eta!., 1993; 
Reed, 1995a; 1995b; 1998). Conversely, reductions in Bcl-2 achieved by antisense 
methods sensitize cells to multiple chemotherapeutic drugs (Webb et al., 1997). 
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Therefore, the ability ofBcl-2 to block cell death induced by all types of anticancer drugs 
indicates that Bcl-2 represents a novel :MDR protein. Overexpression of Bcl-2 protein 
prevents drug-induced apoptosis. Antineoplastic agents interfere with DNA synthesis, or 
interfere with microtubule formation in tumor cells that contain high levels of Bcl-2, but 
the cells remain viable for protracted periods of time, resulting in enhanced clonogenic 
survival. Bcl-XL, another anti-apoptotic Bcl-2 family member, can also confer high-level 
resistance to chemotherapeutic agents (Minn et al., 1995; Taylor et al., 1999). 
Downregulation of pro-apoptotic Bcl-2 family proteins can result m drug 
resistance. Consistent with this notion, overexpression of Bax protein rendered tumor 
cells more sensitive to many anticancer drugs (Bargou et al., 1996). Ablating Bax 
expression reduced drug-induced apoptosis (Perez et al., 1997). 
The Bcl-2 family members are also linked to drug sensitivity and resistance through 
their regulation by p53. Numerous studies have linked p53 to apoptosis in cases when 
DNA is damaged by anticancer drugs (see section 1.1.4). Inactivation of p53 correlates 
with enhanced resistance to anticancer drugs and a poorer prognosis in most human 
malignancies (Harris and Hollstein, 1993; Lowe et al., 1994). In a controlled experiment 
using genetically defined tumors in immunocompromised mice, mutation of p53 was 
associated both with resistance to chemotherapy and with tumor relapse (Lowe et al., 
1994). 
1.3. Molecular mechanism of multistage cervical cell carcinogenesis 
1.3.1. The role ofHPVs in cervical oncogenesis 
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Cervical cancer was recognized as a sexually transmitted disease more than a 
century ago and since then numerous infectious agents have been SU!ggested to play a 
causative role (reviewed by zur Hausen and de Villiers, 1994; Alani and Mfinger, 1998). 
A subset of the more than 90 papillomaviruses (HPV s) was detected in more than 90% of 
cases of cervical carcinoma, providing compelling evidence for HPV infection as a 
causative factor (zur Hausen, 1991a; Bosch eta!., 1995; Alani and Miin:_ger, 1998). 
HPV s are small DNA viruses that are found in many vertebrate species and contain 
approximately 8 kb double-stranded circular genomes, which are generally divided into 
three distinct regions: early (E), late (L), and long control regions (LCR) (Figure 1.4). 
The early region open reading frames (ORFs) are designated El, E2, E-4, E5, E6 and E7, 
and encode proteins required for viral DNA replication, viral RNA t:Iranscription, viral 
and cellular gene regulation, and oncogenesis. The late ORFs, L1 an<i L2, encode viral 
capsid proteins. The LCR, also called the noncoding region or up:stream regulatory 
region, is found between the 3' end of the late region and 5' end of th-e early region. It 
contains DNA elements that regulate HPV RNA transcription and DNA replication by 
interacting with viral and cellular transcription and replication factors (Eoppe-Seyler and 
Butz, 1994). 
The anogenital HPV s are generally categorized into two groups based on their 
ability to induce viral-associated cancers: low-risk (not associated with cancer) and high-
risk (cancer-associated) (de Villiers, 1989). Generally, low-risk HPVs, smch as HPV6 and 
11, are associated with benign genital condylomas and oral and other papillomas; while 
high-risk HPV s, such as HPV16 and 18, are increasingly associ::-.ted with normal 
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Figure 1.4. Genomic organization of HPV16 (adapted from Alani and MOnger, 1998). 
All papillomaviruses contain a double-stranded circular DNA genome of approximately 8 
kb. Transcription occurs from only one strand of DNA. Nucleotide positions are 
indicated in the circle. 
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epithelia, low-grade squamous intraepthelial lessions (LSILs ), high-grade squamous 
intraepthelial lessions (HSILs), and invasive carcinomas (zur Hausen, 1991a). 
Although infection with high-risk HPV types is relatively common, few infected 
women eventually develop cervical carcinoma. In addition, the interval between primary 
HPV infection and cervical cancer is usually several decades, suggesting that HPV 
infection alone is insufficient to generate the fully malignant phenotype (zur Hausen, 
1994; Ponten et al., 1995). Therefore, other events are also required for the development 
of cervical cancer. 
In vitro studies demonstrated that transfection of high-risk HPVs, such as HPV16 
and 18, can initiate immortalization of ectocervical and endocervical cells (Pirisi et a/., 
1987; Woodworth et al., 1988; Tsutsumi et al., 1992; Pecoraro et al., 1989; Woodworth 
et al., 1989). Furthermore, cotransfection ofHPV16 or 18 with an oncogene, such as c-
myc, v-fos or H-ras, transformed rodent cells and primary human fibroblasts and 
keratinocytes in vitro (DiPaolo et al., 1989; Durst et al., 1990; Pei et al., 1993), 
suggesting that HPV s can cooperate with oncogenes in carcinogenesis. 
1.3.2. Functional consequences of high-risk HPV E6 and E7 oncogenes 
Two genes of the high risk HPV s, namely E6 and £7, can immortalize and 
transform cells by cooperating with other oncogenes (Bedell et al., 1989; Phelps et al., 
1988; Storey et al., 1988; Storey and Banks, 1993). The E6 and E7 viral oncoproteins of 
high-risk HPV s have also been shown to be selectively maintained in most virally 
induced tumors (Schneider-Gadicke and Schwarz, 1986; Pater and Pater, 1988; Hawley-
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Nelson et al.~ 1989; Woodworth et a/.~ 1989; van den Brule et al.~ 1991; zur Haus~ 
1991b). 
One property of E6 and E7 that may contribute to oncogenic genetic changes is 
their fortuitous modulation of the cellular response genes to DNA damage (Figure 1.5). 
Normally~ DNA damage results in the accumulation of wild-type p53 protein (section 
1.1.4), which increases p21 wafl/cipl, which in tum inhibits the activation of cyclin-cdk 
complexes that phosphorylate retinoblastoma tumor suppressor protein (pRB). 
Consequently E2F transcription factors therefore remain associated with pRB and are 
unable to activate transcription of genes required for progression from G 1 into S phase. 
Consequently~ cells ~e arrested in G1, and this G1 arrest is thought to allow repair of 
damaged DNA. 
The immortalization and transformation activities of high-risk HPV E6 and E7 
correlate, at least in part, with their inactivation of p53 and pRB (Dyson et al.~ 1989; 
Heck et a/.~ 1992; Mansur et al.~ 1993; Mtinger et al.~ 1989; Nakagawa et al., 1995; 
Wemess et al., 1990). The E6 oncoprotein of the high-risk HPVs 16 and 18 binds p53 
and promotes its ubiquitin-mediated degradation (W emess et al., 1990; Scheffuer et al., 
1990; 1994). Similarly, the E7 protein has been shown to bind pRB and modify pRB 
function (Dyson et al., 1989; Dyson eta/., 1992; Davies et al., 1993). The cyclins, cdk 
and other cellular targets that regulate normal cellular function may also be dysregulated 
by viral E6 and E7 oncoproteins. Moreover, apoptotic cell death is another important 
response to DNA damage that may also be influenced by HPV oncoprotein expression. 
In cervical tumors that are not associated with HPV infectio~ p53 and pRB may be 
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Figure 1.5. Effects of HPV oncoproteins on the cell cycle and apoptosis pathway 
(adapted from Alani and Miinger, 1998). 
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inactivated by mutations, such as deletions, splice site changes and codon substitutions, 
rather than by binding to a viral protein (Crook et al., 1992). 
1.3.3. In vitro cervical cell model of in vivo multistage carcinogenesis 
The initiation of cervical cancers is mostly caused by HPV infection (section 1.3.1 ). 
After initiation, the cells may be exposed to some tumor promoting reagents and 
experience further genetic alterations, such as mutation and activation or inactivation of 
oncogenes and tumor suppressor genes (section 1.3.2). A single cell acquires a growth 
advantage and/or inhibition of apoptosis to form a clonal malignant tumor (section 
1.1.5.1). Both physical and chemical factors could contribute to the further progression 
of cervical cancers after initiation. 
Carcinogenesis, or the process of cancer development, in most instances involves a 
long period of latency. During this time, endogenous and/or exogenous carcinogenic 
agents act on individual cells and cause genetic alterations, mostly involving oncogenes 
and tumor suppressor genes. Most cancers are clonal in origin. Cancer development 
involves several successive rounds of gene mutations, and tumor progression is usually a 
multistage progression. 
Similar to the preceeding description of cervical carcinogenesis in vivo, the 
multistage nature of cancer also can be observed in the carcinogenesis of human cervical 
cells in vitro. Figure 1.6 is a schematic representation of in vivo and in vitro cervical 
carcinogenesis. In this scheme, HPVs initiate carcinogenesis in vivo after infecting 
endocervix-derived metaplastic cells at the transformation zone, where almost all cervical 
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Figure 1.6. In vivo and in vitro cervical multstep carcinogenesis. 
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neoplasia is formed (Vousden, 1989; Sun et al., 1997). Alternatively, normal metaplastic 
endocervical cells in vitro are HPV -transfect~ im.mortaliz~ and become transformed 
(Tsutsumi eta/., 1992; Sun et al., 1992; 1997; Yang eta/., 1996a). 
High-risk and low-risk HPV s are found in low-grade squamous intraepithelial 
lesions (LSILs) in vivo and both types also extended the cell life span in in vitro cell 
culture. Further modifications of cellular genes resulted in mainly high-risk HPV-
containing high-grade squamous intraepitheliallesions (HSILs) in vivo or isolated clones 
of immortalized cells in vitro. However, these events are insufficient to transform 
cervical cells in vivo or in vitro and produce invasive cervical carcinoma. Other factors, 
such as smoking, or cigarette smoke condensate (CSC) are required to efficiently induce 
further changes in other cellular genes and transform some of the high-risk HPV-
containing HSILs, or -immortalized cells to form invasive tumors (Yang et al., 1996a; 
Nakao et al., 1996). 
1.4. BAG-1 and its associated proteins 
BAG-1 is a protein with multiple isoforms: p50, p46, p33 and p29. Each isoform is 
initiated from an alternate translational start site (Yang et al.. 1998a; Zapata eta/., 1998). 
The BAG-I p50 isoform is distributed predominantly in the nucleus, while other isoforms 
are located mainly in the cytoplasm or membranes (Yang et al., 1998a), suggesting that 
BAG-1 is a multifunctional protein. 
BAG-1 was initially identified as Bcl-2 binding proteins (Takayama et al., 1995). 
Bcl-2 is a key inhibitor of apoptosis (see section 1.1.4), and BAG-1 can enhance the 
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ability of Bcl-2 to inhibit apoptosis induced by staurosporine and anti-Fas antibody in 
Jurkat T cells (Takayama et al., 1995), or by NGF withdrawal in neuronal PC12 cells 
(Schulz et al.. 1997). BAG-1 can interact with Raf-1, which can bind to Bcl-2 and 
cooperate in the suppression of apoptosis, and activates its protein kinase in vitro and in 
vivo (Wang et al., 1996). In addition, BAG-1 was found to bind hepatocyte growth factor 
(HGF) and platelet-derived growth factor (PDGF) receptors, and enhance their ability to 
inhibit apoptosis (Bardell et al., 1996). Further, overexpression of BAG-I inhibits the 
apoptosis induced by staurosporine in 3T3 fibroblasts and C33A cervical carcinoma cells 
(Takayama et al., 1995; Yang et al., 1999a), heat shock in GM701 immortalized 
fibroblasts (Takayama et al., 1997), and IL-3 withdrawal in IL-3-dependent B cell line 
Ba/F3 (Clevenger et al., 1997). Thus, BAG-1 was identified as a Bcl-2-dependent and-
independent anti-apoptotic molecule. 
BAG-1 is capable of interacting with various other cellular proteins (Figure 1. 7). 
BAG-1 can to form. complexes with a number of steroid hormone receptors, such as 
estrogen receptor (ER), androgen receptor (AR), and glucocorticoid receptor (GR) and 
modulates their function (Zeiner and Gehring, 1995; Froesch et al., 1998; Kullm.ann et 
a/., 1998). Recently, BAG-1 was demonstrated to interact with Siah-1A, which can 
inhibit p53-dependent cell-cycle arrest, and to inhibit Siah-1A function (Matsuzawa et 
a/., 1998). In late 1997, BAG-1 was demonstrated to interact with heat shock protein 70 
chaperones (Hsp70s) and modulate their chaperone activity (Takayama et a!., 1997, 
Zeiner eta/., 1997, Hohfeld and Jentsch, 1997). I also independently identified Hsp70 
and Hsp70-2 as BAG-1-binding proteins using the yeast two-hybrid system during that 
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Figure 1. 7. BAG-1-interacting proteins. Proteins in blue color were demonstrated to 
interact with BAG-I before 1997. Proteins in yellow were demonstrated to interact with 
BAG-1 since 1997, when screening for BAG-1-interacting proteins using the yeast two-
hybrid system began. 
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time. The Hsp70 family comprises molecular chaperones that play a key role in the 
folding, translocation and degradation of proteins in eukaryotic cells through their 
capacity to bind and stabilize non-native protein conformations (Hartl, 1996; Rudiger et 
a/., 1997; Bakau and Horwich, 1998). Hsp70 is also known to regulate apoptosis (Gabai 
et al., 1995; Mosser et a/., 1997; Jaattela et al., 1998) and may thus play a role in 
tumorigenicity and drug resistance (Kaur and Ralban 1995, Ralban eta/., 1995; JaatteHi 
1995; Vargas-Roig et al., 1998). 
BAG-1 was demonstrated to increase pulmonary metastases in mice (Takaoka et 
a/., 1997). Furthermore, BAG-1 is present at much higher levels in cervical tumors and 
breast tumors than in surrounding normal tissue (Yang et a!.. 1999a, 1999b ). BAG-1 bas 
also been shown to be expressed at higher levels in lung, breast and cervical tumor cell 
lines than their non-tumor counterparts (Takayama et al.. 1998; Yang et a/., 1998b; 
1999a; 1999b; Zapata et a/., 1998). Moreover, the increased expression of BAG-1 
correlates with enhanced resistance of cervical carcinoma cells to apoptosis induced by 
cisplatin (Yang et al.. 1998b). All these observations suggest that BAG-1 may have an 
important role in carcinogenesis and drug resistance through inhibition of apoptosis. 
1.5. Objective of this study 
From the foregoing review of the literature, it can be concluded that apoptosis plays 
an important role both in multistep carcinogenesis and in cancer chemotherapy resistance. 
Apoptosis is controlled through cellular genes including pro-apoptotic genes (e.g., p53, 
Bax, Bak) and anti-apoptotic genes (e.g., Bcl-2. Bcl-XL andBAG-1). Also, alterations in 
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these apoptosis-regulating genes have been implicated to have an important role i:n 
carcinogenesis and cancer drug resistance. The expression patterns of these apoptosis-
regulating proteins vary in different cell types. Therefore, my hypothesis is that 
deregulation of apoptosis plays a role in the process of multistep carcinogenesis an-d 
MDR of human endocervical cancer. 
The molecular mechanism of apoptosis in the multistep carcinogenesis process an-d 
MDR is still poorly understood. An understanding of the role of apoptosis in multistq> 
carcinogenesis and :MDR of endocervical cancer is important in cancer research. Th-e 
objective of this study is to further characterize the role of apoptosis in carcinogenesi_s 
and ::MDR of human cervical cells. 
For these purposes, firstly, HPV 16-i.mmortalized endocervical cells were treatecl 
with cisplatin and a multidrug-resistant endocervical cell line was established. Then, th-e 
response to various apoptotic stimuli, cellular morphology, growth characteristics, 
tumorigenicity, and cellular apoptosis-regulating gene expression of the immortalized anlrl 
multidrug-resistant cells were analyzed. 
Secondly, since BAG-I was found to be overexpressed in our multidrug resistamt 
cells, BAG-I was then stably transfected into the low BAG-1-expressing cervicad 
carcinoma cell line, C33A, to determine whether overexpression of BAG-I cam. 
recapitulate the drug-resistance. 
Thirdly, the yeast two-hybrid system was established and employed to screen ca. 
complementary DNA (eDNA) library. Hsp70 and Hsp70-2 were isolated as BAG-1-
binding proteins. Furthermore, mutation analyses of the functional domain of BAG-• 
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which is required for interaction with Hsp70 and Hsp70-2 were conducted in vitro and in 
vivo. The effect ofBAG-1 on Hsp70 chaperones-mediated protein refolding activity in 
vivo was also assayed. Additionally, Hsp70 and Hsp70-2 were stably transfected into 
C33A cells and the role of their interaction with BAG-1 in drug resistance was further 
characterized. 
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2.1. Materials 
CHAPTER2 
MATERIALS AND :METHODS 
Keratinocyte growth medium (KGM) and Dulbecco' s modified Eagle medium 
(DMEM) were purchased from GffiCO-BRL and ICN, respectively. GIBCO-BRL was 
the supplier for the fetal calf serum (FCS) and trypsin-ethylenediamine tetraacetic acid 
(EDTA). Penicillin-streptomycin was obtained from ICN. HEN-16-2 and HEN-16-2T 
cells were established by Dr. K. Tsutsumi and Dr. X. Yang in the laboratory, respectively 
(Tsutsumi et al., 1992; Yang et al., 1996a). HeLa and C33A cell lines in the laboratory 
stock were previously purchased from ATCC. 
Taq DNA polymerase, restriction endonucleases and their respective 1 Ox reaction 
buffers were obtained from GffiCO-BRL. The coupled transcription/translation TNT 
system was supplied by Promega. 
GffiCO-BRL supplied the 1 kb and 100 bp DNA ladder markers. Low melting 
point agarose, agarose, acrylamide, N,N'-methylenebisacrylamide, urea and 10 mM 
dNTPs (dGTP, dATP, dTTP and dCTP) were all purchased from GffiCO-BRL. Baker 
Inc., Bio-Rad, and Carnation were the suppliers of 2-mercaptoethanol, N,N,N',N'-tetra-
methylethylenediamine (TEMED) and skim milk powder respectively. 
Cisplatin, actinomycin D, doxorubicin, etoposide, 5-FU, staurosporine, 
sanguinarine, paclitaxel (taxol), N-(4-hydroxyphenyl)retinamide (4-HPR or fenretinide) 
and all-trans retinoic acid (ATRA) were all purchased from Sigma Chemical Co .. 
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Mouse anti-BAG-1 monoclonal antibody (mAb) was generated and prepared in our 
lab (Yang et al., 1998a). Rabbit polyclonal antibodies for Bcl-XL, Bax and mouse mAbs 
for Bak, Bcl-2, Hsp70 and caspase-3 were obtained from Santa Cruz Biotechnology. 
Other mouse mAbs used were: anti-p53 (DA.KO), anti-actin (Sigma Chemical Co.) and 
anti-P ARP (PharMingen International). 
The yeast two-hybrid system kit was purchased from Clontech. Invitrogen and 
United States Biochemical Co. supplied theTA Cloning Kit version 3.0 and Sequence 
Version 2.0 Sequencing Kit, respectively. Kodak was the supplier of X-ray film. 
Eight-well tissue chamber slides; 35 mm, 60-mm and 1 00-mm tissue culture plates; 
and culture tubes were obtained from NUNC. Eppendorf micro test tubes for PCR v1ere 
obtained from Fisher. 
2.2. Cell culture 
HEN-16-2 and HEN-16-2/CDDP were cultured in serum-free KGM containing 1% 
penicillin/streptomycin. HeLa, HEN-16-2T, C33A, C33A-BAG-l, C33A-Hsp70 and 
C33A-Hsp70-2 were cultured in DMEM containing 10% FCS and 1% 
penicillin/streptomycin. 
All cells were maintained at 3 7 °C in a humidified incubator containing 5% C02. 
After three days or when the cells had reached approximately 80% confluence, the 
medium was aspirated from the plates and the cells were washed with phosphate-buffered 
saline (PBS). Then, 2 m1 oftrypsin-EDTA was added into each plate, which was placed 
in the incubator for 10 minutes. For cells cultured in KGM, 8 ml of PBS containing 10% 
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FCS was added to the trypsinized cells to quench the activity of trypsin. The cells were 
then suspended and centrifuged at 1,000 rpm for 10 minutes. The cell pellets were 
resuspended with KGM and passaged at a dilution of 1:10, 1 :4, or 1:2 into plates. For 
cells cultured in DMEM containing 10% FCS, 8 ml of this medium was added directly to 
the trypsinized cells, which were further passaged at 1:10, 1:4, or 1:3 into fresh plates. 
2.3. Establishment of endocervical MDR HEN-16-2/CDDP cell line 
As shown in Figure 2.1, the multidrug-resistant human endocervical cell line HEN-
16-2/CDDP was established from the HPV-imm.ortalized human endocervical cell line 
HEN-16-2. HEN-16-2 cells which were normally maintained in KGM were first adapted 
to grow in DMEM. At each passage, they were incubated for 24 hours in DMEM 
containing 5 J.LM CDDP. The COOP-containing medium was then replaced with fresh 
DMEM for additional incubation for 3 days. This treatment was repeated for 
approximately 50 passages, and then the cells were cultured in KGM (Figure 2.1). 
2.4. Clonogenic survival assays 
Clonogenic assays were performed, as previously described (Vasey et a/., 1996). 
Briefly, 103 cells were seeded into 60-mm diameter tissue culture plates and allowed to 
attach overnight. Cells were then incubated with each drug for 24 h, washed twice with 
sterile PBS at 37°C, and incubated in drug-free KGM for 10-14 days. The cells were 
were stained with 2% crystal violet in methanol and colonies of 50 or more cells were 
scored. The surviving fraction was calculated as the ratio of the colony-forming 
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Figure 2.1. Schematic representation of method used to establish HEN-16-2/CDDP cells. 
The dotted lines indicate the initiation and termination of serum adaption. 
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efficiency of drug-treated and untreated cells. The drug concentration resulting in 50% 
cell viablility inhibition (IC50) was determined from each clonogenic survival curve 
(Nagane et al., 1997). 
2.5. Measurement of growth rate and saturation density 
Exponentially growing cells were trypsinized, centrifuged, and resuspended in 2 ml 
medium. Cell numbers were counted with a hemocytometer, and approximately 2 x 104 
cells were dispensed into 60-mm plates for each cell line. Cell numbers were counted 
from each of three plates every two days for 8 days. 
The saturation density of each cell line was measured by the same procedure 5 days 
after the cells reached confluence. 
2.6. Light microscopy and scanning electron microscopy 
For light microscopic analysis of morphology, cells were cultured in 8-well tissue 
culture chamber slides. The chamber frame was released from the slides, before the cells 
were studied under light microscopy. Cell morphology was documented with Kodak 
Tmax 400 film. 
For SEM analysis, approximately 50,000 cells were seeded on 24-well tissue-
culture plates containing acid-cleaned coverslips (Thermanox, no. 5414; Lux Scientific 
Corp.). Cells were allowed to attach to the coverslips at 37 °C in a humidified incubator 
containing 5% C02 overnight. Cells were fixed with Kamovsky fixative 2.5% 
glutaraldehyde (J. B. EM Services) in 0.1 M sodium cacodylate buffer. Cells were 
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dehydrated in a 25%, 50%, 75% and 100% graded ethanol series followed by Freon-113 
substitution. All samples were dried simultaneously, sputter-coated with gold and 
examined in a Hitachi S-570 SEM, as previously described (Liepins and Younghusband, 
1985). 
2. 7. Soft agar or anchorage-independent growth assays 
The 0. 7% agarose underlying gel was prepared by mixing equal volumes of 
2x DivfEM containing 20% FCS and low melting point agarose melted in sterilized water, 
dispensing 2.5 m1 into 60-mm. plates, and leaving the plates at room temperature until the 
gel solidified. Subseqently, HEN-16-2 and HEN-16-2/CDDP and positive control HEN-
16-2T and HeLa cells were trypsinized, resuspended in 2x DMEM, and counted using a 
hemocytometer. The 0.35% agarose overlaying gel was prepared by mixing 
approximately 105 cervical cells in 2.5 m1 of 2x DMEM with 2.5 m1 of 0. 7% low melting 
point agarose in sterilized water, pouring the mixture into the 60-mm. plates containing 
the 0. 7% underlying gel. The plates were placed at 4 °C for 5 minutes, and then 
incubated at 37 °C. One week later, 1 m1 DMEM was carefully added onto the surface of 
the soft agar to replenish nutrients. Colony formation was monitored every two days for 
2-4 weeks. Triplicate assays were performed for each cell line. Representative 
photographs were taken for documentation. 
2.8. In vivo tumorigenicity assays 
HEN-16-2 and HEN-16-2/CDDP cells were trypsinized and resuspended in PBS. 
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PBS (0.1 ml) containing 107 cells was injected into each of six 2-3 month old female 
immunocompremised nude mice, and tumor incidence was monitored weekly for 4-8 
weeks. HeLa cells were similarly treated as a positive controL The average diameter of 
each tumor was measured when the mouse was sacrificed after 8 weeks. 
The tumors were excised and fixed in 10% paraformaldehyde. The fixed tumors 
were embedded in paraffin, sectioned with a microtome, and then stained with 
hematoxylin and eosin (Sun et a/., 1992). Stained sections were examined and 
photographed with Kodak Tmax 400 film for documentation by light microscopy. 
2.9. Western blotting 
For protein extraction, cells were washed twice with ice-cold PBS, and proteins 
were extracted from 107 cells by lysis in 1 ml ice-cold extraction buffer [50 mM Tris-HCl 
pH 8.0, 150 mM NaCl, 0.02% sodium azide, 1% NP-40, 0.1% sodium dodecyl sulfate 
(SDS), 0.5% sodium deoxycholate, 200 J.Lg/ml phenylmethylsulfonyl fluoride (PMSF) 
and 20 J.lg/ml aprotinin] for 30 minutes and centrifuged at 4°C for 10 minutes, after which 
the supernatants were stored at -70°C. Protein concentration was determined using the 
DC Lowry Protein Assay Kit (Bio-Rad) as instructed by the manufacturer. 
Protein extracts were boiled in 2x SDS-polyacrylamide gel electrophoresis (PAGE) 
gel loading buffer [200 mM Tris-HCI (pH 6.8), 4% SDS, 0.2% bromophenol blue, 20% 
glycerol] for 3 minutes and resolved in an SDS-P AGE gel. The running gel was prepared 
with 8-12% acrylamide, 375 mM Tris-HCl (pH 8.8), 0.1% SDS, 0.1% ammonium 
persulphate, and 6 J.ll TEMED. The stacking gel was composed of 5% acrylamide, 125 
45 
mM Tris-HCI (pH 6.8}, 0.1% SDS, 0.1% ammonium persulphate and 5 J.Ll TEMED. 
Electrophoresis was at 20V in SDS-PAGE running buffer (25 mM Tris, 250 mM glycine) 
using a Protean II minigel apparatus (Bio-Rad). 
The proteins were subsequently transferred to Hybond enhanced-
chemiluminescence nitrocellulose membranes (Amersham Corp) under semidry 
conditions in Towbin transfer buffer (25 mM Tris, 192 mM glycine and 20% methanol) 
using a Trans-Blot SD transfer apparatus (Bio-Rad). Membranes were blocked by gentle 
shaking for 1 hour in TBST (20 mM Tris-HCI (pH 7.6), 137 mM NaCI, 0.1% Tween-20] 
and 5% skim milk powder. Membranes were incubated with the primary antibody diluted 
in TBST containing 5% skim milk powder overnight at 4 °C, and then washed in TBST. 
Membranes were incubated with horseradish peroxidase-conjugated secondary antibody 
diluted in TBST with 5% skim milk powder for 1 hour at room temperature, and then 
washed in TBST. Signals were detected using the enhanced chemilumiscence (ECL) 
system (Amersham) and subsequently exposing the membranes to ECL film, as 
instructed by the manufacturer. 
After primary signals were detected with the ECL system, they were removed from 
the membranes by incubation in stripping buffer (1 00 mM 2-mercaptoethanol, 2% SDS, 
62.5 mM Tris-HCl, pH 6. 7) at 50 °C for 30 minutes with occasional agitation. Then, 
membranes were rinsed with TBST and reprobed with anti-actin mAb and the signals 
were detected as for the primary signaL 
Signal intensities were quantified by densitometry of bands with Eagle Eye II Still 
Video system (Stratagene ). 
46 
2.10. Apoptosis assays 
Pilot experiments were conducted to determine the optimum dose of anticancer 
drugs, anti-Fas antibody and UV for apoptosis by morphological criteria, such as 
blebbing, using light microscopy and SEM, as described in section 2.6; and two 
biochemical characteristics, activation of caspase-3 and cleavage of P ARP, using 
Western blotting, as described in section 2.9. Unless otherwise stated, apoptosis was 
evaluated using the trypan blue exclusion assay to assess the percentage cell survival/cell 
death. This was done by trypsinizing cells, incubating them with 0.4% trypan blue 
solution (Sigma), and scoring more than 200 cells using a hemocytometer. 
Stock solutions were stored in aliquots at -20°C after preparation as follows: 1mM 
actinomycin D, 5 mM cisplatin, 10 mM doxorubicin, 10 mM 5-FU, 1 J.lg/ml sanguinarine 
were prepared in sterile distilled water; 100 mM etoposide and 1 mM 4-HPR in DMSO; 
30 ID.!."\1 ATRA acid, 4 mM paclitaxel (taxol), 2 mM staurosporine in ethanol; and 500 
flg/ml anti-human Fas antibody in PBS containing 50% glyceroL 
Approximately 24 hours prior to all treatments, about 5 x 104 cells were seeded per 
well in 12-well plates. Immediately prior to treating cells, all stock solutions were 
thawed and diluted in medium. UV treatment was as described (Aragane et al., 1998). 
Briefly, immediately before UV treatment, cells were washed twice with prewarmed PBS 
and exposed to UV-B (290-320 nm) with an emission peak of 312 nm through PBS. A 
UV dose of 50 mJ/cm2 was used. For heat shock, cells were incubated at 45°C for 45 
minutes, then returned to culture at 3 7°C for 2 days. 
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2.11. Stable transfeetion of C33A eeUs 
The coding regions of Hsp70 and Hsp70-2 eDNA were subcloned into the 
expression plasmid pCR3.1 (Figure 2.2A). 
C33A cells were then transfected using LipofectAMINE (Life Technologies, Inc., 
Gaithersburg, MD) with 5 Jlg eDNA-containing, or empty vector PCR3.1, according to 
the protocol recommended by the manufacturer. Briefly, approximately 5 x 105 cells 
were seeded per 1 0-mm culture dish. Cells were then exposed to transfection mixtures 
for 5 hours at 3 7 °C. The transfection mixtures were then replaced with fresh DMEM. 
Cells were passaged 48 hours after transfection into three 1 00-mm. plates and selected in 
the presence of 800 J!g/ml G418 for 5-7 days. Well separated colonies were trypsinized, 
transferred to 96-well plates, then subcultured into 24-well and finally into 6-well plates 
in the presence of G418 until enough cells were present for protein extraction. 
2.12. The yeast two-hybrid system eDNA library screening for identification of 
BAG-I interacting proteins 
2.12.1. Strategy of eDNA library screening 
The yeast two-hybrid system (Fields and Song, 1989; Chien et al., 1991; Fields and 
Stemglanz, 1994; Figure 2.3) was used as a genetic system to isolate BAG-1-interacting 
proteins in vivo. It uses the restoration of transcriptional activation to assay the interaction 
between BAG-1 and novel proteins. It relies on the modular nature of many site-specific 
transcriptional activators, such as yeast GAL4, consisting of a DNA-binding domain 
(BD) and a transcriptional activation domain (AD) (Figure 2.3A) (Keegan et al., 1986). 
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Figure 2.2. Construction of plasmids. A. pCR3.1. B. pGEX-4T. C. pAS2-L D. 
pACT2. Parental vectors and their sizes are indicated in the circles. 
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Figure 2.3. Mechanism of the method of the yeast two-hybrid system. A. Yeast GAL4 
protein, the transcriptional activator required for the expression of genes encoding 
enzymes of galactose utilization, consists of two physically discrete modular domains. B. 
If a protein X from the library cannot interact with human BAG-1, the AD will not be 
brought to the DNA binding site to activate the reporter gene. C. If the protein Y, 
another protein fr9m the library, can bind to human BAG-1, protein Y will bring the AD 
to the DNA binding site and thus activate reporter gene expression. 
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The BD serves to target the activator to the specific genes that will be expressed, and AD 
contacts other proteins of the transcriptional machinery to enable transcription to occur. 
The yeast two-hybrid system is based on the observation that the two domains of the 
activator need not be a single polypeptide and can be brought together by any two 
interacting fusion proteins, one of which contains the BD while the other has the AD. 
The application of this system requires that two hybrid fusion plasmids be 
constructed for expressing BD and AD fusion proteins: a BD fused to the bait protein (in 
this case GAL4 BD-BAG-1, Figure 2.3B and C), and an AD fused to some proteins 
which may interact with the bait protein [in this case the human Keratinocyte 
MATCHMAKE eDNA Library (Clontech) proteins, such as AD-X and AD-Y (Figure 
2.3B and C)]. The two hybrid plasmids are cotransformed into a yeastS. cervisiae host 
strain Y190 harboring the yeast HIS3 and the bacteriallacZ reporter genes, which contain 
an upstream GAL4 binding site. In Fig. 2.3, the interaction of BAG-1 with a novel 
library protein Y will activate the HIS3 and the lacZ reporter genes (Figure 2.3C), while 
library proteins not interacting with BAG-1, such as X, will not activate the reporter 
genes (Figure 2.3B). 
2.12.2. Construct pSA2-1-BAG-1 plasmid 
To construct a plasmid expressing GAL4 BD-BAG-1 p46 fusion protein, the BAG-
I isoform p46 eDNA fragment was amplified by PCR in a Hybraid Thermal Reactor 
(Bio/CAN). The forward primer was Ding1, and the reverse primer was B3-1 (Table 
2.1). PCR of the BAG-1 p46 isoform. was performed, as recommended by the 
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manufacturer (Stratagene), with minor modifications. 1 J.ll 50 ng/J.ll DNA and lJ.1l 10 
pmol!J.ll of both primers, were mixed with 2 J.Ll of lOx PCR buffer (Stratagene), 0.4 of J.l.l 
10 mM dNTP (GffiCO-BRL), 0.2 J.Ll of 5 U/Jll polymerase (Stratagene) and 14.4 J.Ll 
water. PCR was performed as follows: 94°C for 3 minutes; 35 cycles of 94°C for 1 
minute, 55°C for 1 minute, 72°C for 1 minute; 94°C for 1 minute, 55°C for 1 minute, and 
72°C for 8 minutes. 
The GAL4 BD plasmid (pAS2-1-BAG-1) was then constructed by subcloning the 
PCR product into the vector pAS2-1 in-frame with GAL4 BD (Figure 2.2C). 
2.12.3. Screening the human keratinocyte MATCHMAKE eDNA Library 
The human keratinocyte MATCHJviAKE eDNA Library of plasmids inserted into 
the yeast two-hybrid system AD vector pACT2 (Figure 2.2D) was purchased from 
Clontech. S. cerivisiae strain Y190 (MATa, ura3-52, his3-200, lys2-801, ade2-101, trpl-
901, leu2-3, 112, ga14L\, gal80A, cyhr2, LYS2::GALluAs-IllS3TATA-ffiS3, 
URA3::GALluAS-GALlTATA-lacZ), which was Trp-, Leu- and His-, was cotransformed 
with pAS2-1-BAG-1 and the MATCHMAKE eDNA Library, using the lithium acetate 
procedure as described by the manufacturer (Figure 2.4). The transformation mixture 
was then plated on 150-mm petri dishes containing synthetic dropout (SD) media lacking 
tryptophan, leucine, and histidine but including 25 mM 3-amino-1,2,4-triazole (3-AT), 
and incubated at 30 °C for 3-5 days. The transformants were screened for ~-galactosidase 
activity using a filter lift assay, according to the protocol recommended by the 
manufacturer (Clontech). Briefly, colonies were transferred to Whatman #5 filters and 
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Figure 2.4. eDNA library screening for BAG-1-interacting protein positive clones. 
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cells were perm.eabilized by freezing for 10 seconds in liquid nitrogen, and thawing at 
room temperature. Filters were then overlaid onto another Whatman #5 filter saturated 
with Z buffer/X-gal solution (16.1 mglml Na2HP04.7 H20, 5.5 mg/ml NaH2P04.H20, 
0.75 mglml KCI, 0.246 mglml MgCh.7 H20, 0.327 mg/ml X-gal, 0.3% (v/v) 2-
mercaptoethanol], and incubated at room temperature for 30 minutes to overnight for 
color development. Approximately 2.5 x 106 yeast trans formants were screened for 
BAG-1-interacting proteins. 
2.12.4. Verifying postitive clones in yeast 
As diagrammed in Figure 2.5, each of the initial His+ and Lac.z+ yeast colonies was 
streaked out one to five times to segregate multiple pACT2-library plasmids within each 
single colony and J3-gal filter lift assays were repeated on well-isolated colonies. The 
plasmids were then isolated from yeast, transfected into E. coli, and further amplified. 
These pACT2-library plasmids isolated from E. coli were then individually retransformed 
into yeast strain Y190 to test the specific interaction of the candidate library clones with 
pAS2-1-BAG-1, pAS2-1-LAM5, and pAS2-1 vector. Nonspecific interactions (those 
conferring His+, Lac.z+ when paired with pAS2-1 or pAS2-1-LAM5) were considered 
false positives and eliminated, while clones specific for pAS2-1-BAG-1 bait fusion were 
retained. 
2.12.5. DNA sequencing and analysis 
Clones retained above were analyzed by DNA sequencing of both strands using a 
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Figure 2.5. Method for verifying BAG-1-interacting protein positive clones. 
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Sequenase Version 2.0 kit (United States Biochemical Co.), according to the protocol 
recommended by the manufacturer. The sequences were then analyzed for sequence 
homology using the National Center for Biotechnology Information sequence databases 
through the Basic Alignment Search Tool (BLAST) program through the internet 
http ://www.ncbi.nlm.nih.gov/BLAST/. 
2.13. In vitro binding assay 
2.13.1. In vitro transcription/translation 
Hsp70, Hsp70 ATPase domain, Hsp70-2, and BAG-I eDNA were 
transcribed/translated in vitro in the presence of e5s]-methionine (Amersham) using the 
TNT system (Promega), as described by the manufacturer. 
2.13.2. GST -fusion protein production 
To obtain GST-Hsp70 and GST-Hsp70-2, the coding regions of Hsp70 and Hsp70-
2 eDNA in pACT2 plasmids were subcloned in-frame into pGEX-4T-2 GST vector 
(Pharmacia, Biotech) (Figure 2.2B). The resulting plasm.ids were then transfected into 
the BL21 strain of E. coli. GST fusion proteins were purified according to the 
instructions of the GST gene fusion system manufacturer. Briefly, E. coli BL21 
containing either parental pGEX-4T-2 plasmid or the plasmid with the inserted eDNA 
were grown at 30 °C with shaking until the ~0 reaches 1.0. At this time, isopropyl-(3-D-
thiogalactoside (IPTG) was added to a final concentration of 0.1 mM and the bacteria 
were cultured for an additional 5 hours, centrifuged, resuspended in PBS and sonicated in 
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eight 15 second bursts on ice. Triton X-100 was then added to a final concentration of 
1% and the tubes were mixed gently for 30 minutes. Lysates were centrifuged at 12,000 
xg and supernatants were collected, combined with 400 J.Ll of GSH sepharose beads and 
incubated at room temperature for 30 minutes with gentle agitation. After this, the 
unbound proteins were removed with three PBS washes. GST fusion proteins were eluted 
with 10 mM reduced GSH in 50 mM Tris-HCI, pH 8.0. GST fusion protein level and 
purity were determined by SDS-P AGE of 1 J.Ll of protein samples and bovine serum 
albumin standards, and staining in Coommassie Brilliant Blue. 
2 .. 13.3. In vitro binding assays ofBAG-1 and Hsp70s 
GST protein interaction assays were performed, as previously described (Hanada et 
al, 1995). Briefly, 10 J..Lg of GST fusion protein was incubated with 10 J.Ll of GST-
sepharose beads for one hour in 100 J..Ll binding buffer (1 0 mM HEPES pH 7 .2, 140 mM 
NaCl, 5 mM MgCh, 1 mM EDTA and 0.15% Nonidet P-40) to attach the proteins to the 
beads. Then, 5 J.ll of C5S]-methionine in vitro-translated products were incubated with the 
GST fusion proteins for 2 hours at 4°C. The mixture was washed six times with binding 
buffer. The beads (in 20 J.Ll binding buffer) were boiled in 20 J.Ll 2x SDS gel loading 
buffer and 20 !ll of centrifuge supernatants were subjected to SDS-P AGE. After 
electrophoresis, the gel was dried and X-ray film was exposed. GST and binding buffer 
were incubated with in vitro transcribed/translated proteins as negative controls. 
2.14. Deletion mutation analysis ofBAG-1 domains for binding Hsp70s in vivo 
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BAG-1 p50, p46, p33, and p29 isoforms, as well as a series of deletion mutations 
which were in-frame with the GAL4 BD of pAS2-1 were generated by PCR (Figure 2.6) 
using the the primers listed in Table 2. L 
The BAG-1 isoforms and mutations were then inserted into the pAS2-1 plasmid. 
These plasmids were then cotransformed with pACT2-Hsp70 or pACT2-Hsp70-2 into 
Y190, and the interactions were then determined by filter lift assays (see section 2.12.3). 
Table 2.1. Primers used to generate BAG-1 isoforms and deletion mutations 
Primer Strand Sequence Amino BD-BAG-1 
acids plasmid 
B5-0K Sense 5'-CACCATGGCTCAGCGCGGG-3' 1-345 p50 
B3-1 Antisense 5'-GCTCACTCCACATCGTCTIT-3' 
Dingl Sense 5'-GATGAAGAAGAAAACCCGG-3' 72-345 p46 
B3-1 Antisense 5'-GCTCACTCCACATCGTCTIT -3 I 
B5-2K Sense 5'-CACCATGGATCGGAGCCAGGAGGT-3' 116-345 p33 
B3-l Antisense 5'-GCTCACTCCACATCGTCTIT-3' 
B5-3K Sense 5'-TCATCTCCfCCAAGATCTICAT-3' 139-345 p29 
B3-l Antisense 5'-GCfCACTCCACATCGTCTIT -3' 
B5-4K Sense 5'-CACCATGGAAACACCGTIGTCAG-3' 200-345 Lll 
B3-l Antisense 5'-GCTCACTCCACATCGTCTIT-3' 
B5-5K Sense 5'-CACCATGGAGATCTTGGAGGAGA-3' 286-345 Ll2 
B3-1 Antisense 5'-GCTCACTCCACATCGTCTIT -3' 
B5-6K Sense 5'-CACCATGGTTCAGGCATICCTAG-3' 315-345 Ll3 
B3-1 Antisense 5'-GCTCACTCCACATCGTCTIT-3' 
BS-lK Sense 5'-CACCATGGAGAAGAAAACCCGG-3' 72-320 a4 
B3-5 Antisense 5'-TCACTCGGCTAGGAATGCCTGAAC-3' 
B5-1K Sense 5'-CACCATGGAGAAGAAAACCCGG-3' 72-291 Ll5 
B3-5K Antisense 5'-TCATCTCCTCCAAGATCTICAT-3' 
BS-lK Sense 5'-CACCATGGAGAAGAAAACCCGG-3' 72-215 Ll6 
B3-4 Antisense 5'-TCACCCAATTAACATGACCCG-3' 
BS-lK Sense 5'-CACCATGGAGAAGAAAACCCGG-3' 72-156 /17 
B3-3 Antisense 5'-TCAAAGGTCGTGCTTCTCATIGC-3' 
B5-1K Sense 5'-CACCATGGAGAAGAAAACCCGG-3' 72-121 /18 
B3-2 Antisense 5'-TCATACCTCCTGGCTCCGATICAT-3' 
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Figure 2.6. BAG-I isoforms and deletion mutants. Numbers indicate the amino acids. 
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2.15. In vivo protein refolding assays 
2.15.1. Transient transfection 
Approximately 1 x 106 C33A-BAG-1 or C33A-NEO cells were seeded into 60-mm 
culture dishes, cultured 24 hours and transiently cotransfected with 1.0 J.lg of pSV-
luciferase vector and 2.0 flg of pSV -J3-galactosidase vector (Promega) using 
LipofectAMINE (Life Technologies, Inc.) for 5 hours at 37 °C. The transfection mixtures 
were then replaced with DMEM containing 10% FCS and 1% penicillin/streptomycin. 
Cotransfected cells were cultured for 24 hours, trypsinized and 1 x 105 cells were 
aliquoted into each cell culture tube (Nunc) and cultured for a further 24 more hours. 
2.15.2. Heat shock inactivation and refolding 
For heat shock inactivation, transiently transfected cells were preincubated in a 
water bath at 37 °C for about 15 minutes and transferred within 3 seconds to 42 °C for 45 
minutes. 
For refolding experiments, the medium was replaced 30 minutes prior to heat shock 
with medium containing 20 J.lg/ml cycloheximide to inhibit new protein synthesis. After 
heat shock treatment, cells were incubated at 37 °C for 30 or 60 minutes to allow protein 
to refold. Luciferase or (3-galactosidase activities before heat shock were taken as 100%. 
2.15.3. Luciferase assays 
Cells were chilled to 4 °C, washed with ice-cold PBS and lysed in 500 J.ll buffer A 
[25 mM H3POJTris-HCl, pH 7.8, 10 mM MgCh, 1% (v/v) Triton X-100, 15% (v/v) 
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glycerol, 1 mM EDTA] containing 0.5% (v/v) 2-mercaptoethanol. The lysates were 
stored at -70 °C. 
After mixing 20 J.ll cell extract and 100 J.llluciferase reagent (Biorad), luminescence 
was measured for 60 seconds in a Monolight 2010 luminometer (Analytical 
Luminescence Laboratory). 
2.15.4. (3-galactosidase assays 
f3-galatosidase expression assays were performed on the same lysates, using 10 J.Ll 
cell extract and 200 J.ll buffer Z (60 mM Na2P04, 40 mM NaH2P04, pH 7.0, 10 mM KCl, 
1 mM MgS04, 50 mM (3-mercaptoethanol) and 40 J.ll 4 mg/ml ortho-nitrophenyl-n-D-
galacto-pyranoside (ONPG). The reaction mixture was incubated at 37 °C for 50 
minutes. The assays were terminated with 100 f.ll 0.5 M Na2C03 and the absorbance was 
measured at 412 nm. 
2.16. Statistical analysis 
Statistical analysis was conducted using the Student's t-test. Differences with a 
value of p < 0.05 were considered to be significant. 
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CHAPTER3 
RESULTS 
3.1. Establishment ofMDR endocervical cell line HEN-16-2/CDDP 
HPV16-immortalized endocervical cells, HEN-16-2, were treated with or without 
cisplatin and then subjected to clonogenic survival assays. Two structurally and 
functionally unrelated antineoplastic agents, cisplatin and paclitaxel, were used in these 
assays. Cisplatin is a platinum compound. Several mechanisms of anticancer action are 
proposed for cisplatin: intrastrand crosslinking of DNA, inhibiting DNA precursors, and 
unmasking antigenic sites on the cell membrane. Paclitaxel is a taxane alkaloid, which 
binds to microtubules and promotes the rate and extent of tubulin assembly into stable 
microtubules, thus preventing tubulin depolymerization and cell division. 
Clonogenic survival cUIVes showed that cisplatin-treated HEN-16-2 cells, and 
HEN-16-2/CDDP, were more resistant to cisplatin than their parental HEN-16-2 cells 
(Figure 3.1A), as well as to paclitaxel (Figure 3.1B). The resistance to cisplatin or 
paclitaxel is calculated as the concentration of drug resulting in 50% cell viablility 
inhibition (ICso) and was 830 nM for cisplatin and 31 nM for paclitaxel, respectively. 
Compared to HEN-16-2, HEN-16-2/CDDP cells were found to be significantly more 
resistant to cisplatin (more than 8 fold) or paclitaxel (more than 5 fold), respectively. This 
indicates that HEN-16-2/CDDP cells have acquired resistance to structurally and 
functionally unrelated antineoplastic agents, cisplatin and paclitaxel, and thus have a 
phenotype of:MDR. 
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Figure 3.1. Dose-dependent clonogenic survival of HEN-16-2 and HEN-16-2/CDDP 
after cisplatin and paclitaxel treatment. About 1,000 cells were seeded into 60-mm 
diameter tissue culture plates and allowed to attach overnight in KGM. Cells were then 
incubated with various concentrations of cisplatin (A) and paclitaxel (B) in KGM for 24 
hours, washed twice with sterile PBS at 3 7°C and incubated in drug-free KGM for 10-14 
days. Colonies were stained with 2% crystal violet in methanol and counted. Survival 
cell fraction was expressed as the ratio of the colony-forming cells of drug-treated and 
untreated control cells. Results represent the mean + the standard deviation from three 
independent experiments. 
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3.2. Response of multidrug resistant cells and its parental cells to various 
apoptotic stimuli 
Abnormalities in apoptosis control can influence the sensitivity of cancer cells to 
chemotherapeutic drugs and other onslaughts (see section 1.2). Overexpression of anti-
apoptotic proteins, such as Bcl-2, in some types of cells cause drug resistance. Bcl-2 does 
not interfere with the accumulation of drugs in tumor cells, obviate the initial damage 
induced by drugs, or alter the rate of cellular damage repair. It simply increases the 
threshold to apoptosis and prevents drug-induced cellular damage leading to apoptosis. 
Increasing the apoptosis threshold confers an :MDR phenotype which can render cells 
more resistant to various apoptotic stimuli, including essentially all chemotherapeutic 
drugs (Reed, 1998b). 
To determine whether the increased apoptotic threshold is the major mechanism of 
HEN-16-2/CDDP :MDR., further studies were conducted on their apoptotic rate and that 
of the parental HEN-16-2 cells using various apoptotic stimuli that may induce apoptosis 
through different mechanisms, such as chemotherapeutic drugs, heat shock, UV light 
irradiation and anti-Fas antibody. 
Compared with HEN-16-2, HEN-16-2/CDDP, displayed a significant inhibition of 
apoptosis induced by cisplatin (Figure 3.2 and 3.3), Sanguinarine (Figure 3.4), 
actinomycin D (Figure 3.5), doxorubicin (Figure 3.6), etoposide (Figure 3.7), paclitaxel 
(Figure 3.8), 5-FU (Figure 3.9A), staurosporine (Figure 3.9B), ATRA (Figure 3.10A) and 
4-HPR(Figure 3.10B). 
Furthermore, HEN-16-2/CDDP exhibited a higher survival rate than HEN-16-2, 
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Figure 3.2. Dose- and time-dependent induction ofapoptosis in HEN-16-2 and HEN-16-
2/CDDP cells by cisplatim. The percentage of viable cells was determined by trypan blue 
dye exclusion assays. Results represent the mean + the standard deviation from three 
independent experiments_ *, p < 0.05, is the statistical significance of the difference in 
cell viability between HEN-16-2 cells and HEN-16-2/CDDP cells. A. Dose dependence. 
Cells were incubated with the indicated concentrations of cisplatin for 48 h. B. Time 
dependence. Cells were Encubated with 20 J..LM cisplatin for the indicated periods. 
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Figure 3.3. Representive result of caspase-3 activation and PARP cleavage in HEN-16-2 
and HEN-16-2/CDDP cells. Lysates from cells treated in 0 ~(lanes 1 and 5) or 5 p.M 
(lanes 2 and 6), or l 0 ~ (lanes 3 and 7), or 20 ~ (lanes 4 and 8) cisplatin were 
immunoblotted \vith anti-caspase-3 or anti-P ARP. 
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Figure 3.4. Representative result of morphological changes of cells undergoing apoptosis 
induced by sanguinarine. Apoptosis was induced by 1.5 J.lg/J.Ll sanguinarine for 4 hours 
and examined by light microscopy (A and B) or scanning electronic microscopy (C and 
D). Panels E and F represent untreated cells examined by scanning electronic 
microscopy. 
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Figure 3.5. Dose- and time-dependent induction of apoptosis by actinomycin D in HEN-
16-2 and HEN-16-2/CDDP cells. The percentage of viable cells was determined by 
trypan blue dye exclusion assays. Results represent the mean + the standard deviation 
from three independent experiments. *, p < 0.05, is the statistical significance of the 
difference in cell viability between HEN-16-2 cells and HEN-16-2/CDDP cells. A. dose-
dependence. Cells were incubated with the indicated concentrations of actinomycin D 
for 48 h. B. Time-dependence. Cells were incubated with 1 J,LM actinomycin D for the 
indicated periods. 
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Figure 3.6. Dose- and time-dependent induction of apoptosis by doxorubicin in HEN-16-
2 and HEN-16-2/CDDP cells. The percentage of viable cells was determined by trypan 
blue dye exclusion assays. Results represent the mean + the standard deviation from three 
independent experiments. *, p < 0.05, is the statistical significance of the difference in 
cell viability between HEN-16-2 cells and HEN-16-2/CDDP cells. A. Dose dependence. 
Cells were incubated with the indicated concentrations of doxorubicin for 48 h. B. Time 
dependence. Cells were incubated with 1 J,.LM doxorubicin for the indicated periods. 
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Figure 3.7. Dose- and time-dependent induction ofapoptosis by etoposide in HEN-16-2 
and HEN-16-2/CDDP cells. The percentage of viable cells was determined by trypan 
blue dye exclusion assays. Results represent the mean+ the standard deviation from three 
independent experiments. *, p < 0.05, is the statistical significance of the difference in 
cell viability between HEN-16-2 cells and HEN-16-2/CDDP cells. A. dose dependence. 
Cells were incubated with the indicated concentrations of etoposide for 48 h. B. time 
dependence. Cells were incubated with 40 J,J.M etoposide for the indicated periods. 
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Figure 3.8. Dose- and time-dependent induction ofapoptosis by paclitaxel in HEN-16-2 
and HEN-16-2/CDDP cells. The percentage of viable cells was determined by trypan 
blue dye exclusion assays. Results represent the mean + the standard deviation from three 
independent experiments. *, p < 0.05, is the statistical significance of the difference in 
cell viability between HEN-16-2 cells and HEN-16-2/CDDP cells. A. Dose dependence. 
Cells were incubated with the indicated concentrations of paclitaxel for 48 h. B. Time 
dependence. Cells were incubated with 5 J.1M paclitaxel for the indicated periods. 
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Figure 3.9. Dose-dependent induction of apoptosis by 5-FU and staurosporine in HEN-
16-2 and HEN-16-2/CDDP cells. Cells were incubated with the indicated concentrations 
of 5-FU or staurosporine for 48 h. A. 5-FU. B. Staurosporine. The percentage of viable 
cells was determined by trypan blue dye exclusion assays. Results represent the mean + 
the standard deviation from three independent experiments. *, p < 0.05, is the statistical 
significance of the difference in cell viability between HEN-16-2 cells and HEN-16-
2/CDDP cells. 
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Figure 3.10. Dose-dependent induction ofapoptosis by ATRA and 4-HPR in HEN-16-2 
and HEN-16-2/CDDP cells. Cells were incubated with the indicated concentrations of 
ATRA or 4-HPR for 48 h. The percentage of viable cells was determined by trypan blue 
dye exclusion assays. Results represent the mean + the standard deviation from three 
independent experiments. *, p < 0.05, is the statistical significance of the difference in 
cell viability between HEN-16-2 cells and HEN-16-2/CDDP cells. A. ATRA. B. 4-HPR. 
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when treated with 0.5 J..Lg/ml anti-Fas antibody~ 50 mJ/cm2 UV irradiation or heat shock 
at45 °C for45 minutes (Figure 3.11). 
3.3. Morphology ofHEN-16-2/CDDP 
The morphology of cultured cervical epithelial cells is an indication of the 
differentiation potential and oncogenicity of the normal or abnormal tissue from which 
the cells are derived (Turyk et al., 1989; Vooijs, 1991). In KGM, a serum-free medium 
that contains 0.15 mM calcium, both types of the cell grew actively and formed 
keratinocyte-like cells (Figure 3.12A and B). However, when the cells were cultured in 
10% serum plus high calcium-containing DMEM, HEN-16-2 immortalized cells were 
slow growing and flat, branched, heterogeneously sized and unevenly distributed (Figure 
3.12C). In contrast, HEN-16-2/CDDP cell line cultures had higher nucleus/cytoplasm 
ratio, and showed morphology and distribution that were comparable to those of the cells 
cultured in serum-free KGM (Figure 3.l2D). 
3.4. Growth characteristics ofHEN-16-2/CDDP 
Table 3.1 summarizes the growth rate, the saturation density and anchorage-
independent growth in soft agar of HEN-16-2/CDDP compared with its parental cell line 
HEN-16-2. 
In serum-free KGM, the average growth rate decreased slightly in multidrug 
resistant HEN-16-2/CDDP cells (Figure 3.13 and Table 3.1). The doubling times of 
HEN-16-2 and HEN-16-2/CDDP in KGM were 37 hours and 44 hours, respectively. In 
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Figure 3.11. Induction of apoptosis by anti-Fas antibody, UV irradiation and heat shock 
in HEN-16-2/CDDP and HEN-16-2 cells. Cells were exposed to 0.5 J.lg/ml anti-Fas 
antibody for 24 h, heat shock at 45 °C for 45 minutes or 50 mJ/cm2 UV irradiation. Cells 
subjected to heat shock and UV irradiation were then returned to normal culture for 48 
hours. The percentage of viable cells was determined by trypan blue dye exclusion 
assays. Results represent the mean ± the standard deviation from three independent 
experiments. *, p < 0.05, is the statistical significance of the difference in cell viability 
between HEN-16-2 cells and HEN-16-2/CDDP cells. 
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HEN-16-2 HEN-16-2/CDDP 
Figure 3.12. Morphology ofHEN-16-2 and HEN-16-2/CDDP in monolayer culture. A. 
HEN-16-2 in KGM. B. HEN-16-2/CDDP in KGM. C. HEN-16-2 in DMEM. D. HEN-
16-2/CDDP in DMEM plus 10% FCS. All panels show light microscopy photos at the 
same magnification. 
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Figure 3.13. Growth rates of HEN-16-2 and HEN-16-2/CDDP cells in monolayer 
culture. Cells were grown in 60-mm plates in the indicated media. Each value represents 
the mean + the standard deviation from three individual experiments. 
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contrast, a different pattern was observed in serum-supplemented high calcium level 
DMEM. HEN-16-2 immortalized cells proliferated more slowly than the multidrug-
resistant cells. The doubling times ofHEN-16-2 and HEN-16-2/CDDP in DMEM were 
significantly different (p < 0.05) ( 44 hours and 34 hours, respectively). Further, there 
was a significant difference (p < 0.05) in the saturation densities of MDR cells and their 
parental cells in KGM (306 x 103 and 144 x 103 cells/em?, respectively); and in Dl\ffiM 
plus 10% FCS (333 x 103 and 55 x 103 cells/cm2, respectively) (Table 3.1). 
Table 3.1. Growth characteristics ofHEN-16-2/CDDP compared with HEN-16-2 cells 
Growth characteristic1 
Doubling time 
KGM 
DMEM+FCS 
Saturation density 
KGM 
Dl\ffiM+FCS 
Anchorage-independent growth 
HEN-16-2 
144± 10 
55±3 
44+10 
34+2* 
306 +65* 
333 + 32* 
+ 
1The values for the doubling time (hours), saturation density (x 103 cells/cm2}, are the mean± the standard deviation for three 
independent experiments. Anchorage-independent growth assays were conducted for three independent experiments. •, p < 
0.05, is the significance of the difference between the values for HEN-16-2/CDDP and HEN-16-2 cells. 
To further characterize the oncogenic phenotype, anchorage-independent growth in 
soft agar assays were performed, in which HEN-16-2 and HEN-16-2/CDDP cells were 
assayed for growth in soft agar for 2-3 weeks. HeLa cells and HEN-16-2T (Yang et al., 
1996a) served as positive controls. Generally, the formation of colonies could be 
observed after one week of incubation, and the colonies were unequivocally identified 
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after two weeks. The immortalized cells, HEN-16-2, remained as single cells and did not 
form colonies in soft agar (Figure 3.14B), whereas :MDR cells, HEN-16-2/CDDP, formed 
colonies (Figure 3.14A) that were similar to those formed from HEN-16-2T (Figure 
3.14C), but were smaller than those formed fromHeLa (Figure 3.14D). 
3.5. Tumorigenicity of MDR endocervical cells 
HEN-16-2, HEN-16-2/CDDP and positive control HeLa cells were injected into 
nude mice. Table 3.2 summarizes the results for each cell line. 
Table 3.2. Tumorigenicity ofHEN-16/CDDP compared with HEN-16-2 in nude mice 
Tumor incidence Tumor size 
Cell line Passage 
(No. tumors/no. injections) (cm2) 
HEN-16-2/CDDP 50-80 6/6 1.5-1.8 
HEN-16-2 50-80 0/6 N/A 
He La N/A 2/2 2.0-2.5 
All injections ofHEN-16-2/CDDP cells led to tumor formation in nude mice. The 
tumors were generally apparent after three weeks and continued to grow until the mice 
were sacrificed (Figure 3.15). HeLa cells also gave rise to tumors in all injected nude 
mice. None of the untreated immortalized cells induced tumors in nude mice after 2 
months, indicating that induction of tumors in nude mice was due to cisplatin treatment. 
Two tumors, formed from injection ofHEN-16-2/CDDP cells into nude mice, were 
examined histologically. Both tumors were invasive squamous cell carcinomas 
characterized by the loss of normal epithelial cell arrangement, growth into the mouse 
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HEN-16-2T He La 
Figure 3.14. Anchorage-independent (soft agar) growth ofHEN-16-2/CDDP. A. HEN-
16-2/CDDP. B. HEN-16-2. C. HEN-16-2T. D. HeLa. 
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2cm. 
Figure 3.15. HEN~ 16-2/CDDP tumorigenesis on nude mouse. 
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substratuin, high nucleus/cytoplasm ratio and high densities of chromtain staining 
(Figure 3.16). 
3.6. Expression of apoptosis-related cellular genes 
The levels of the apoptosis-promoting proteins p53, Bale, and Bax were examined 
by Western blot analysis. There was no significant difference in the levels of expression 
ofp53, Bale, or Bax between HEN-16-2 and HEN-16-2/CDDP (Figure 3.17 and Table 
3.3). 
Table 3.3. Expression of apoptosis-regulating proteins in HEN-16-2/CDDP 
compared withHEN-16-21 
Protein HEN-16-2 HEN-16-2/CDDP 
p53 1.0 + 0.3 0.8 + 0.5 
Bak 1.0 + 0.1 0.9 + 0.2 
Bax 1.0 + 0.3 1.0 +0.3 
Bcl-2 1.0 + 0.4 0.9 + 0.3 
Bcl-XL 1.0 + 0.1 1.7 + 0.2* 
BAG-1 p50 1.0 ± 0.2 22.9 ± 6.1* 
BAG-1 p46 1.0 ± 0.1 1.2 + 0.4 
BAG-1 p33 1.0 + 0.3 3.3 + 0.8* 
1The levels of cellular proteins were quantified relative to those of HEN-16-2 after normalization to actin control. 
Protein expression was quantified by measuring the optical density of bands at medium exposure on X-ray films. The 
data represent the mean ±: the standard deviation of three experiments. •, p < 0.05, is the significance of the difference 
between the values for HEN-16-2/CDDP and HEN-16-2 cells. 
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Figure 3.16. Histology of HEN-16-2/CDDP tumor. A. Squamous cell carcinomas 
formed in nude mice. B. Higher magnification showing dysplastic cells in a second 
tumor, demonstrating mitotic cells (arrowheads) proximal to the mouse substratum on the 
left. 
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Figure 3.17. Expression ofapoptosis-associated proteins in HEN-16-2/CDDP and HEN-
16-2 cells. Western blot analysis is shown for HEN-16-2 (left lanes) and HEN-16-
2/CDDP (right lanes). f3-actin was an internal control. 
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The expression of the anti-apoptotic protein Bcl-2 and BAG-I p46 isofonn was not 
significantly different between HEN-16-2 and HEN-16-2/CDDP cells (Figure 3.17 and 
Table 3.3). However, there was a significantly (p < 0.05) higher (1.7-fold) level of the 
expression ofBcl-XL in HEN-16-2/CDDP cells than in HEN-16-2 cells (Figure 3.17 and 
Table 3.3). The expressions of BAG-1 isoforms p50 and p33 were increased 
significantly (p < 0.05) from HEN-16-2 cells to HEN-16-2/CDDP cells, 22.9-fold and 
3.3-fold respectively (Figure 3.17 and Table 3.3). The shortest isoform ofBAG-1, p29, 
was not detectable in either of these two cell lines. 
3.7. Effect of overexpressing BAG-1 in C33A cervical cells on the sensitivity to 
apoptotic stimuli 
Having determined that a high-level of anti-apoptotic BAG-I expression was 
associated with insensitivity of HEN-16-2/CDDP cells to different cytotoxic drugs and 
other apoptotic stimuli, a potential role ofBAG-1 in the direct regulation of apoptosis in 
cervical cells was examined. The BAG-1 p50 stably transfected C33A cell line, C33A-
BAG-l, was kindly provided by Dr. Xiaolong Yang (Yang et al., 1999b). C33A-BAG-l 
cells overexpressing BAG-I (Figure 3.18) were found to be more resistant to cell death 
induced by cisplatin than C33A transfected with a control vector (C33A-NEO) (Figure 
3.19). Similarly, C33A-BAG-1 cells were more resistant to cell death induced by 
doxorubicin (Figure 3.20) and etoposide (Figure 3.21A) than the control cells. Moreover, 
C33A-BAG-1 cells were found to have a higher survival rate when exposed to heat shock 
or UV (Figure 3.21B) than the control cells. However, parallel studies indicated that 
95 
BAG-1 
.: ·..... ~ J3-actin _,.,.,.__~ 
Figure 3.18. BAG-I expression levels in C33A-BAG-l versus C33A-NEO cells. ~-actin 
was an internal control. 
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Figure 3.19. Effect of BAG-1 on dose- and time-dependent induction of apoptosis by 
cisplatin in C33A-BAG-1 versus C33A-NEO cells. The percentage of viable cells was 
determined by trypan blue dye exclusion assays. Results represent the mean + the 
standard deviation from three independent experiments. *, p < 0.05, is the statistical 
significance of the difference in cell viability between stably transfected NEO control 
cells and full-length BAG-1 overexpressing cells. A. Dose-dependence. Cells were 
treated with the indicated concentrations of cisplatin for 48 h. B. Time-dependence. 
Cells were exposed to 5 J.LM cisplatin for the indicated periods. 
97 
A 
-;fl. 
-
..!!! 
Q) 
(.) 
0,) 
:a 
as 
5 
B 
-;fl. 
-
..!!! 
Q) 
(.) 
Q) 
:0 
as 
> 
100 
80 
60 
40 
20 
0 _.___ 
100 
80 
60 
40 
20 
5.0 
Cisplatin (J.~.M) 
- C33A-NEO 
~ C33A-BAG-1 
---- C33A-NEO 
-o- C33A-BAG-1 
0 +---------------~------------------------------~~ 
0 24 48 72 
Time (hours) 
98 
Figure 3.20. Effect of BAG-1 on dose- and time-dependent induction of apoptosis by 
doxorubicin in C33A-BAG-1 versus C33A-NEO cells. The percentage of viable cells was 
determined by trypan blue dye exclusion assays. Results represent the mean + the 
standard deviation from three independent experiments. *, p < 0.05, is the statistical 
significance of the difference in cell viability between stably transfected NEO control 
cells and full-length BAG-1 overexpressing cells. A. Dose-dependence. Cells were 
treated with the indicated concentrations of doxorubicin for 48 h. B. Time-dependent. 
Cells were exposed to 1 J,.LM doxorubicin for the indicated periods. 
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Figure 3.21. Effect of BAG-1 on induction of apoptosis by etoposide, UV irradiation and 
heat shock in C33A-BAG-1 versus C33A-NEO cells. The percentage of viable cells was 
determined by trypan blue dye exclusion assays. Results represent the mean + the 
standard deviation from three independent experiments. *, p < 0.05, is the statistical 
significance of the difference in cell viability between stably transfected NEO control 
cells and full-length BAG-1 overexpressing cells. A. Dose-dependent induction of 
apoptosis by etoposide. Cells were treated with the indicated concentrations of etoposide 
for 48 h. B. Induction of cell death by UV irradiation and heat shock. Cells were 
subjected to heat shock at 45 °C for 45 minutes or 50 mJ/cm2 UV irradiation, and then 
were returned to normal culture for 48 hours. 
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overexpression of BAG-1 failed to protect the cervical C33A cells from apoptosis 
induced by actinomycin D or paclitaxel (Figure 3.22). 
3.8. Isolation and identification ofBAG-1-interacting proteins 
Previous studies have indicated that BAG-1 interacts with various proteins and 
modulates their functions (see section 1.4; Figure 1.7). It appears that BAG-1 plays an 
important role in signal transduction pathways in apoptosis. However, how BAG-1 
accomplishes these multiple functions is still unclear. To further characterize BAG-1 and 
understand its role in regulating apoptosis, screening a human keratinocyte eDNA library 
was conducted to clone novel BAG-1-interacting proteins using the yeast two-hybrid 
system. 
Because BAG-I full-length (p50) had not been cloned in the laboratory before the 
eDNA library screening, BAG-1 p46 isoform was used as bait for interacting proteins in 
the yeast two-hybrid system (Figure 3.23). 18 positive clones were isolated from 
approximately 2.5 x 106 yeast transformants. After verification of 17 positive clones 
(Figure 3.24), both strands of the eDNA obtained were sequenced and analyzed for 
sequence homology through the Basic Alignment Search Tool (BLAST} in the National 
Center for Biotechnology Information Sequence Databases. One 2406 bp and two 1822 
bp eDNA sequences obtained from positive clones were found to be Hsp 70 (Figure 
3.25A and Table 3.4). Two 2589 bp eDNA sequences obtained from positive clones was 
found to be Hsp70-2 (Figure 3.25B and Table 3.4). One 1832 bp and ten 1530 bp eDNA 
sequences obtained from positive clones were found to be Hsc70 pseudogene (Figure 
103 
Figure 3.22. Effect of BAG-1 on induction of apoptosis by actinomycin D and paclitaxel 
in C33A-BAG-1 versus C33A-NEO cells. Cells were seeded and incubated with the 
indicated concentrations of actinomycin D or paclitaxel for 48 hours. The percentage of 
viable cells was determined by trypan blue dye exclusion assays. Results represent the 
mean + the standard deviation from three independent experiments. *, p < 0.05, is the 
statistical significance of the difference in cell viability between stably transfected NEO 
control cells and full-length BAG-1 overexpressing cells. A. By actinomycin D. B. By 
paclitaxel. 
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Figure 3.23. Representative result of screening and identifying possible BAG-1-
interacting-protein positive clones from the yeast two hybrid system. A. Yeast colones 
on SD/-Trp/-Leu/-His agar plate. B. 13-galatosidase filter lift assay result (blue color) for 
the same colony indicated on A and B by arrows. 
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Figure 3.24. Representative results of verification of BAG-1-interacting-protein positive 
clones from the yeast two hybrid system. BAG-1 was the bait and lamin and pAS2-1 
vector plasmids was negative controls to verify the specificity of the interaction between 
BAG-1 and Hsp70Y. A. Yeast colones on SD/-Trp/-Leui-His agar plates. B. 13-
galatosidase filter lift assay result 
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Figure 3.25. BAG-1-interacting-protein cDNAs clones indentically to previously known 
sequences. A. Hsp70 (top) and two eDNA clones (bottom). B. Hsp70-2 (top) and a 
eDNA clone . C. Hsc70 pseudogene (top) and two eDNA clones (bottom). 
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3.25C and Table 3.4). Furthermore, one 5340 bp eDNA sequence was found to be 
identical to Hsc70 at the both 5' and 3' ends. However, the total length of the eDNA is 
much longer than Hsc70 mRNA, indicating that this eDNA may be different from Hsc70 
and any other Hsp70 genes. Therefore, this 5340 bp eDNA was a candidate novel heat 
shock protein (Hsp) gene _eDNA and arbitrarily named Hsp70Y (Figure 3.26 and Table 
3.4). 
Table 3.4. Positive BAG-1-interacting eDNA clones identified from Keratinocyte 
MATCHMAKE eDNA library using yeast two-hybrid system 
Identity Clone numbers Size (bp) 
Hsp70 1 2406 
2 1822 
Hsp70-2 2 2589 
Hsc70 pseudogene 1 1832 
10 1530 
Hsp70Y 1 5340 
3.9. Mutation analysis of BAG-1 functional domain for interaction with Hsp70 and 
Hsp70-2 
3.9.1. In vitro interaction 
The BAG-1 domains involved in the interaction of BAG-I with Hsp70 and Hsp70-2 
were characterzed using in vitro protein binding assays. GST -Hsp70 and GST -Hsp70-2 
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Figure 3.26. A candidate novel heat shock protein family member identifed as BAG-1-
interacting-protein. 
110 
were prepared (Figure 3.27). GST-BAG-1 wild-type and mutated fusion proteins were 
kindly provided by Dr. Xiaolong Yang. 35S-labeled in vitro transcribed/translated (IVT) 
proteins were prepared (Figure 3.28A and B). GST -fusion proteins immobilized on 
glutathione sepharose were tested for binding to 35S-labeled NT proteins. IVT -Hsp70 or 
IVT-Hsp70-2 bound in vitro to GST-BAG-1 p46 (amino acids 72 to 345), GST-BAG-1 
p33 (amino acids 116 to 345), GST-BAG-1 p29 (amino acids 139 to 345), GST-BAG-
1aN4 (amino acids 200 to 345), but not to GST-BAG-l~C1 (amino acids 72 to 320), 
GST-BAG-1~C2 (amino acids 72 to 219), GST-BAG-1~C3 (amino acids 72 to 156), or 
GST negative controls (Figure 3.29 and 3.30). Similarly, GST -Hsp70, or GST -Hsp70-2 
bound to NT -BAG-1 p50 (amino acids 1 to 345) but not to GST negative control (Figure 
3.31). These results indicated that all of the four isoforms ofBAG-1 are able to interact 
with Hsp70 or Hsp70-2 and the carboxyl-terminal 145 amino acids (amino acids 200 to 
345) are important in the mediation of the interaction. 
Hsp70 family members contain two major domains: the amino-terminal 44 kDa 
ATPase domain and carboxyl-terminal domain (Sriram et al., 1997). To determine 
whether the Hsp70 ATPase domain was responsible for the interaction between BAG-1 
and Hsp70, sequences encoding this Hsp70 ATPase domain were generated by PCR and 
inserted into the expression vector pCR3.1. IVT-Hsp70 ATPase domain was found to 
interact with GST-BAG-1 p50 (Figure 3.31). 
3.9.2. In vivo interaction 
The yeast two-hybrid system is highly sensitive, and can be used to assay the 
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Figure 3.27. GST-Hsp70 and GST-Hsp70-2 preparation. Bovine serum albumin (BSA) 
was used to determine the concentration of GST -Hsp70 or GST -Hsp70-2. A Coomassie 
Brilliant Blue R250 stained SDS-polyacrylamide gel is shown. 
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Figure 3.28. In vitro transcription/translation of proteins used in BAG-l-Hsp70s in vitro 
interaction assays. A. In vitro transcripted/translated Hsp70 (IVT -Hsp70) and Hsp70-2 
(IVT -Hsp70-2). Lysate was loaded as a negative control, and IVT -luciferase was positive 
control. B. In vitro transcripted/translated ATPase domain of Hsp70 [IVT-Hsp70 
(ATPase}], BAG-I p50 [IVT-BAG-1 (p50)], and BAG-I p46 [IVT-BAG-1 (p46)]. 
Lysate was loaded as a negative control, and IVT-Hsp70 was positive controL 
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Figure 3.29. In vitro assay of interaction between Hsp70 and BAG-1. GST protein was 
used as a negative controL IVT-Hsp70 was directly loaded as positive control. 
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interaction of short peptides with proteins. Moreover, the assays are performed in 
eukaryotic yeast cells, which produce proteins with a conformation more closely 
resembling human proteins than those produced in the bacterial system. To further 
characterize the structural domain of BAG-1 responsible for the interaction between 
BAG-1 and Hsp70 or Hsp70-2, BAG-1 p50, p46, p33 and p29 isoforms, and a series of 
nested BAG-1 deletion mutations were generated by PCR (Figure 3.32) and inserted in-
frame with the GAL4 BD to the pAS2-1 plasmid. The interaction of the different 
isoforms and deletion mutations of BAG-1 with Hsp70 was detected by the yeast two-
hybrid system (Figure 3.33). Table 3.5 summarizes the interactions in the yeast two-
hybrid system. These results indicated that the carboxyl-terminal 30 amino acids from 
315 to 345 are responsible for the interaction between BAG-I and Hsp70 or Hsp70-2. 
3.10. Effect ofBAG-1 on Hsp70s-mediated protein refolding activity in vivo 
To examine whether the interaction of BAG-1 with Hsp70 chaperones affects 
Hsp70 chaperone-mediated protein refolding function, C33A-BAG-1 and C33A-NEO 
cells were transiently transfected with plasmids expressing luciferase and ~­
galactosidase. The luciferase and ~-galactosidase expressing cells were subjected to 
heat-shock to partially inactivate luciferase and ~-galactosidase enzymatic activity. After 
returning the cells to 37 °C for 30 minutes, luciferase activity in C33A-BAG-1 cells was 
1.68 fold compared to that before recovery. After 60 minutes, luciferase activity ·was 
1.83 fold that prior to recovery. In comparison, luciferase activity in C33A-NEO cells 
was 1.37 fold and 1.42 fold at 30 minutes and 60 minutes after recovery. Thus, 
117 
bp 
2036-
1636-
1018-
506-
396-
344-
298-
220-
134-
\0 
v 
c.. 
...... ~ ~ I 
0 ...... N 
< z z I:Q <I <I 
~ ~ ~ ~ ~ ~ ~ ~ ("ti v V'l N ("ti v V'l z z z u u u u u 
<I <I <I <I <I <I <I <I 
Figure 3.32. Analysis of PCR products of BAG-1 isoforms and deletion mutants. 
An ethidium bromide-stained agarose gel is shown. 
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A 
B 
pACT2-Hsp70 
pAS2-l-BAG-I ~3 
pACT2-Hsp70 
pAS2-l-BAG-lA2 
pACT2-Hsp70 
pAS2-l-BAG-1~8 
pACT2-Hsp70 
pAS2-l-BAG-IA7 
pACT2-Hsp70 
pAS2-l-BAG-l p50 
pACT2-Hsp70 
pAS2-I-BAG-1Al 
pACT2-Hsp70 
pAS2-l 
pACT2-Hsp70 
pAS2-I-BAG-1A6 
pACT2-Hsp70 
pAS2-l-BAG-I p33 
pACT2-Hsp70 
pAS2-l-BAG-l p29 
pACT2-Hsp70 
pAS2-l-BAG-IA4 
pACT2-Hsp70 
pAS2-l-BAG-IA5 
Figure 3.33. In vivo interaction between BAG-I deletion mutants and Hsp70. r3-
galactosidase filter lift assays. A. Interactions between Hsp70 and BAG-1 isoforms and 
BAG-1~1, t1.2 and ~3 mutants were detected. B. No interaction between Hsp70 and 
BAG-1 ~4 to t1.8 mutants was detected. 
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Table 3.5. Deletion mutation analysis of the functional domain of human BAG-I 
binding with Hsp70 or Hsp70-2 in the yeast two-hybrid system 
Plasmid (amino acids) 
-
pACT2 pACT2- pACT2-
Hsp70 Hsp70-2 
- ND 
- - -
pAS2-1 (-) 
- - - -
pAS2-l-BAG-1 p50 (1-345) 
- -
+ + 
pAS2-1-BAG-1 p46 (72-345) 
- -
+ + 
pAS2-1-BAG-1 p33 (116-345) 
- - + + 
pAS2-1- BAG-1 p29 (139-345) 
- - + + 
pAS2-l-BAG-1~1 (200-345) - - + + 
pAS2-1-BAG-l~ (286-345) - - + + 
pAS2-l-BAG-l~ (315-345) - - + + 
pAS2-1-BAG-184 (72-320) - - - -
pAS2-l-BAG-1.6.5 (72-291) 
- - - -
pAS2-l-BAG-1~6 (72-215) - - - -
pAS2-l-BAG-187 (72-156) - - - -
pAS2-l-BAG-1.6.8 (72-121) - - - -
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overexpression of BAG-1 in C33A-BAG-1 cells (Figure 3.18) led to a small, but 
significant increase in luciferase refolding (Figure 3.34A). Similarly, the expression of 
BAG-1 led to a small but significant increase in the refolding of J3-galactosidase, 
compared with that of C33A-NEO control cells (Figure 3.34B). ~-Galactosidase activity 
in C33A-BAG-1 was found to recover 1.59 fold BAG-1 after refolding for 30 minutes 
and 1.90 fold after refolding for 60 minutes, whereas J3-galactosidase activity in C33A-
NEO recovered only 1.05 fold and 1.28 fold at 30 and 60 minutes, respectively (Figure 
3.34B). 
3.11. Effect of overexpression of Hsp70 or Hsp70-2 in cervical C33A ceUs on 
sensitivity to apoptotic stimuli 
Although induction of hsp70 protein synthesis led to an enhancement of apoptosis 
in human leukemia cells (Chant et al., 1996) and other cell types (Murdoch, 1995; Furlini 
et al., 1994, Galea-Lauri et al., 1996), Hsp70 chaperones are thought to play 
cytoprotective roles in most types of cells during times of stress by inhibiting apoptosis 
(Palla et al., 1996). 
To determine the role of Hsp70 in cervical cell apoptosis, C33A cells were 
transfected with a plasmid expressing Hsp70 (pCR3.1-Hsp70) or Hsp70-2 (pCR3.1-
Hsp70-2), or the control plasmid (pCR3.1), and stable clones overexpressing Hsp70s 
were obtained (Figure 3 .35). 
When challenged with 45 minutes of heat shock at 45°C, C33A cells 
overexpressing Hsp70s displayed enhanced survival compared with control transfectants 
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Figure 3.34. Effect of BAG-I on In vivo protein refolding in C33A cells following heat 
shock. BAG-I promotes Hsp70s mediated refolding of denatured luciferase and f3-
galactosidase in vivo. C33A-NEO and C33A-BAG-1 cells were transiently transfected 
with pSV-luciferase and pSV-(3-galactosidase. One day after transfection, cells were 
distributed into cell culture tubes and cultured for one more day, and then subjected to 
42°C heat shock for 45 minutes. After returning cells to 3 7°C culture for 30 minutes or 
60 minutes to allow protein refolding, the cells were lysed for detection of enzymatic 
activity. The luciferase or ~-galactosidase activities before heat shock were taken as 
100%. Results represent the mean + the standard deviation from three independent 
experiments. *, p < 0.05, is the statistical significance of the difference in relative 
enzymatic activity between stably transfected NEO control cells and full-length BAG-I 
overexpressing cells. A. luciferase. B. (3-galactosidase. 
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Hsp70s· 
f3-actin 
Figure 3.35. Hsp70s protein expression in C33A-hsp70 and C33A-hsp70-2. (3-actin was 
an internal control. 
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(Figure 3.36). It was also found that Hsp70s overexpression led to the inhi.oition of cell 
death induced by various chemotherapeutic drugs and UV irradiation (Figure 3.36). 
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Figure 3.36. Effect of overexpressing of Hsp70s on induction of apoptosis by 
different agents. Cells exposed to heat shock at 45 °C for 45 minutes or 50 mJ/cm2 UV 
irradiation and then returned to 3 7 °C culture for 48 hours. Cells were also treated with 5 
J.1.M cisplatin, 0.25 J.LM doxorubicin, 40 J.LM paclitaxel, 25 nM actinomycin D or 20 J.lM 
etoposide for 48 hours. The percentage of viable cells was determined by trypan blue dye 
exclusion assays. Results represent the mean + the standard deviation from three 
independent experiments. *, p < 0.05, is the statistical significance of the difference in 
cell viability between stably transfected NEO control cells and full-length BAG-1 
overexpressing cells. 
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CHAPTER4 
DISCUSSION AND FUTURE DIRECTIONS 
4.1. Cisplatin treatment of human endocervical cells immortalized by HPV16 and 
the multidrug-resistant phenotype 
Cisplatin was discovered in the 1800s. Its biologic activity was first noted by 
Rosenberg in 1961. After multiple preclinical trials, it was released for clinical use in 
1972 (Eustace, 1980). Since that time, it has become one of the most commonly used 
chemotherapy drugs and it is efficacious in a multitude of cancers. 
Cisplatin is one of the most effective chemotherapeutic agents in treating cervical 
cancer. However, the response to cisplatin is generally short in duration, and acquired 
drug resistance is the greatest obstacle to the success of chemotherapy. 
The cellular mechanisms of drug resistance depend upon altered levels or function 
of key gene products. These alterations may result from changes that occur at any point 
along the pathways of gene expression and regulation. Indeed, multiple molecular 
processes have been shown to be involved in examples of drug resistance, including 
altered drug influx and efflux, altered drug metabolism, altered drug targets, and altered 
cellular response to their damage (see section 1.2). The prevalence of these changes 
reflects the phenotypic and genetic instability of cancer cells under the mutagenic 
pressure of antineoplastic agents. This acquired drug resistance may result from the 
selection of clones originally insensitive to the drug or from the induction of resistance 
through the disruption or modulation of gene expression. 
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The endocervix is the origin of over 95% of cervical tumors. A human 
endocervical in vitro system has been used to study the role ofHPV in the oncogenesis of 
endocervical cancer. It has provided the direct evidence that linked HPV to 
immortalization and further transformation of the HPV -immortalized cervical cells by 
carcinogens including smoking (Yang 1996a). In vitro endocervical AIDR systems, 
however, have not yet been established to mimic and study acquired MDR in 
endocervical cancers. 
The sensitivity to chemotherapeutic drugs is determined by a variety of cellular 
factors, including drug uptake and retention, ability to repair damage and propensity to 
undergo irreversible growth arrest or apoptosis. Drug treatment can inhibit tumor growth 
in at least two distinct ways: irreversible growth arrest and apoptosis. Irreparable damage 
to chromosomes prevents cell division, and therefore cells will no longer be able to 
generate progeny. This process occurs in all cell types and is sometimes referred to as 
mitotic death. In some cell types, the cellular damage may trigger apoptosis. For both 
effects of drug treatment, the indicator for success or failure of anti-cancer therapy is 
whether cells can survive the onslaught of drug treatment and retain the capacity to 
divide. Therefore, drug resistance of tumors is often determined by clonogenic survival of 
drug-treated cells. 
As was expected, our clonogenic survival assays indicated that the cisplatin-treated 
endocervical cells acquired resistance to cisplatin (Figure 3.1A). Moreover, these 
cisplatin-resistant cells also acquired cross-resistance to paclitaxel (Figure 3.1B), an 
anticancer drug structurally and functionally different from cisplatin. Therefore, cisplatin 
128 
treatment of human endocervical cells immortalized by HPV16 conferred an 1\IDR 
phenotype. 
An in vitro endocervical cell system mimicking drug-resistance acquisition in vivo 
will be advantageous to study the molecular mechanism underlying the development of 
drug resistance. However, in vitro cell monolayers and in vivo epithelia are markedly 
different. The status and expression of HPV genes, three-dimensional cell-cell 
interactions and other cofactors, such as hormones, growth factors and the host immune 
surveillance, are some key differences (Herrington, 1995). Despite this limitation, the in 
vitro model system in this study remains a useful model to analyze the cellular 
mechanisms of acquired 1\IIDR in cervical cancer, particularly in understanding the role of 
apoptosis in endocervical cells carcinogenesis and acquired MDR. 
4.2. Response of endocervical MDR ceUs and parental ceUs to various apoptotic 
stimuli 
Clinical studies with patients suffering from acute myeloid leukemia have 
identified a correlation between high levels ofBcl-2 protein and a poor prognosis for the 
outcome of chemotherapy (Campos et al., 1993). Also, experiments have shown that 
over-expression of Bcl-2 or the absence of p53 can significantly increase clonogenic 
survival of at least some types of tumour cells after radiation or drug treatment (Lowe et 
al., 1993a; b; Strasser et al., 1994). These results provide evidence that abnormalities in 
apoptosis control can influence the sensitivity of cancer cells to chemotherapeutic drugs 
(section 1.2.2.6). Overexpression of anti-apoptotic proteins in some types of cells causes 
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resistance to nearly all apoptotic stimuli, conferring an MDR phenotype that differs from 
other types of drug-resistance mechanisms (Reed, 1998b). 
To determine whether the inhibition of apoptosis is the major mechanism of the 
MDR of endocervical cells, HEN-16-2/CDDP, further experiments were conducted to 
study the response of multidrug resistant endocervical cells and their parental cells to 
various apoptotic stimuli, including therapeutic drugs, heat shock, UV light irradiation 
and anti-Fas antibody. 
4.2.1. Induction of apoptosis by cancer chemotherapeutic agents 
In a study investigating the mechanism of action of etoposide (a topo II inhibitor), it 
was found that etoposide induced intemucleosomal DNA fragmentation (Kaufi:nann, 
1989). This observation raised the possibility that etoposide causes apoptosis. Since 
then, the spectrum of chemotherapy agents causing apoptosis has expanded, and the 
evidence supporting the role of apoptosis in chemotherapy continues to accumulate. The 
chemotherapeutic agents that have been identified as apoptosis-inducing include 
etoposide, dexamethasone, cisplatin, paclitaxel, 5-FU, doxorubicin ATRA and 4-HPR 
(Kaufinann, 1989; Walker et al., 1991; Shinomiya et al., 1994; Havrilesky et al., 1995; 
Huschtscha et al., 1996). The occurrence of apoptosis has been documented by 
demonstration of endonucleosomal DNA breakdown and other biochemical and 
morphologic criteria of apoptosis. 
In vivo studies have also provided evidence that chemotherapeutic agents induce 
apoptotic tumor cell death. For example, a retinoic acid-treated T -cell lymphoma was 
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shown to undergo apoptosis in vivo (Su et al., 1993). In a study of esophageal squamous 
cell carcinoma, it was shown that both radiation and chemotherapy (5-FU, cisplatin, and 
bleomycin) induced apoptotic cell death in vivo, as determined by examination of biopsy 
specimens (Moreira et al., 1995). In vitro and in vivo studies clearly show the induction 
of apoptosis by chemotherapeutic agents in various cell lines and tumors. In this study, 
compared with HEN-16-2, endocervical :MDR HEN-16-2/CDDP cells showed a 
significant inhibition of apoptosis induced by cisplatin (Figure 3.2 and 3.3), actinomycin 
D (Figure 3.5), doxorubicin (Figure 3.6), etoposide (Figure 3.7), paclitaxel (Figure 3.8), 
5-FU (Figure 3.9A), staurosporine (Figure 3.9B), ATRA (Figure 3.10A) and 4-HPR 
(Figure 3.10B). These result suggest that inhibition ofapoptosis might be responsible for 
the :MDR phenotype ofHEN-16-2/CDDP cells. 
4.2.2. Induction of apoptosis by UV irradiation 
A variety of extrinsic and intrinsic signals can trigger apoptosis, including 
environmental stress such as UV (Sachs and Lotem, 1993; Buttke and Sandstrom, 1994; 
Kyriakis et a/., 1994; Thompson, 1995). In this study, HEN-16-2/CDDP showed 
inhibition of apoptosis induced by 50 m.J/cm2 dose UV (Figure 3.11), further suggesting 
that the phenotype of this MDR of human endocervical cells may be due to the inhibition 
of apoptosis, rather than by overexpression ofPgp or other classic MDR proteins. 
4.2.3. Induction of apoptosis by heat shock 
The spectrum of tissue susceptibility to apoptosis induction by heat shock is 
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essentially similar to cancer therapeutic agents and radiation (Allan and Harmon, 1986; 
Barry et al., 1990; Sellins and Coh~ 1991; Takano et al., 1991;). In this study, HEN-
16-2/CDDP cells were more resistant than parental cells to apoptosis induced by heat 
shock at 45 °C for 45 minutes (Figure 3.11). This result supports the concept that 
inhibition of apoptosis may cause the MDR phenotype found in human endocervical 
cells. 
4.2.4. Induction of apoptosis by anti-Fas antibody 
Fas (also called CD95), a receptor for Fas ligand (FasL), belongs to the TNF 
receptor family, and transduces the FasL apoptotic signal into cells (Nagata and Golstein, 
1995). The molecular mechanism for Pas-induced apoptosis is currently being 
elucidated. Aggregation of the Fas receptor by binding to FasL, or by crosslinking with 
an anti-Fas antibody induces the formation of a death-inducing signaling complex (DISC) 
of proteins composed of Fas, an adaptor called F ADD, and the inactive pro form of 
caspase-8 (K.ischkel et al., 1995; Nuiiez et al., 1998). Oligomerization ofprocaspase-8 in 
DISC seems to induce self-processing into the mature, active, p20 and p 10 subunits of 
caspase-8 protease. The activated caspase-8 is then released from DISC, and activates 
other downstream caspases by proteolytic cleavage of their zymogen forms (Medema et 
al., 1997). 
In many cells, overexpression of anti-apoptotic proteins, such as Bcl-2 and Bcl-XL, 
inhibits apoptosis induced by a variety of stimuli, including anti-Fas antibody (Cory, 
1995; Korsmeyer, 1995; Reed, 1997). Consistently, the cell death rate induced by anti-
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Fas antibody is less in HEN-16-2/CDDP cells than HEN-16-2 cells (Figure 3.11), further 
suggesting that resistance of HEN-16-2/CDDP to multiple drugs is due to the 
dysregulation in apoptosis pathways, but less likely due to the enhanced drug effiux, 
enhanced drug detoxification, altered drug targets, or altered cellular damage repair. 
4.3. Evidence of tumorigenicity of cervical cells by anticancer drug cisplatin 
It has been well recognized that cervical carcinogenesis is a multistage process in 
which HPV and other co-factors are necessary for the full malignant transformation of 
primary cervical cells (zur Hausen, 1991; 1994; Herrington, 1995). Many carcinogens, 
such as those in cigarette smoke, have been demonstrated to be risk factors for cervical 
cancer (Phillips and Smith, 1994; Yang, et al., 1996a; Nakao et al., 1996). 
The HEN-16-2/CDDP cell line possesses the general growth characteristics of 
cervical tumors (Li eta/., 1992): faster growth in medium containing serum and a high 
calcium level, higher saturation density, and anchorage-independent growth (Figures 
3.13, 14 and Table 3.1). Moreover, HEN-16-2/CDDP cells formed tumors in nude mice, 
whereas a similar passage of untreated HEN-16-2 cells remained non-tumorigenic in 
nude mice (Figure 3.15 and Table 3.2). These results provided the first in vitro evidence 
that cisplatin treatment can further transform HPV -immortalized endocervical cells, 
supporting the hypothesis that cisplatin has carcinogenic potential (Greene, 1992). 
The carcinogenic potential of drugs used in cancer therapy has been recognized for 
decades {Haddow eta/., 1948). In laboratory animals, cisplatin has been found to produce 
malignancies, notably acute leukemia (Kaldor eta/., 1988, Barnhart and Bowden, 1985; 
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Kempf and Ivankovic, 1986). Cisplatin-associated second malignancies were found to 
develop in many cancer patients (see review Green, 1992). 
DNA damage upon cisplatin treatment may occur in both neoplastic and non-
neoplastic cells. Lethal injury to neoplastic cells is obviously the desired effect; however, 
non-neoplastic cells may also be killed or damaged. If the nonlethal DNA damage in 
normal cells can be faithfully repaired, the cells return to normaL However, if the 
cellular damage cannot be repaired, normal cells will undergo apoptosis. Alternatively, 
the damaged cells may have undergone initial stages of oncogenic progression. Such 
cells may enter the cell cycle again without DNA damage repair, thus mutation occurs in 
these cells. Then, if the accumulated mutations cause an upregulation of cell 
proliferation or downregulation of apoptosis, new primary neoplastic cells can arise. 
Carcinoma in situ can then progress to invasion and metastasis if the host defenses are 
compromised. 
When the HPV16 E6 protein is expressed in cervical cells, baseline p53 protein 
levels are reduced dramatically following ubiquitin-mediated proteolysis through 
interaction with E6 (section 1.3.2). This causes the loss of cell cycle arrest following 
DNA damage (Kessis et al., 1993; Demers et al., 1994; Foster et al., 1994; Hickman et 
al., 1994; Slebos et al., 1994). Inactivation ofp53 by the HPV16 E6 protein was found to 
increase the rate of mutagenesis (Havre et al., 1995). Thus, the inactivation of p53 
function by HPV16 E6 in HEN-16-2 cells allows the survival of cells mutated by 
cisplatin treatment that would otherwise be eliminated by apoptosis. 
Therefore, high-risk HPV s may indirectly contribute to cervical tumorigenesis by 
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11romoting genomic instability and the accumulation of mutations in HPV -infected cells 
after treatment with cisplatin. 
In view of the fact that many human premalignancies contain disabled or 
dysregulated genes such as p53 that effectively induce apoptosis or Bcl-2 that effectively 
block apoptosis, clonogenic cells surviving such genotoxic treatment in vivo are likely to 
induce mutations contributing to progression of a benign disease as a paradoxical 
consequence of attempts to eradicate a malignant one. Therefore, the use of carcinogenic 
drugs for cancer treatment needs clear justification according to the susceptibility of cells 
to the DNA-damage-induced apoptosis versus oncogenic mutation. The benefits from the 
cancer therapy should be carefully evaluated. Abrogation of apoptosis provides a double 
hazard of tumorigenicity and multidrug-resistance in the face of genotoxic therapy, such 
as cisplatin. 
4.4. Role of apoptosis-related cellular genes in multidrug resistance and 
tumorigenesis of human endocervical ceUs 
Recent clinical studies have shown a strong correlation between apoptosis and 
:progression of premalignant cervical lesions (lsacson et al., 1996; Shoji et al., 1996). 
Cellular, but not HPV, genes regulating apoptosis such as the bcl-2 family, are considered 
t~ be important for this correlation (Shoji et al., 1996; Pillai er al., 1996; Yang et al., 
1998b ). However, the precise role of apoptosis-associated genes in this oncogenic 
progression is still poorly understood. One purpose of this study was to determine 
whether the expression of apoptosis-associated proteins varied during the process of 
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acquired MDR and tumorigenesis induced by the anticancer drug cisplatin. The 
expression of these anti-apoptotic proteins, Bcl-XL and BAG-1 p50 and p33 isoforms, 
increased significantly in HEN-16-2/CDDP, indicating that these proteins may be 
involved in the aquired MDR and tumorigenesis of human endocervical cells. In 
contrast, the levels of the apoptosis-promoting proteins p53, Bak, and Bax varied little 
when the expression of each was compared inHEN-16-2 andHEN-16-2/CDDP. 
Deletions or mutations of the tumor suppressor gene, p53, have been detected in a 
majority of various common human cancers (Hollstein et al., 1991; Levine et al., 1991; 
Levine, 1997). p53 was found to play an important role in apoptosis; for example, the p53 
protein is required for DNA damage-induced apoptosis in lymphocytes and colonic 
epithelial cells (Clarke et al., 1993; Lowe et al., 1993a; Clarke et al., 1994; Strasser et al., 
1994). Loss of p53 function was reported to cause resistance to apoptosis induced by 
DNA-damaging reagents in various human cells (Zhan et al., 1994). Conversely, 
overexpression of p53 was shown to induce apoptosis in certain cell types (Oren, 1994; 
Yonish-Rouach et al., 1991; 1995). It has become clear that the p53 response varies not 
only according to the insulting stimulus but also according to the tissue and cell type 
involved (Midgley et al., 1995; MacCallum et al., 1996). Although much data regarding 
p53 is now available (over 10,000 p53-related papers published since 1992), the precise 
mechanism of p53 function is still uncertain. 
Since p53 expression varied little in HEN-16-2 and HEN-16-2/CDDP (Figure 3.17 
and Table 3.3), expression levels ofBax and Bak: were examined. They are Bcl-2 family 
members that antagonize the function ofBcl-2 and promote apoptosis under conditions of 
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stress (Oltvai et a/., 1993). Bax was shown to be downstream of p53 and transactivated 
by p53 (Miyashita et al., 1994; 1995). Like p53, Bax can function as a tumor-suppressor 
gene by inducing apoptosis in tumor cells (Yin et al., 1997). In support of this 
hypothesis, inactivation ofBax accelerated transformation of epithelial cells in transgenic 
mice expressing a truncated SV 40 large T antigen that inactivates the tumor suppressor 
pRB but not p53 (Yin et al., 1997). Bax and Bcl-2 appear to have intrinsic independent 
functions as effectors of apoptosis and survival, respectively. The evidence includes 
observations of mutants of Bax and Bcl-2 that are incapable of dim.erizing, but still 
display antagonistic activity towards each other and remain capable of inducing or 
repressing apoptosis, respectively (Cheng et al., 1996; Simonian et al., 1996a,b; 1997; 
Zha and Reed, 1997; Wang et al., 1998;). Experiments with knock-out mice 
demonstrated that Bax promoted cell death in the absence of Bcl-2 (Knudson and 
Korsmeyer, 1997). 
No changes were found in the expression of Bax or Bale proteins when comparing 
HEN-16-2 with HEN-16-2/CDDP cells (Figure 3.17 and Table 3.3), suggesting that 
dysregulation of apoptosis may not be caused by dysregulated expression of Bax or Bak. 
This was consistent with results using the HEN-16-2 cell line transformed by CSC (Yang 
et al., 1996a; 1998b ). 
Overexpression of Bcl-2 renders pre-B lymphocyte cells resistant to apoptosis 
(V aux et al., 1988). Recently, high levels of Bcl-2 mRNA or protein were found in 
neuroblastoma, lymphoma, breast, lung, prostate and cervical cancers (Haldar et al., 
1994; Ikegaki et al., 1994, Bargou et al., 1995, Liang et al., 1995; McDonnell et al., 
137 
1992; Reed et al., 1991; Yang et al., 1998b). However, no mutations in Bcl-2 were 
found. Overexpression of Bcl-2 was found to prevent cell death induced by a wide 
variety of apoptotic stimuli, including chemotherapeutic drugs (White, 1996; Reed, 
1994). The expression ofBcl-2 was found to be progressively enhanced after primary 
cells were immortalized by HPV16 and again after the immortalized cells were 
transformed by CSC (Yang et al., 1998b ), suggesting that abnormal activation of the Bcl-
2 gene was involved in cervical cell immortalization by HPV16 and late events of 
cervical tumorigenesis induced by CSC. In this study, however, the expression of Bcl-2 
was found to be not significantly different between HEN-16-2 and HEN-16-2/CDDP 
(Figure 3.17 and Table 3.3). Therefore, in HEN-16-2/CDDP cells, dysregulation of 
apoptosis may be caused by altered expression of other apoptosis-related genes. 
Two splice forms ofBcl-X , Bcl-XL and Bcl-Xs, have different functions: Bcl-XL is 
the longer form and has an anti-apoptotic effect, whereas Bcl-Xs is the shorter form and 
promotes apoptosis (Boise et al., 1993). Overexpression ofBcl-XL mRNA and protein 
was reported in human lung cancer cell lines, lymphomas, colorectal adenocarcinomas, 
gastric cancers and cervical cancers (Hirose et al., 1997; Krajewska et al., 1996; Kondo 
et al., 1996; Reeve et al., 1996; Xerri et al., 1996; Yang et al., 1998b). Bcl-XL was the 
predominant form of Bcl-X expressed in human cervical cells, and it was overexpressed. 
in both the HPV16-immortalized and the CSC-transformed cell lines; whereas the 
expression of Bcl-Xs protein was undetectable in all the cell lines (Yang et al., 1998b). 
Consistent with these observations, the expression of Bcl-XL was found to be higher in 
HEN-16-2/CDDP than HEN-16-2 cells (Figure 3.17 and Table 3.3). 
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BAG-1 is a gene which was isolated through the interaction of its protein with Bcl-
2 (section 1.4). Cotransfection of BAG-1 with Bcl-2 was shown to increase the 
protection from cell death induced by several stimuli, including staurosporine, anti-Fas 
antibody, cytolytic T cells, and cytokine withdrawal (Takayama et al., 1995; Clevenger et 
al., 1997). BAG-1 is not a member of the Bcl-2 family and may have unique function in 
protection from apoptosis. Overexpression of BAG-1 protected GM70 1 immortalized 
fibroblasts from heat shock-induced cell death, but did not similarly protect 293 human 
kidney epithelial cells {Takayama et al., 1997). 
Recently, BAG-1 was found to be overexpressed in human cervical carcinoma cell 
lines and tissues. Enhanced resistance to apoptosis induced by staurosporine was found to 
correlate well with expression of the BAG-1 p50 isoform in human cervical cells. 
Further study has indicated that the overexpression of BAG-1 p50 in cervical carcinoma 
C33A cells enhanced the resistance to apoptosis induced by staurosporine (Yang et al., 
1999b ). In agreement with these findings, the expression of BAG-I p50, and p33 
isoforms was higher in HEN-16-2/CDDP than in HEN-16-2. However, in HEN-16-2 
cells and HEN-16-2/CDDP cells, the expression level of the p46 isoform of BAG-1 is 
similar (Figure 3.17 and Table 3.3), and the shortest isoform of BAG-1, p29 was 
undetectable (Figure 3.17). 
Consistent with the effects of staurosporine, in this study, overexpression ofBAG-1 
p50 in cervical C33A cells conferred resistance to apoptosis induced by anticancer drugs 
including cisplatin, doxorubicin and etoposide (Figure 3.19, 20, 21). Also, this 
overexpression conferred resistance to apoptosis induced by UV and heat shock (Figure 
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3.21). However; it failed to protect C33A cells from apoptosis induced by two other 
anticancer drugs~ actinomycin D and Paclitaxel (Figure 3.22). To further determine 
whether BAG-1 or Bcl-XL play a direct role in the process of multidrug resistance and 
carcinogenesis of HPV16-immortalized endocervical cells, it would be interesting to 
overexpress Bcl-XL or BAG-1 different isoforms in HEN-16 cells and assay oncogenic 
properties and the pheotype of drug-resistance. 
The precise roles and mechanisms of BAG-1 in regulating apoptosis in cervical 
cells are complex and not well understood. Avenues to be considered are the functional 
interactions ofBAG-1 with other apoptosis-related proteins (Figure 1. 7). 
The recognition that the expression of apoptosis-related genes can be regulated by 
various biologic response modifiers, such as retinoids, cytokines, and growth factors, 
suggests opportunities for modulating apoptosis by combination chemotherapy. Because 
different chemotherapeutic agents have different mechanisms of action to induce 
apoptosis, it would be of interest to examine their efficacies in various combinations in 
the induction of apoptosis in HEN-16-2/CDDP cells. 
Alternatively, antisense approaches to downregulate protein expression could be 
envisioned. Indeed, sequence-specific down-regulation of Bcl-2 or Bcl-XL expression in 
vitro has been reported to markedly enhance sensitivity to chemotherapeutic drugs 
(Campos et al., 1994; Kitada et a/., 1994; Ziegler et al., 1997; Taylor et al., 1999). 
Therefore, it would be interesting to assay whether inhibition of BAG-1 or Bcl-XL 
expression by antisenses could sensitize the HEN-16-2/CDDP cells to apoptotic stimuli. 
Apoptosis is controlled through cellular genes including apoptosis-promoting genes 
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(p53, Bad, Bak Bax, Bcl-Xs. Bid, Bik Bim/Bod, Blk Bo~ Hrk/Dp5, Nip3 and Nik) and 
apoptosis-inhibiting genes (Bcl-2, Bcl-w. Bcl-XL Bjl-1, Mcl-1, and BAG-1) (for review, 
see Chao and Korsmeyer, 1998; Zamzami et al., 1998; Reed, 1998a). Alterations in these 
apoptosis-regulating gene products may have important roles in carcinogenesis and MDR 
in HEN-16-2/CDDP cells. Therefore, it could be interesting to further examine those 
apoptosis-related genes that have not yet been studied in HEN-16-2/CDDP. 
4.5. Identification ofHsp70 and Hsp70-2 chaperones as BAG-1 interacting proteins 
from a eDNA library using the yeast two-hybrid system 
The anti-apoptotic protein BAG-1 has been reported to form complexes with and 
modulate the functions of Bcl-2, the serine/threonine-specific protein kinase Raf-1, 
steroid hormone receptors, such as ER, AR., and GR, retinoic acid receptor (RAR), HGF 
and PDGF receptors, and Siah-IA (Takayama et al., 1995; Wang et al., 1996; Bardelli et 
al., 1996; Kullmann et al., 1998; Liu et al., 1998; Matsuzawa eta/., 1998; Froesch et al., 
1998; see section 1.4). These observations Suggest a general regulatory role for BAG-I 
in signal transduction pathways involved in cell survival and possibly other cellular 
processes as well. However, how BAG-1 accomplishes these multiple functions is still 
unclear. 
To further characterize and understand the role of BAG-I in regulating apoptosis, a 
eDNA library was screened for novel BAG-1 interacting proteins. Using BAG-1 p46 as 
bait in yeast two-hybrid screening, 17 human eDNA sequences of Hsp 70, Hsp 70-2, 
Hsc70 pseudogene and Hsp70Y were cloned (Table 3.4; Figure 3.25 and 3.26). Hsp70Y 
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was highly homologous to Hsc70 at its amino-terminal and carboxyl-terminal ends; 
however, the total length of Hsp70Y eDNA was much longer than Hsc70 mRNA, 
indicating that Hsp70Ywas a different gene from Hsc70 and any other Hsp70 genes, and 
therefore was a novel candidate Hsp (Figure 3.26). Since Hsp70Y was 5340 bp, the 
analysis of this gene is still ongoing. 
A variety of strategies, including Southwestern blots, phage display, and the yeast 
two-hybrid system, have been devised to screen large libraries for genes or fragments of 
genes whose products may interact with a protein of interest. The yeast two-hybrid 
system is an in vivo method that uses yeast GAL4 protein transcriptional activity as a 
screening method and an assay of exogenous protein-protein interactions (Fields and 
Song, 1989; Chien et al., 1991; Fields and Stemglanz, 1994; Figure 2.3; section 2.12.1). 
After the yeast two-hybrid system was developed and refined, various genes were 
identified through its use. In fac4 Hsc70/Hsp70 was identified to be BAG-1-interacting 
protein by Takayama et al.(1997) using mouse BAG-1 as bait in the yeast two-hybrid 
system, at the time that I independently identified Hsp70, Hsp70-2, and Hsp70Y to be 
BAG-1-interacting proteins using human BAG-1 p46 as bait in the yeast two-hybrid 
system (see sections 2.12 and 3.7). These independently reproducible results indicate the 
high efficiency and specificity of the yeast two-hybrid system to screen eDNA libraries. 
The yeast two-hybrid system has several advantages over other techniques for 
characterizing protein-protein interactions. First, it is highly sensitive, being able to 
detect weak and transient interactions that are not detected by other methods. Second, it 
enables not only identification of interacting proteins, but also the rapid cloning of genes 
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encoding these proteins. Moreover, because it is performed in vivo, the proteins 
produced in this euk:aryotic system are probably more similar to their counterparts 
produced in native cells than those produced in bacterial systems. 
The BAG-1 p50 isoform has 71 more amino-terminal amino acids compared to 
BAG-I p46. The BAG-1 p50 isoform. was reported to collaborate with AR, enhancing its 
transactivation function, whereas the BAG-1 p46 isoform did not (Froesch et al., 1998), 
indicating an important functional difference between the BAG-I p50 and p46 isoforms. 
Therefore, it would be valuable to screen a eDNA library using BAG-1 p50, or even 
using the amino-terminal fragment as bait in the yeast two-hybrid system. eDNA 
encoding proteins that would include, but would not be limited to, AR should be 
identified as BAG-1 p50 isoform amino-terminal domain binding proteins. 
Although BAG-1 was initially identified as a Bcl-2-binding protein, attempts to 
demonstrate interactions between BAG-1 and Bcl-2 using purified proteins have not been 
successful. It is possible that BAG-1 interacts with Bcl-2 using Hsp70 chaperones or 
other proteins as adaptors. 
A novel yeast system based on the yeast two-hybrid system, termed the yeast three-
hybrid system, has been recently used to identify interactions among three proteins 
(Licitra and Liu, 1996), and this system appears to be a potentially useful tool to further 
characterize BAG-1. Because it is possible that BAG-I indirectly interacts with other 
proteins using Hsp70 chaperones as adaptors, BAG-1 could be expressed as a fusion 
protein with the GAL4 BD, and Hsp70 could be conditionally expressed from the Pmet25 
promoter in pBridge plasmid (Figure 4.1). The GAL4 AD fusion protein from a eDNA 
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Hbrary (the same eDNA library that was used in the yeast two-hybrid system), would 
then be screened, as for the yeast two-hybrid system (Figure 4.1). 
It is also possible that interactions between Hsp70 chaperones and BAG-1 may 
confer a BAG-1 conformation that facilitates the direct interaction of BAG-1 with other 
proteins. In this case, the yeast three-hybrid method described above would be useful to 
identify and clone these proteins and characterize their interactions. However, Hsp70 
would need to be inserted in-frame with GAL4 BD, whereas BAG-1 would be 
conditionally expressed from the P met25 promoter pBridge plasmid. 
4.6. Region ofBAG-1 interacting with Hsp70 and Hsp70-2 
Human BAG-1 contains several structural domains that have the potential to be 
involved in protein-protein interactions (Dr. Xiaolong Yang, unpublished data). There is 
an a.-helical domain located between amino acids 225 and 261. The a-helical domain is a 
structure with potential for mediating protein-protein interactions (Muchmore et al., 
1996). In addition, there is a ubiquitin-like domain located between amino acids 163 and 
199. The ubiquitin-like domain is also a candidate for facilitating protein-protein 
interaction, since ubiquitin is involved in interactions with many proteins through this 
domain on target proteins (for review, see Hershko and Ciechanover, 1992). The yeast 
two-hybrid system results demonstrated that the BAG-1 carboxyl-terminal amino acids 
315 to 345 are responsible for the interaction with Hsp70 and Hsp70-2 (Figure 3.33 and 
Table 3.5). These findings confirmed the result of in vitro binding assays (Figure 3.29; 
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Figure 4.1 
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3.30; 3.31). My results are consistent with those of other independent studies (Takayama 
et al., 1997; Zeiner et al., 1997). Recently, the BAG-1 carboxyl-terminal domain 
responsible for interaction with Hsp70 chaperones was demonstrated to be located in a 
domain conserved among BAG-1 family members {Takayama et al., 1999). 
4.7. BAG-1 modulation ofHsp70s chaperone activity 
Exposure of cells to sublethal temperature or other stress induces the synthesis and 
accumulation in the cytoplasm of a set of proteins, collectively known as Hsps which 
subsequently makes the cells resistant to normally lethal temperatures or to other forms 
of cellular injury (Lindquist, 1986; Parsell and Lindquist, 1993). These phylogenetically 
similar and highly conserved proteins function as enhancers of cell survival and behave 
as molecular protein chaperones at the biochemical leveL Hsps bind to nascent or 
misfolded polypeptides under normal conditions or to denatured proteins created under 
the influence of physical agents, leading either to their correct folding or to rapid 
elimination (Beckmann et al., 1990; Parsell and Lindquist, 1993; Welch, 1993). 
The family of Hsp70 molecular chaperones are known to play key roles in 
protecting mammalian cells. The ATP-bound form of Hsp70 binds and releases 
polypeptides or proteins quickly, whereas the ADP-bound form maintains tight binding to 
substrates (Flynn et al., 1989; Palleros et al., 1991; Schmid et al., 1994). BAG-I has 
been suggested to have the activity of a nucleotide exchange factor for Hsp 70 chaperones 
in vitro, analogous to the role of GrpE in the bacterial DnaK/DnaJ cycle (Hohfeld and 
Jentsch, 1997). In contrast, other data indicated that BAG-1 was a negative regulator of 
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Hsp70 chaperone activity in vitro (Takayama et al., 1997; Zeiner et al., 1997; Bimston et 
al., 1998). However, the in vitro conditions, such as ATP concentration in the reaction 
buffer of these experiments were different. 
These contradictory results suggest that BAG-1 could either inhibit or promote the 
ATPase activity of Hsp70 chaperones probably dependent on the reagent composition 
and levels in the interaction buffer, and thus modulate the Hsp70s-mediated refolding of 
thermally denatured proteins. Thus far, the precise mechanisms by which BAG-1 
regulates Hsp70s-mediated refolding activity in vitro remain unclear. 
In my in vivo experiments, after heat shock, luciferase and J3-galactosidase in C33A 
human cervical carcinoma cells were denatured, and had reduced levels of enzymatic 
activity. After returning to normal culture conditions, it appears that the expression of 
BAG-1 protein led to a small but significant increase in the refolding of luciferase and P-
galactosidase, compared with C33A-NEO control cells (Figure 3.34A and B). 
The chaperone function of the mammalian Hsp70s is modulated by their physical 
interactions with other proteins. This modulation involves cooperation among multiple 
chaperone cofactors in complexes that include Hsp70s, Hsp40, Hip, Hop, CHIP and 
BAG-1 (Hohfeld, 1998; Kelley, 1998; Ballinger et al., 1999). 
A recent study found that the carboxyl terminal domain of BAG-1, which was 
responsible for the interaction with Hsp70s, was conserved among several novel BAG-1 
family members, including BAG-2 and BAG-3 (Takayama et al., 1999). This 
observation suggested that the modulation of Hsp70s-mediated protein refolding activity 
by BAG-I may be redundantly shared with other novel BAG-1 family members. 
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Moreover, different cell types have distinct intracellular contexts, which could also affect 
the Hsp70s-mediated protein refolding activity. To delineate a general mechanism 
whereby BAG-1 modulates Hsp70s-mediated protein refolding in vivo, other cell types 
will also need to be studied. 
Hsp70 chaperones are multiple function proteins, and play a role in signal 
transduction pathways, which lead to adaption to stressful conditions in cells and 
organisms. Evidence has accumulated for their participation in regulating the activity of 
signaling proteins (Kimura et al., 1995), such as the steroid receptors (Picard et al., 1990; 
Tsai et al., 1994; Nathan and Lindquist, 1995) and Ras and Rafkinases (Stancato et al., 
1993). Therefore, it would be interesting to investigate how BAG-1 regulates other 
functions of Hsp70s, such as protein complex assembly, translocation and Hsp70-
associated protein-ubiquitin-proteasome pathway protein-degradation. 
4.8. The role of Hsp70s in inhibition of apoptosis 
Hsp70s are highly expressed in many tumor cells and have reported to be an 
indicator of poor therapeutic outcome in breast cancer (Mivechi and Rossi, 1990; 
Ferrarini et al., 1992; Kaur and Ralhan, 1995; Ciocca et al., 1993). Furthermore, 
transgenic mice overexpressing the human Hsp70 develop T -cell lymphomas (Seo et al., 
1996). All these data suggested that Hsp70 may play a role in tumorigenesis and drug 
resistance. 
The role that Hsp70s play in the regulation of apoptosis is unclear. Conflicting 
reports on the subject possibly stem from the various mechanisms that different cells use 
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in response to different stimuli that induce apoptosis. After induction of Hsp70 
accumlation, protective effects against Pas-stimulated apoptosis and protection from 
apoptosis-inducing drugs have been reported (Polla et al., 1996; Mehlen eta/., 1996; 
Samali and Cotter, 1996), although the induction of Hsp70 may not protect from 
apoptosis (Cox et al., 1994). In this study, it was found that Hsp70 or Hsp70-2 
overexpression in cervical carcinoma C33A cells conferred protection from cell death 
induced by various stimuli, including several chemotherapeutic drugs, UV irradiation and 
heat shock (Figure 3.36). 
The precise molecular mechanism whereby Hsp70 expression leads to cell survival 
or inhibition of apoptosis is not understood. It has been suggested to be due to protection 
from protein denaturation, misfolding and degradation (Hartl et al., 1994; Craig et al., 
1994; Laroia eta/., 1999). Others have suggested that Hsp70s-mediated cell survival 
mechanism may arise from its assistance in the transfer of newly synthesized proteins 
into mitochondria helping to maintain overall mitochondrial integrity (Ungermann et al., 
1994; Pfanner eta/., 1994), which plays an important role in regulating the cell death 
pathway (for review, see Green and Reed, 1998; Gross et a/., 1999; see section 1.1.4). 
One study indicated that Hsp70-mediated cell survival involves the inhibition of caspase 
activity (Mosser et a/., 1997); whereas another recent study suggested that Hsp70 exerts 
its anti-apoptotic function downstream of caspase-3-like effector pro teases (JaatteUi et al., 
1998). 
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4.9. Future directions 
To more fully understand the molecular mechanism of apoptosis in carcinogenesis 
and MDR in human endocervical cells, several experiments could be done using this in 
vitro HEN-16-2 and HEN-16-2/CDDP model: 
L It would be interesting to overexpress Bcl-XL or BAG-I different isoforms in HEN-
16 cells and to determine whether BAG-I and Bcl-XL play a direct role in the process 
of multidrug resistance and carcinogenesis. 
2. Assay mRNA and protein expression levels of BAG-1, Bcl-XL and other related genes 
after treating both cell types with cisplatin or other agents. 
3. Examine other apoptosis-related genes, which may also contribute to the inhibition of 
apoptosis in HEN-16-2/CDDP cells, and their role in MDR and tumorigenesis. 
4. Use mRNA differential display method (Yang et al., 1996b) or eDNA microarrays 
(Duggan et a/., 1999) to identify genes that are differentially expressed in the process 
of inhibition of apoptosis. Such studies are critical to better understand the molecular 
mechanisms whereby apoptosis is dysregulated in human cervical cells, since, as 
discussed above, MDR and tumorigenesis are driven by a series of changes in gene 
expression. Thus, identifying genes that are differentially expressed, especially 
oncogenes, tumor suppressor genes, in the process of :MDR and tumorigenesis are 
critical to understanding the molecular mechanisms involved in apoptosis. 
5. Assay whether inhibition of BAG-1, Bcl-XL or other related gene expression by 
antisenses or other agents could sensitize the HEN-16-2/CDDP cells to apoptotic 
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stimuli. 
6. Compare the results obtained for HEN-16-2 and HEN-16-2/CDDP with similar 
experiments using primary human ectocervical cells. 
151 
CHAPTERS 
REFERENCES 
Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M, Altieri DC. Anti.-apoptosis gene, 
survivin, and prognosis of neuroblastoma. Lancet 351(9106):882-3, 1998. 
Alani RM, Miinger K. Human papillomaviruses and associated malignancies. J Clin 
Oncol16(1):330-7, 1998. 
Allan DJ, Harmon BV. The morphologic categorization of cell death induced by mild 
hyperthermia and comparison with death induced by ionizing radiation and 
cytotoxic drugs. Scan Electron Microsc (Pt 3):1121-33, 1986. 
Alnemri ES, Livingston DJ, Nicholson DW, Salvesen G, Thornberry NA, Wong WW, 
Yuan J. Human ICE/CED-3 protease nomenclature. Cell87(2):171, 1996. 
Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in 
cancer and lymphoma. Nat Med 3(8):917-21, 1997. 
_.c\mundson SA, Myers TG, Fomace AJ Jr. Roles for p53 in growth arrest and apoptosis: 
putting on the brakes after genotoxic stress. Oncogene 17(25):3287-99, 1998. 
Antony AC, Kane MA, Portillo RM, Elwood PC, Kolhouse JF. Studies of the role of a 
particulate folate-binding protein in the uptake of 5-methyltetrahydrofolate by 
cultured human KB cells. J Bioi Chern 260(28):14911-7, 1985. 
Aragane Y, Kulms D, Metze D, Wilkes G, Poppelmann B, Luger TA, Schwarz T. 
Ultraviolet light induces apoptosis via direct activation of CD95 (Fas/AP0-1) 
independently of its ligand CD95L. J Cell Biol140(1):171-82, 1998. 
152 
Baker SJ, Reddy EP. Modulation of life and death by the TNF receptor superfamily. 
Oncogene 17(25):3261-70, 1998. 
Ballinger CA, Connell P, Wu Y, Hu Z, Thompson LJ, Yin L Y, Patterson C. Identification 
of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat 
shock proteins and negatively regulates c:ltaperone functions. Mol Cell Bioi 
19(6):4535-45, 1999. 
Bardelli A, Longati P, Albero D, Goruppi S, Schmeider C, Ponzetto C, Comoglio PM. 
HGF receptor associates with the anti-apoptotic protein BAG-I and prevents cell 
death. EMBO J 15(22):6205-12, 1996. 
Bargou RC, Daniel PT, Mapara MY, Bommert K., Wagener C, Kallinich B, Royer HD, 
Dorken B. Expression of the bcl-2 gene fm:nily in normal and malignant breast 
tissue: low bax-alpha expression in tumor c~Jls correlates with resistance towards 
apoptosis. Int J Cancer 60(6):854-9, 1995. 
Bargou RC, Wagener C, Bommert K, Mapara MY, Daniel PT, Arnold W, Dietel M, 
Guski H, Feller A, Royer HD, Dorken B. Overexpression of the death-promoting 
gene bax-alpha which is downregulated in breast cancer restores sensitivity to 
different apoptotic stimuli and reduces tumor- growth in SCID mice. J Clin Invest 
97(11):2651-9, 1996. 
Barnhart KM, Bowden GT. Cisplatin as an initiatting agent in two-stage mouse skin 
carcinogenesis. Cancer Lett 29(1):101-5, 1985_ 
Barry MA, Behnke CA, Eastman A. Activation of programmed cell death (apoptosis) by 
cisplatin, other anticancer drugs, toxins ancl hyperthermia. Biochem Pharmacol 
153 
40(10):2353-62, 1990. 
Beck WT, Qian XD. Photoaffinity substrates for P-glycoprotein. Biochem Pharmacol 
43(1):89-93, 1992. 
Beckmann RP, Mizzen LE, Welch WJ. Interaction of Hsp 70 with newly synthesized 
proteins: implications for protein folding and assembly. Science 248( 4957):850-4, 
1990. 
Bedell MA, Jones KH, Grossman SR, Lairnins LA. Identification of human 
papillomavirus type 18 transforming genes in immortalized and primary cells. J 
Virol63(3):1247-55, 1989. 
Bernhard EJ, Kao G, Cox AD, Sebti SM, Hamilton AD, Muschel RJ, McKenna WG. The 
fam~syltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo 
fibroblasts. Cancer Res 56(8):1727-30, 1996. 
Bhushan A, Abramson R, Chiu JF, Tritton TR. Expression of c-fos in human and murine 
multidrug-resistant cells. Mol Pharmacol42(1):69-74, 1992. 
Bimston D, Song J, Wmchester D, Takayama S, Reed JC, Morimoto RI. BAG-1, a 
negative regulator of Hsp70 chaperone activity, uncouples nucleotide hydrolysis 
from substrate release. EMBO J 17(23):6871-8, 1998. 
Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, 
Nuiiez G, Thompson CB. bcl-x, a bcl-2-related gene that functions as a dominant 
regulator ofapoptotic cell death. Cell 74(4):597-608, 1993. 
Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, · Schiffinan MH, 
Moreno V, Kurman R, Shah KV. Prevalence of human papillomavirus in cervical 
154 
cancer: a worldwide perspective. International biological study on cervical cancer 
(IBSCC) Study Group. J Natl Cancer Inst 87(11 ):796-802, 1995. 
Bosch I, Croop J. P-glycoprotein multidrug resistance and cancer. Biochim Biophys Acta 
1288(2):F37-54, 1996. 
Boudreau N, Sympson CJ, Werb Z, Bissell MJ. Suppression of ICE and apoptosis in 
mammary epithelial cells by extracellular matrix. Science 267(5199):891-3, 1995. 
Breuninger LM, Paul S, Gaughan K, Miki T, Chan A, Aaronson SA, Kruh GD. 
Expression of multidrug resistance-associated protein in NIH/3T3 cells confers 
multid.rug resistance associated with increased drug efllux and altered intracellular 
drug distribution. Cancer Res 55(22):5342-7, 1995. 
Buk:au B, Horwich AL. The Hsp70 and Hsp60 chaperone machines. Cell 92(3):351-66, 
1998. 
Buttke TM, Sandstrom P A. Oxidative stress as a mediator of apoptosis. Immunol Today 
15(1):7-10, 1994. 
Campos L, Rouault JP, Sabido 0, Oriol P, Roubi N, V asselon C, Archimbaud E, Magaud 
JP, Guyotat D. High expression ofbcl-2 protein in acute myeloid leukemia cells is 
associated with poor response to chemotherapy. Blood 81(11):3091-6, 1993. 
Campos L, Sabido 0, Rouault JP, Guyotat D. Effects of BCL-2 antisense 
oligodeoxynucleotides on in vitro proliferation and survival of normal marrow 
progenitors and leukemic cells. Blood 84(2):595-600, 1994. 
Canman CE, Gilmer TM, Coutts SB, Kastan rviB. Growth factor modulation of p53-
mediated growth arrest versus apoptosis. Genes Dev 9, 600-611, 1995. 
155 
Chant ID, Rose PE, Morris AG. Suscepb'bility of AML cells to in vitro apoptosis 
correlates with heat shock protein 70 (hsp 70) expression. Br J Haematol 93( 4):898-
902, 1996. 
Chao DT, Korsmeyer SJ. BCL-2 family: regulators of cell death. Annu Rev .Immunol 
395-419, 1998. 
Cheng EH, Levine B, Boise LH, Thompson CB, Hardwick JM. Bax-independent 
inhibition of apoptosis by Bcl-XL. Nature 379(6565):554-6, 1996. 
Chien CT, Bartel PL, Sternglanz R, Fields S. The two-hybrid system: a method to 
identify and clone genes for proteins that interact with a protein of interest. Proc 
Natl Acad Sci USA 88(21):9578-82, 1991. 
Ciocca DR, Clark GM, Tandon AK, Fuqua SA, Welch WJ, McGuire WL. Heat shock 
protein hsp70 in patients with axillary lymph node-negative breast cancer: 
prognostic implications. J Natl Cancer Inst 85(7):570-4, 1993. 
Clarke AR, Gledhill S, Hooper ML, Bird CC, Wyllie AH. p53 dependence of early 
apoptotic and proliferative responses within the mouse intestinal epithelium 
following gamma-irradiation. Oncogene 9(6):1767-73, 1994. 
Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wyllie AH. 
Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 
362(6423):849-52, 1993. 
Clevenger CV, Thickm.an K., Ngo W, Chang WP, Takayama S, Reed JC. Role of Bag-1 
in the survival and proliferation of the cytokine-dependent lymphocyte lines, Ba!F3 
and Nb2. Mol Endocrinol 11(5):608-18, 1997. 
156 
Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz 
EU, Duncan AM, Deeley RG. Overexpression of a transporter gene in a multidrug-
resistant human lung cancer cell line. Science 258(5088):1650-4, 1992. 
Cory S. Regulation of lymphocyte survival by the bcl-2 gene family. Annu Rev Immunol 
13:513-43, 1995. 
Coukos G, Rubin SC. Chemotherapy resistance in ovarian cancer: new molecular 
perspectives. Obstet Gynecol91(5 Pt 1):783-92, 1998. 
Cox G, Oberley L W, Hunninghake GW. Manganese superoxide dismutase and heat 
shock protein 70 are not necessary for suppression of apoptosis in human peripheral 
blood neutrophils. Am J Respir Cell Mol Bioi 10(5):493-8, 1994. 
Craig EA., Weissman JS, Horwich AL. Heat shock proteins and molecular chaperones: 
mediators of protein conformation and turnover in the cell. Cell 78(3):365-72, 1994. 
Crook T, Wrede D, Tidy JA, Mason WP, Evans DJ, Vousden KH. Clonal p53 mutation 
in primary cervical cancer: association with human-papillomavirus-negative 
tumours. Lancet 339(8801):1070-3, 1992. 
Croop JM, Guild BC, Gros P, Housman DE. Genetics of multidrug resistance: 
relationship of a cloned gene to the complete multidrug resistant phenotype. Cancer 
Res 47(22):5982-8, 1987. 
Cryns V, YuanJ. Proteases to die for. Genes Dev 12(11):1551-70, 1998. 
Cyster JG, Hartley SB, Goodnow CC. Competition for follicular niches excludes self-
reactive cells from the recirculating B-cell repertoire. Nature 371(6496):389-95, 
1994. 
157 
Danesi R, Nardini D!t Basolo F, Del Tacca M!t Samid D, Myers CE. Phenylacetate inhibits 
protein isoprenylation and growth of the androgen-independent LNCaP prostate 
cancer cells transfected with the T24 Ha-ras oncogene. Mol Pharmacal 49(6):972-9, 
1996. 
Davies R, Hicks R, Crook T, Morris J!t Vousden K. Human papillomavirus type 16 E7 
associates with a histone HI kinase and with p 107 through sequences necessary for 
transformation. J Virol67(5):2521-8, 1993. 
de Villiers EM. Heterogeneity of the human papillomavirus group. J Virol 63(11 ):4898-
903, 1989. 
Deb bas M, White E. Wild-type p53 mediates apoptosis by E lA, which is inhibited by 
E1B. Genes Dev 7(4):546-54, 1993. 
Demers GW, Foster SA, Halbert CL, Galloway DA. Growth arrest by induction ofp53 in 
DNA damaged keratinocytes is bypassed by human papillomavirus 16 E7. Proc 
Natl Acad Sci USA 91(10):4382-6, 1994. 
Deveraux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of 
cell-death proteases. Nature 388(6639):300-4, 1997. 
DiPaolo JA, Woodworth CD, Popescu NC, Notario V, Doniger J. Induction of human 
cervical squamous cell carcinoma by sequential transfection with human 
papillomavirus 16 DNA and viral Harvey ras. Oncogene 4(4):395-9, 1989. 
Dixon KH, Lanpher BC, Chiu J, Kelley K, Cowan KH. A novel eDNA restores reduced 
folate carrier activity and methotrexate sensitivity to transport deficient cells. J Bioi 
Chern 269(1):17-20, 1994. 
158 
Donehower L~ Godley LA, Aldaz M, Pyle R, Shi YP, Pinkel D, Gray J, Bradley A. 
Medina D, V armus HE. Deficiency of p53 accelerates mammary tumorigenesis in 
Wnt-1 transgenic mice and promotes chromosomal instability. Genes Dev 9, 882-
895, 1995. 
Dong M, Penin F, Baggetto LG. Efficient purification and reconstitution of P-
glycoprotein for functional and structural studies. J Bioi Chern 271(46):28875-83, 
1996. 
Dragovich T, Rudin CM, Thompson CB. Signal transduction pathways that regulate cell 
survival and cell death. Oncogene 17(25):3207-13, 1998. 
Drahovsky D, Kreis W. Studies on drug resistance. II. Kinase patterns in P815 neoplasms 
sensitive and resistant to 1-beta-D-arabinofuranosylcytosine. Biochem Pharmacal 
19(3):940-4, 1970. 
Duggan DJ, Bittner M, Chen Y, Meltzer P, Trent JM. Expression profiling using eDNA 
microarrays. Nat Genet 21(1 Supp1):10-4, 1999. 
Durst M, Gallahan D, Jay G and Rhim JS. Neoplastic transformation of human 
keratinocytes by human papilomavirus type 16 and activated ras oncogene. In 
papillomaviruses, pp.255-263. Wiley-Liss, Inc., New York. 1990. 
Dyson N, Guida P, Munger K, Harlow E. Homologous sequences in adenovirus ElA and 
human papillomavirus E7 proteins mediate interaction with the same set of cellular 
proteins. J Viro166(12):6893-902, 1992. 
Dyson N, Howley PM, Munger ~ Harlow E. The human papilloma virus-16 E7 
oncoprotein is able to bind to the retinoblastoma gene product. Science 
159 
243(4893):934-7, 1989. 
Eastman A. Activation of programmed cell death by anticancer agents: cisplatin as a 
model system. Cancer Cells 2, 275-280, 1990. 
Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu ~Nagata S. A caspase-
activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. 
Nature 391(6662): 43-50, 1998. 
Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. 
Annu Rev Biochem 58:137-71, 1989. 
Eustace P. History and development of cisplatin in the management of malignant disease. 
Cancer Nurs 3(5):373-8, 1980. 
Eytan GD, Regev R, Oren G, Hurwitz CD, Assaraf YG. Efficiency of P-glycoprotein-
mediated exclusion of rhodamine dyes from multidrug-resistant cells is determined 
by their passive transmembrane movement rate. Eur J Biochem 248(1):104-12, 
1997. 
Ferrarini M, Heltai S, Zocchi MR., Rugarli C. Unusual expression and localization of 
heat-shock proteins in human tumor cells. Int J Cancer 51(4):613-9, 1992. 
Fields S, Song 0. A novel genetic system to detect protein-protein interactions. Nature 
340(6230):245-6, 1989. 
Fields S, Stemglanz R. The two-hybrid system: an assay for protein-protein interactions. 
Trends Genet 10(8):286-92, 1994. 
Flynn GC, Chappell TG, Rothman IE. Peptide binding and release by proteins implicated 
as catalysts ofprotein assembly. Science 245(4916):385-90, 1989. 
160 
Foster SA, Demers GW, Etscheid BG, Galloway DA. The ability of human 
papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their 
ability to abrogate actinomycin D-induced growth arrest. J Virol 68(9):5698-705, 
1994. 
Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. 
J Cell Biol124(4):619-26, 1994. 
Froesch BA, Takayama S, Reed JC. BAG-1L protein enhances androgen receptor 
function. J Bioi Chern. 273(19):11660-6, 1998. 
Fung CY, Fisher DE. p53: from molecular mechanisms to prognosis in cancer. J Clin 
Oncol13, 808-811, 1995. 
Furlini G, Vignoli M, Re MC, Gibellini D, Ramazzotti E, Zauli G, LaPlaca M. Human 
immunodeficiency virus type 1 interaction with the membrane of CD4+ cells 
induces the synthesis and nuclear translocation of 70K heat shock protein. J Gen 
Viral 75 ( Pt 1):193-9, 1994. 
Gabai VL, Zamulaeva IV, Masin AF, Makarova YM, Mosina VA, Budagova KR, 
Malutina YV, Kabakov AE. Resistance of Ehrlich tumor cells to apoptosis can be 
due to accumulation ofheat shock proteins. FEBS Lett 375(1-2):21-6, 1995. 
Gajewski TF, Thompson CB. Apoptosis meets signal transduction: elimination of a BAD 
influence. Cell 87( 4):589-92, 1996. 
Galea-Lauri J, Richardson AJ, Latchman DS, Katz DR. Increased heat shock protein 90 
(hsp90) expression leads to increased apoptosis in the monoblastoid cell line U93 7 
following induction with TNF-alpha and cycloheximide: a possible role in 
161 
immunopathology. J Immunol157(9):4109-18, 1996. 
Gallagher WM, Caimey M, Schott B, Roninson m, Brown R. Identification of p53 
genetic suppressor elements which confer resistance to cisplatin. Oncogene 
14(2):185-93, 1997. 
Germann UA, Pastan I, Gottesman lVIM:. P-glycoproteins: mediators of multidrug 
resistance. Sem.in Cell Biol4(1):63-76, 1993. 
Gerson SL, Berger SJ, V ames :ME, Donovan C. Combined depletion of 06-alkylguanine-
DNA alk:yltransferase and glutathione to modulate nitrosourea resistance in breast 
cancer. Biochem Pharmacol48(3):543-8, 1994. 
Gerson SL, Willson JK. 06-alkylguanine-DNA alkyltransferase. A target for the 
modulation of drug resistance. Hematol Oneal Clin North Am 9(2):431-50, 1995. 
Goldenberg GJ, Vanstone CL, Israels LG, lise D, Bibler I. Evidence for a transport 
carrier of nitrogen mustard in nitrogen mustard-sensitive and -resistant L5178Y 
lymphoblasts. Cancer Res 30(9):2285-91, 1970. 
Green DR, Reed JC. Mitochondria and apoptosis. Science 281(5381):1309-12, 1998. 
Greene MIL Is cisplatin a human carcinogen? J Natl Cancer Inst 84(5):306-12, 1992. 
Gros P, Ben Neriah YB, Croop JM, Housman DE. Isolation and expression of a 
complementary DNA that confers multidrug resistance. Nature 323(6090):728-31, 
1986. 
Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in 
apoptosis. Genes Dev 13(15):1899-911, 1999. 
Haber DA, Beverley SM, Kiely ML, Schimke RT. Properties of an altered dihydrofolate 
162 
reductase encoded by amplified genes in cultured mouse fibroblasts. J Bioi Chem 
256(18):9501-10, 1981. 
Haddow ~ Harris R, Kon G, Roe E. The growth-inhibitory and carcinogenic properties 
of 4-aminostilbene and derivatives. PhiL Trans. A. Roy. Soc. A: 241-247, 1948. 
Haldar S~ Negrini M, Monne M, Sabbioni S, Croce CM. Down-regulation ofbcl-2 by p53 
in breast cancer cells. Cancer Res 54(8):2095-7, 1994. 
Hanada M, Aime-Sempe C, Sato T, Reed JC. Structure-:function analysis of Bcl-2 
protein. Identification of conserved domains important for homodimerization with 
Bcl-2 and heterodimerization with Bax. J Biol Chern 270(20):11962-9, 1995. 
Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J 
Med 329(18):1318-27, 1993. 
Hartl FU, ffiodan R, Langer T. Molecular chaperones in protein folding: the art of 
avoiding sticky situations. Trends Biochem Sci 19(1):20-5, 1994. 
Hartl FU. Molecular chaperones in cellular protein folding. Nature 381(6583):571-9, 
1996. 
Havre P A, Yuan J, Hedrick L, Cho KR, Glazer PM. p53 inactivation by HPV16 E6 
results in increased mutagenesis in human cells. Cancer Res 55(19):4420-4, 1995. 
Havrilesky LJ, Elbendary A, Hurteau JA, Whitaker RS, Rodriguez GC, Berchuck A. 
Chemotherapy-induced apoptosis in epithelial ovarian cancers. Obstet Gynecol 
85(6):1007-10, 1995. 
Heck DV, Yee CL, Howley PM, Munger K. Efficiency of binding the retinoblastoma 
protein correlates with the transforming capacity of the E7 oncoproteins of the 
163 
human papillomaviruses. Proc Natl Acad Sci USA 89{1 0):4442-6, 1992. 
Hermeking H, Eick D. Mediation of c-Myc-induced apoptosis by p53. Science 265, 
2091-2093. 1994. 
Herrington CS. Human papillomaviru.ses and cervical neoplasia. IT. Interaction of HPV 
with other factors. J Clin Pathol48(1):1-6, 1995. 
Hershko A, Ciechanover A. The ubiquitin system for protein degradation. Annu Rev 
Biochem 61:761-807, 1992. 
Hickman ES, Picksley SM, Vousden KH. Cells expressing HPV16 E7 continue cell cycle 
progression following DNA damage induced p53 activation. Oncogene 9(8):2177-
81, 1994. 
Hickman JA. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev 11 (2): 121-
39, 1992. 
Hill BT, Bailey BD, White JC, Goldman ID. Characteristics of transport of 4-amino 
antifolates and folate compounds by two lines of L5178Y lymphoblasts, one with 
impaired transport of methotrexate. Cancer Res 39(7 Pt 1):2440-6, 1979. 
Hirose Y, Yoshimi N, Suzui M, Kawabata K, Tanaka T, Mori H. Expression ofbcl-2, 
bax, and Bcl-XL proteins in azoxymethane-induced rat colonic adenocarcinomas. 
Mol Carcinog 19(1):25-30, 1997. 
Hohfeld J, Jentsch S. GrpE-like regulation of the hsc70 chaperone by the anti-apoptotic 
protein BAG-I. E:MBO J 16(20):6209-16, 1997. 
Hohfeld J. Regulation of the heat shock conjugate Hsc70 in the mammalian cell: the 
characterization of the anti-apoptotic protein BAG-I provides novel insights. Bioi 
164 
Chern 379(3):269-74, 1998. 
Hollstein M, Rice K, Greenblatt MS, Soussi T, Fuchs R, Sorlie T, Hovig E, Smith-
Sorensen B, Montesano R, Harris CC. Database of p53 gene somatic mutations in 
human tumors and cell lines. Nucleic Acids Res 22(17):3551-5, 1994. 
Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. 
Science 253(5015):49-53, 1991. 
Hoppe-Seyler F, Butz K. Cellular control of human papillomavirus oncogene 
transcription. Mol Carcinog 10(3):134-41, 1994. 
Hunt SW 3d, Ho:ffee P A. Amplification of adenosine deaminase gene sequences in 
deoxycoformycin-resistant rat hepatoma cells. J Biol Chern 258(21):13185-92, 
1983. 
Huschtscha LI, Bartier W A, Ross CE, Tattersall :MH. Characteristics of cancer cell death 
after exposure to cytotoxic drugs in vitro. Br J Cancer 73(1):54-60, 1996. 
Hyde SC, Emsley P, Hartshorn MJ, Mimmack :MM, Gileadi U, Pearce SR, Gallagher 
1\fll, Gill DR, Hubbard RE, Higgins CF. Structural model of ATP-binding proteins 
associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature 
346(6282):362-5, 1990. 
Ikegaki N, Katsumata M, Minna J, Tsujimoto Y. Expression ofbcl-2 in small cell lung 
carcinoma cells. Cancer Res 54(1):6-8, 1994. 
Irmler M, Thome M, Hahne M, Schneider P, Hofinann K, Steiner V, Bodmer JL, 
Schroter M, Burns K, Mattmann C, Rimoldi D, French LE, Tschopp J. Inhibition of 
death receptor signals by cellular FLIP. Nature 388(6638):190-5, 1997. 
165 
Irmler M, Thome M, Hahne M, Schneider P, Hofi:nann ~ Steiner V, Bodmer JL, 
Schroter M, Bums K, Mattmann C, Rimoldi D, French LE, Tschopp J. Inhibition of 
death receptor signals by cellular FLIP. Nature 388(6638):190-5, 1997. 
Isacson C, Kessis TD, Hedrick L, Cho KR. Both cell proliferation and apoptosis increase 
with lesion grade in cervical neoplasia but do not correlate with human 
papillomavirus type. Cancer Res 56(4):669-74, 1996. 
Izquierdo MA, Scheffer GL, Flens MJ, Schroeijers AB, van der Valk P, Scheper RJ. 
Major vault protein LRP-related multidrug resistance. Eur J Cancer 32A(6):979-84, 
1996. 
JaatteUi M, Wissing D, Kokholm K, Kallunki T, Egeblad M. Hsp70 exerts its anti-
apoptotic function downstream of caspase-3-lik:e proteases. EMBO J 17(21):6124-
34, 1998. 
JaatteHi M. Over-expression of hsp70 confers tumorigenicity to mouse fibrosarcoma 
cells. Int J Cancer 60(5):689-93, 1995. 
Janicke RU, Sprengart ML, Wati MR., Porter AG. Caspase-3 is required for DNA 
fragmentation and morphological changes associated with apoptosis. J Bioi Chem 
273(16):9357-60, 1998. 
Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese 
hamster ovary cell mutants. Biochim Biophys Acta 455(1):152-62, 1976. 
Kaina B, Lohrer H, Karin M, Herrlich P. Overexpressed human metallothionein IIA gene 
protects Chinese hamster ovary cells from killing by alkylating agents. Proc N atl 
Acad Sci USA 87(7):2710-4, 1990. 
166 
Kaldor JM, Day NE, Hemminki K. Quantifying the carcinogenicity of antineoplastic 
drugs. Eur J Cancer Clin Oncol24(4):703-11, 1988. 
Kastan MB, Zhan Q, el-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, 
Vogelstein B, Fomace AJ Jr. A mammalian cell cycle checkpoint pathway utilizing 
p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71(4):587-97, 1992. 
Kat A, Thilly WG, Fang WH, Longley MJ, Li GM, Modrich P. An alkylation-tolerant, 
mutator human cell line is deficient in strand-specific mismatch repair. Proc Natl 
Acad Sci USA 90(14):6424-8, 1993. 
Kaufinann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG. Specific proteolytic 
cleavage of poly(ADP-n'bose) polymerase: an early marker of chemotherapy-
induced apoptosis. Cancer Res 53(17):3976-85, 1993. 
Kaufinann SH. Induction of endonucleolytic DNA cleavage in human acute myelogenous 
leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a 
cautionary note. Cancer Res 49(21):5870-8, 1989. 
Kaur J, Ralhan R. Differential expression of 70-kDa heat shock-protein in human oral 
tumorigenesis. Int J Cancer 63(6):774-9, 1995. 
Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of 
apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer 
Res 58(22):5071-4, 1998. 
Kelley SL, Basu A, Teicher BA, Hacker MP, Hamer DH, Lazo JS. Overexpression of 
metallothionein confers resistance to anticancer drugs. Science 241(4874):1813-5, 
1988. 
167 
Kelley WL. The J-domain family and the recruitment of chaperone power. Trends 
Biochem Sci 23(6):222-7, 1998. 
Kemp CJ, Wheldon T, Balmain A. p53-deficient mice are extremely susceptible to 
radiation-induced tumorigenesis. Nat Genet 8(1):66-9, 1994. 
Kempf SR, Ivankovic S. Carcinogenic effect of cisplatin ( cis-diammine-dichloroplatinum 
(ll), CDDP) in BD IX rats. J Cancer Res Clin Oncol111(2): 133-6, 1986. 
Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer 
therapy. Cancer 73(8):2013-26, 1994. 
Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-
ranging implications in tissue kinetics. Br J Cancer 26(4):239-57, 1972. 
Kessis TD, Slebos RJ, Nelson WG, Kastan :rvm, Plunkett BS, Han SM, Lorincz AT, 
Hedrick L, Cho KR. Human papillomavirus 16 E6 expression disrupts the p53-
mediated cellular response to DNA damage. Proc Natl Acad Sci USA 90(9):3988-
92, 1993. 
Kimura Y, Y ahara I, Lindquist S. Role of the protein chaperone YDJl in establishing 
Hsp90-mediated signal transduction pathways. Science 268(5215):1362-5, 1995. 
Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH, Peter ME. 
Cytotoxicity-dependent AP0-1 (Fas/CD95)-associated proteins form a death-
inducing signaling complex (DISC) with the receptor. EMBO J 14(22):5579-88, 
1995. 
Kitada S, Takayama S, De Riel K, Tanaka S, Reed JC. Reversal of chemoresistance of 
lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. 
168 
Antisense Res Dev 4(2):71-9, 1994. 
Knudson CM, Korsmeyer SJ. Bcl-2 and Bax function independently to regulate cell 
death. Nat Genet 16(4):358-63, 1997. 
Koi M, Umar A, Chauhan DP, Cherian SP, Carethers JM, Kunkel TA, Boland CR. 
Human chromosome 3 corrects mismatch repair deficiency and microsatellite 
instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon 
tumor cells with homozygous hMLHl mutation. Cancer Res 54(16):4308-12, 1994. 
Kondo S, Shinomura Y, Kanayama S, Higashimoto Y, Miyagawa ll, Minami T, 
Kiyohara T, Zushi S, Kitamura S, Isozaki K, Matsuzawa Y. Over-expression of 
Bcl-XL gene in human gastric adenomas and carcinomas. Int J Cancer 68(6):727-
30, 1996. 
Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJ, Juijn JA, Baas F, Borst P. 
Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MR.PS, 
homologues of the multidrug resistance-associated protein gene (MR.Pl), in human 
cancer cell lines. Cancer Res 57(16):3537-47, 1997. 
Korsmeyer SJ. Regulators of cell death. Trends Genet 11(3):101-5, 1995. 
Kozopas KM, Yang T, Buchan HL, Zhou P, Craig RW. MCL1, a gene expressed in 
programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc 
Natl Acad Sci USA 90(8):3516-20, 1993. 
Krajewska M, Moss SF, Krajewski S, Song K, Holt PR, Reed JC. Elevated expression of 
Bcl-X and reduced Bak in primary colorectal adenocarcinomas. Cancer Res 
56(10):2422-7, 1996. 
169 
Krishnamachary N~ Center MS. The MR.P gene associated with a non-P-glycoprotein 
multidrug resistance encodes a 190-kDa membrane bound glycoprotein. Cancer Res 
53(16):3658-61, 1993. 
Kullmann M, Schneikert J, Moll J, Heck S, Zeiner M, Gehring U, Cato AC. RAP46 is a 
negative regulator of glucocorticoid receptor action and hormone-induced 
apoptosis. J Biol Chern 273(23 ): 14620-5, 1998. 
Kyriakis JM, Banerjee P, Nikolakaki E, Dai T, Rubie EA, Ahmad MF, Avruch J, 
Woodgett JR. The stress-activated protein kinase subfamily of c-Jun kinases. 
Nature 369(6476):156-60, 1994. 
Laroia G, Cuesta R, Brewer G, Schneider RJ. Control of mRNA decay by heat shock-
ubiquitin-proteasome pathway. Science 284(5413):499-502, 1999. 
Lautier D, Canitrot Y, Deeley RG, Cole SP. Multidrug resistance mediated by the 
multidrug resistance protein (MRP) gene. Biochem Pharmacol52(7):967-77, 1996. 
Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 
351(6326):453-6, 1991. 
Levine AJ. p53, the cellular gatekeeper for growth and division. Cell88(3):323-31, 1997. 
Levy N, Yonish-Rouach E, Oren M, Kimchi A. Complementation by wild-type p53 of 
interleukin-6 effects on M1 cells-induction of cell cycle exit and cooperativity with 
c-myc suppression. Mol Cell Bioi 13, 7942-7952, 1993. 
Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial 
damage in the Fas pathway ofapoptosis. Cell94(4):491-501, 1998. 
LiP, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X. 
170 
Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex 
initiates an apoptotic protease cascade. Cell91(4):479-89. 1997. 
Li SL~ Kim MS, Cherrick HM:, Doniger J, Park NH. Sequential combined tumorigenic 
effect ofHPV-16 and chemical carcinogens. Carcinogenesis 13(11):1981-7, 1992. 
Liang XII, Mungal S, Ayscue A, Meissner JD, Wodnicki P, Hockenbery D, Lockett 
S,Herman B. Bcl-2 protooncogene expression in cervical carcinoma cell lines 
containing inactive p53. J Cell Biochem 57(3):509-21, 1995. 
Licitra EJ, Liu JO. A three-hybrid system for detecting small ligand-protein receptor 
interactions. Proc Natl Acad Sci USA 93(23):12817-21~ 1996. 
Liepins A, Bustamante JO. Cell injury and apoptosis. Scanning Microsc 8(3):631-43, 
1994. 
Liepins A, Younghusband HB. Low temperature-induced cell surface membrane vesicle 
shedding is associated with DNA fragmentation. Exp Cell Res 161(2):525-32, 1985. 
Lin EY, Orlofsky A, Berger MS, Prystowsky MB. Characterization of Al, a novel 
hemopoietic-specific early-response gene with sequence similarity to bcl-2. J 
Imm.unol151(4):1979-88, 1993. 
Lindquist S. The heat-shock response. Annu Rev Biochem 55:1151-91, 1986. 
Liu R, Takayama S, Zheng Y, Froesch B, Chen GQ, Zhang X, Reed JC, Zhang XK. 
Interaction of BAG-1 with retinoic acid receptor and its inhibition of retinoic acid-
induced apoptosis in cancer cells. J Biol Chern 273(27):16985-92, 1998. 
Liu X, Zou H, Slaughter C, Wang X. OFF, a heterodimeric protein that functions 
downstream of caspase-3 to trigger DNA fragmentation during apoptosis. Cell 
171 
89(2): 175-84, 1997. 
Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD. Altered cell cycle 
arrest and gene amplification potential accompany loss of wild-type p53. Cell 
70(6):923-35, 1992. 
Lloyd RV, Erickson LA, Jin L, Kulig E, Qian X, Cheville JC, Scheithauer BW. p27kipl: 
a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in 
human cancers. Am J Patholl54(2):313-23, 1999. 
Lohrer H, Robson T. Overexpression of metallothionein in CHO cells and its effect on 
cell killing by ionizing radiation and alkylating agents. Carcinogenesis 
10(12):2279-84, 1989. 
Lotem J, Sachs L. Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of 
apoptosis by heat shock and cancer chemotherapy compounds in differentiation-
competent and -defective myeloid leukemic cells. Cell-Growth Differ· 4(1):41-7, 
1993. 
Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman 
DE,Jacks T. p53 status and the efficacy of cancer therapy in vitro. Science 
266(5186):807-10, 1994. 
Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the 
cytotoxicity of anticancer agents. Cell 74(6):957-67, 1993a. 
Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-
induced apoptosis in mouse thymocytes. Nature 362(6423):847-9, 1993b. 
Lu CD, Altieri DC, Tanigawa N. Expression of a novel anti-apoptosis gene, survivin, 
172 
correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. 
Cancer Res 58(9):1808-12, 1998. 
Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, 
mediates cytochrome c release from mitochondria in response to activation of cell 
surface death receptors. Cell94(4):481-90, 1998. 
MacCallum DE, Hupp TR, Midgley CA, Stuart D, Campbell SJ, Harper A, Walsh FS, 
Wright EG, Balmain A, Lane DP, Hall P A. The p53 response to ionising radiation 
in adult and developing murine tissues. Oncogene 13(12):2575-87, 1996. 
Mansur CP, Androphy EJ. Cellular transformation by papillomavirus oncoproteins. 
Biochim Biophys Acta 1155(3):323-45, 1993. 
Matsuzawa S, Takayama S, Froesch BA, Zapata JM, Reed JC. p53-inducible human 
homologue of Drosophila seven in absentia (Siah) inhibits cell growth: suppression 
byBAG-1. EMBO J 17(10):2736-47, 1998. 
McDonald ER 3rd, Wu GS, Waldman T, El-Deiry WS. Repair Defect m p21 
W AF1/CIP1 -/-human cancer cells. Cancer Res 56(10):2250-5, 1996. 
McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh IT, Tu SM, 
Campbell ML. Expression of the protooncogene bcl-2 in the prostate and its 
association with emergence of androgen-independent prostate cancer. Cancer Res 
52(24):6940-4, 1992. 
Medema JP, Scaffidi C, Kischkel FC, Shevchenko A, Mann M, Krammer PH, Peter ME. 
FLICE is activated by association with the CD95 death-inducing signaling complex 
(DISC). EMBO J 16(10):2794-804, 1997. 
173 
Mehlen P, Schulze-Osthoff K, Arrigo AP. Small stress proteins as novel regulators of 
apoptosis. Heat shock protein 27 blocks Fas/ AP0-1- and staurosporine-induced cell 
death. J Bioi Chern 271(28):16510-4, 1996. 
Midgley CA., Owens B, Briscoe CV, Thomas DB, Lane DP, Hall PA. Coupling between 
gamma irradiation, p53 induction and the apoptotic response depends upon cell type 
in vivo. J Cell Sci 108 ( Pt 5):1843-8, 1995. 
Minn AJ, Rudin CM, Boise LH, Thompson CB. Expression of Bcl-XL can confer a 
multidrug resistance phenotype. Blood 86(5):1903-10, 1995. 
Mivechi NF, Rossi JJ. Use of polymerase chain reaction to detect the expression of the 
Mr 70,000 heat shock genes in control or heat shock leukemic cells as correlated to 
their heat response. Cancer Res 50(10):2877-84, 1990. 
Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman 
B, Reed JC. Tumor suppressor p53 is a regulator ofbcl-2 and bax gene expression 
in vitro and in vivo. Oncogene 9(6):1799-805, 1994. 
Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the 
human bax gene. Cell80(2):293-9, 1995. 
Mizutani Y, Fukumoto M, Bonavida B, Yoshida 0. Enhancement of sensitivity of urinary 
bladder tumor cells to cisplatin by c-myc antisense oligonucleotide. Cancer 
74(9):2546-54, 1994. 
Moreira LF, Naomoto Y, Hamada M, Kamikawa Y, Orita K. Assessment of apoptosis in 
oesophageal carcinoma preoperatively treated by chemotherapy and radiotherapy. 
Anticancer Res 15(2):639-44, 1995. 
174 
Mosser DD, Caron A W, Bourget L, Denis-Larose C, Massie B. Role of the human heat 
shock protein hsp70 in protection against stress-induced apoptosis. Mol Cell Biol 
17(9):5317-27, 1997. 
Mousseau M, Chauvin C, Nissou MF, Chaffanet M, Plantaz D, Pasquier B, Schaerer R, 
Benabid A. A study of the expression of four chemoresistance-related genes in 
human primary and metastatic brain tumours. Eur J Cancer. 29A(5): 753-9, 1993. 
Muchmore SW, Sattler M, Liang H, Meadows RP, Harlan JE, Yoon HS, Nettesheim D, 
Chang BS, Thompson CB, Wong SL, Ng SL, Fesik SW. X-ray and~ structure 
ofhuman Bcl-xL, an inhibitor of programmed cell death. Nature 381(6580):335-41, 
1996. 
Miinger ~ W emess BA, Dyson N, Phelps WC, Harlow E, Howley PM. Complex 
formation of human papillomavirus E7 proteins with the retinoblastoma tumor 
suppressor gene product. EMBO J 8(13):4099-105, 1989. 
Murdoch WJ. Temporal relationships between stress protein induction, progesterone 
withdrawal, and apoptosis in corpora lutea of ewes treated with prostaglandin F2 
alpha. J Anim Sci 73(6):1789-92, 1995. 
Nagane M, Asai A, Shibui S, Nomura ~ Kuchino Y. Application of antisense 
ribonucleic acid complementary to 06-methylguanine-deoxyribonucLeic acid 
methyltransferase messenger ribonucleic acid for therapy of malignant gliomas. 
Neurosurgery 1997 Aug;41(2):434-40; discussion 440-1 
Nagata S, Golstein P. The Fas death factor. Science 267(5203):1449-56, 1995. 
Naito M, Tsuruo T. Reconstitution of purified P-glycoprotein into liposomes. J Cancer 
175 
Res Clin Oncol121(9-10):582-6, 1995. 
Nakagawa S, Watanabe S, Yoshikawa H, Taketani Y, Yoshiike K, Kanda T. Mutational 
analysis of human papillomavirus type 16 E6 protein: transforming function for 
human cells and degradation ofp53 in vitro. Virology 212(2):535-42, 1995. 
Nakao Y, Yang X, Yokoyama M, Pater MM, Pater A. Malignant transformation of 
human ectocervical cells immortalized by HPV 18: in vitro model of carcinogenesis 
by cigarette smoke. Carcinogenesis 17(3):577-83, 1996. 
Nathan DF, Lindquist S. Mutational analysis of Hsp90 function: interactions with a 
steroid receptor and a protein kinase. Mol Cell Biol15(7):3917-25, 1995. 
Neiman PE, Thomas SJ, Loring G. Induction of apoptosis during normal and neoplastic 
B-cell development in the bursa of Fabricius. Proc Natl Acad Sci USA 
88(13):5857-61, 1991. 
Niimi S, Nakagawa K, Yokota J, Tsunokawa Y, Nishio K, Terashima Y, Shibuya M, 
Terada M, Saijo N. Resistance to anticancer drugs in Nlli3T3 cells transfected with 
c-myc and/or c-H-ras genes. Br J Cancer 63(2):237-41, 1991. 
Nuiiez G, Benedict MA, Hu Y, Inohara N. Caspases: the proteases of the apoptotic 
pathway. Oncogene 17(25):3237-45, 1998. 
Oberhammer F, Wilson JW, Dive C, Morris ID, Hickman JA, Wak:eling AE, Walker PR, 
Sikorska M. Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50 
kb fragments prior to or in the absence of intemucleosomal fragmentation. EMBO-
J 12(9): 3679-84, 1993. 
O'Brien ML, Tew KD. Glutathione and related enzymes in multidrug resistance. Bur J 
176 
Cancer 32A(6):967-78, 1996. 
Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved 
homolog, Bax, that accelerates programmed cell death. Cell 74(4):609-19, 1993. 
Oren M. Relationship of p53 to the control of apoptotic cell death. Semin Cancer Bioi 
5(3):221-7, 1994. 
Ozols RF, O'Dwyer PJ, Hamilton TC, Young RC. The role of glutathione in drug 
resistance. Cancer Treat Rev 17 Suppl A:45-50, 1990. 
Palleros DR, Welch WJ, Fink AL. Interaction ofhsp70 with unfolded proteins: effects of 
temperature and nucleotides on the kinetics of binding. Proc Natl Acad Sci USA 
88(13):5719-23, 1991. 
Parsell DA, Lindquist S. The function of heat-shock proteins in stress tolerance: 
degradation and reactivation of damaged proteins. Annu Rev Genet 27:437-96, 
1993. 
Pater MM, Pater A. Expression of human papillomavirus types 16 and 18 DNA 
sequences in cervical carcinoma cell lines. J Med Virol26(2):185-95, 1988. 
Pecoraro G, Morgan D, Defendi V. Differential effects of human papillomavirus type 6, 
16, and 18 DNAs on immortalization and transformation of human cervical 
epithelial cells. Proc Natl Acad Sci USA 86(2):563-7, 1989. 
Pegg AE. Methylation of the 06 position of guanine in DNA is the most likely initiating 
event in carcinogenesis by methylating agents. Cancer Invest 2(3):223-31, 1984. 
Pei XF, Meek JM, Greenhalgh D, Schlegel R. Cotransfection ofHPV-18 and v-fos DNA 
induces tumorigenicity of primary human keratinocytes. Virology 196{2):855-60, 
177 
1993. 
Perez GI, Knudson CM, Leykin L, Korsmeyer SJ, Tilly JL. Apoptosis-associated 
signaling pathways are required for chemotherapy-mediated female germ cell 
destruction. Nat Med 3(11):1228-32, 1997. 
Pfanner N, Craig EA, Meijer M. The protein import machinery of the mitochondrial inner 
membrane. Trends Biochem Sci 19(9):368-72, 1994. 
Phelps WC, Yee CL, Munger K, Howley PM. The human papillomavirus type 16 E7 
gene encodes transactivation and transformation functions similar to those of 
adenovirus EIA. Cell53(4):539-47, 1988. 
Phillips AN, Smith GD. Cigarette smoking as a potential cause of cervical cancer: has 
confounding been controlled? Int J Epidemiol23(1):42-9, 1994. 
Picard D, Khursheed B, Garabedian MJ, Fortin MG, Lindquist S, Yamamoto KR. 
Reduced levels of hsp90 compromise steroid receptor action in vivo. Nature 
348(6297): 166-8, 1990. 
Pillai MR, Halabi S, McKalip A, Jayaprakash PG, Rajalekshmi TN, Nair J\1K, Herman B. 
The presence of human papillomavirus-16/-18 E6, p53, and Bcl-2 protein in 
cervicovaginal smears from patients with invasive cervical cancer. Cancer 
Epidemiol Biomarkers Prev 5(5):329-35, 1996. 
Pirisi L, Yasumoto S, Feller M, Doniger J, DiPaolo JA. Transformation of human 
fibroblasts and keratinocytes with human papillomavirus type 16 DNA. J Virol 
61(4):1061-6, 1987. 
Polla BS, Kantengwa S, Francois D, Salvioli S, Franceschi C, Marsac C, Cossarizza A. 
178 
Mitochondria are selective targets for the protective effects of heat shock against 
oxidative injury. Proc Natl Acad Sci USA 93(13):6458-63~ 1996. 
Ponten J, Adami HO, Bergstrom R, Dillner J, Friberg LG, Gustafsson L, Miller AB, 
Parkin DM, Sparen P, Trichopoulos D. Strategies for global control of cervical 
cancer. Int J Cancer 60(1):1-26, 1995. 
Potmesil M, Hsiang YH, Liu LF, Wu HY, Traganos F, Bank B, Silber R. DNA 
topoisomerase II as a potential factor in drug resistance of human malignancies. 
NCI Monogr 4:105-9, 1987. 
Rabinovitz I, Mercurio AM. The integrin alpha 6 beta 4 and the biology of carcinoma. 
Biochem Cell Biol 74(6):811-21, 1996. 
Raff MC, Barres BA, Burne JF, Coles HS, Ishizaki Y, Jacobson MD. Programmed cell 
death and the control of cell survival: lessons from the nervous system. Science 
262(5134):695-700, 1993. 
Ralhan R, Kaur J. Differential Expression of Mr 70,000 Heat Shock Protein in Normal, 
Premalignant, and Malignant Human Uterine Cervix. Clin Cancer Res 1(10):1217-
1222, 1995. 
Rao L, Deb bas M, Sabbatini P, Hockenbery D, Korsmeyer S, White E. The adenovirus 
E1A proteins induce apoptosis, which is inhibited by the ElB 19-kDa and Bcl-2 
proteins. Proc Natl Acad Sci USA 89(16):7742-6, 1992. 
Reed JC, Meister L, Tanaka S, Cuddy M, Yum S, Geyer C, Pleasure D. Differential 
expression of bcl2 protooncogene in neuroblastoma and other human tumor cell 
lines of neural origin. Cancer Res 51(24):6529-38~ 1991. 
179 
Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Bioi 124(1-2):1-6, 
1994. 
Reed JC. Bcl-2 family proteins. Oncogene 17(25):3225-36, 1998a. 
Reed JC. Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol 
Oncol Clin North Am 9(2):451-73, 1995a. 
Reed JC. Double identity for proteins of the Bcl-2 family. Nature 387(6635):773-6, 1997. 
ReedJC. Dysregulationofapoptosis in cancer. Cancer J Sci Am 4 Suppll:S8-14, 1998b. 
Reed JC. Regulation of apoptosis by bcl-2 family proteins and its role in cancer and 
chemoresistance. Curr Opin Oncol7(6):541-6, 1995b. 
Reeve JG, Xiong J, Morgan J, Bleehen NM. Expression of apoptosis-regulatory genes in 
lung tumour cell lines: relationship to p53 expression and relevance to acquired 
drug resistance. Br J Cancer 73(10):1193-200, 1996. 
Roninson m. Multidrug resistance. Page 1095-1107, In : Encyclopedia of cancer. 
Editor-in-chief, Joseph R. Bertino. San Diego: Academic Press, 1996. 
Roy N, Deveraux QL, Takahashi R, Salvesen GS, Reed JC. The c-IAP-1 and c-IAP-2 
proteins are direct inhibitors of specific caspases. EiviBO J 16(23):6914-25, 1997. 
Rudiger S, Buchberger A, Buk:au B. Interaction ofHsp70 chaperones with substrates. Nat 
Struct Biol4(5):342-9, 1997. 
Ruley HE. p53 and response to chemotherapy and radiotherapy. In Important Advances 
in Oncology 1996. Edited by Devita VT Jr, Hellman S, Rosenberg SA. 
Philadelphia: Lippincott-Raven; 37-56, 1996. 
Sachs L, Lotem J. Control of programmed cell death in normal and leukemic cells: new 
180 
implications for therapy. Blood 82(1):15-21, 1993. 
Saeki T, Shimabuku AM, Ueda K, Komano T. Specific drug binding by purified lipid-
reconstituted P-glycoprotein: dependence on the lipid composition. Biochim 
Biophys Acta 1107(1):105-10, 1992. 
Sak:ahira H, Enari M, Nagata S. Cleavage of CAD inhibitor in CAD activation and DNA 
degradation during apoptosis. Nature 391(6662): 96-9, 1998. 
Samali A, Cotter TG. Heat shock proteins increase resistance to apoptosis. Exp Cell Res 
223(1):163-70, 1996. 
Sanchez-Prieta R, Vargas JA, Camero A, Marchetti E, Romero J, Durantez A, Lacal JC, 
Ramon y Cajal S. Modulation of cellular chemoresistance in keratinocytes by 
activation of different oncogenes. Int J Cancer 60(2):235-43, 1995. 
Scheffner M, Romanczuk H, Munger K, Huibregtse JM, Mietz JA, Howley PM. 
Functions of human papillomavirus proteins. Curr Top Microbiol Immunol 186:83-
99, 1994. 
Scheffner M, Wemess BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein 
encoded by human papillomavirus types 16 and 18 promotes the degradation of 
p53. Cell63(6):1129-36, 1990. 
Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, Dalton WS, van Heijningen TH, van 
Kalken CK, Slovak ML, de Vries EG, van der Valk P, et al. Overexpression of a 
M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug 
resistance. Cancer Res 53(7):1475-9, 1993. 
Schmid D, Baici A, Gehring H, Christen P. Kinetics of molecular chaperone action. 
181 
Science 263(5149):971-3, 1994. 
Schneider-Gadicke A, Schwarz E. Different human cervical carcinoma cell lines show 
similar transcription patterns of human papillomavirus type 18 early genes. EMBO 
J 5(9):2285-92, 1986. 
Schulz JB, Bremen D, Reed JC, Lom.matzsch J, Takayama S, Wullner U, Loscbmann P A, 
K.lockgether T, Weller M. Cooperative interception of neuronal apoptosis by BCL-2 
and BAG-I expression: prevention of caspase activation and reduced production of 
reactive oxygen species. JNeurochem 69(5):2075-86, 1997. 
Schulze-Osthoff K, Walczak H, Droge W, Krammer PH. Cell nucleus and DNA 
fragmentation are not required for apoptosis. J Cell Biol127(1): 15-20, 1994. 
Sellins KS, Cohen JJ. Hyperthermia induces apoptosis in thymocytes. Radiat Res 
126(1):88-95, 1991. 
Seo JS, Park YM, Kim ll, Shim EH, Kim CW, Jang JJ, Kim SH, Lee WH. T cell 
lymphoma in transgenic mice expressing the human Hsp70 gene. Biochem Biophys 
Res Commun 218(2):582-7, 1996. 
Shapiro AB, Ling V. Reconstitution of drug transport by purified P-glycoprotein. J Bioi 
Chern 270(27):16167-75, 1995. 
Sharom FJ, Yu X, Doige CA. Functional reconstitution of drug transport and ATPase 
activity in proteoliposomes containing partially purified P-glycoprotein. J Bioi 
Chern 268(32):24197-202, 1993. 
Shinomiya N, Shinomiya M, Wakiyama H, Katsura Y, Rokutanda M. Enhancement of 
CDDP cytotoxicity by caffeine is characterized by apoptotic cell death. Exp Cell 
182 
Res 210(2):236-42~ 1994. 
Shoji Y, Saegusa M, Takano Y, Ohbu M, Okayasu I. Correlation of apoptosis with 
tumour cell differentiation, progression, and HPV infection in cervical carcinoma. J 
Clin Pathol49(2):134-8, 1996. 
Simonian PL, Grillot DA, Nuii.ez G. Bak can accelerate chemotherapy-induced cell death 
independently of its heterodimerization with Bcl-XL and Bcl-2. Oncogene 
15(15):1871-5, 1997. 
Sirotnak FM, Moccio DM, Kelleher LE, Goutas LJ. Relative frequency and kinetic 
properties of transport-defective phenotypes among methotrexate-resistant L1210 
clonal cell lines derived in vivo. Cancer Res 41(11 Pt 1):4447-52, 1981. 
Sklar MD, Procho\vnik EV. Modulation of cis-platinum resistance in Friend 
erythroleukemia cells by c-myc. Cancer Res 51(8):2118-23, 1991. 
Slebos RJ, Lee MH, Plunkett BS, Kessis TD, Williams BO, Jacks T, Hedrick L, Kastan 
:MB, Cho KR. p53-dependent G 1 arrest involves pRB-related proteins and is 
disrupted by the human papillomavirus 16 E7 oncoprotein. Proc Natl Acad Sci USA 
91(12):5320-4, 1994. 
Srinivasula SM, Ahmad M, Ottilie S, Bullrich F, Banks S, Wang Y, Femandes-Alnemri 
T, Croce CM, Litwack G, Tomaselli KJ, Armstrong RC, Alnemri ES. FLAME-1, a 
novel F ADD-like anti -apoptotic molecule that regulates Fas!TNFR1-induced 
apoptosis. J Biol Chern 272(30):18542-5, 1997. 
Sriram M, Osipiuk J, Freeman B, Morimoto R, Joachimiak A. Human Hsp70 molecular 
chaperone binds two calcium ions within the ATPase domain. Structure 5(3):403-
183 
14, 1997. 
Stancato LF, Chow YH, Hutchison KA, Perdew GH, Jove R, Pratt WB. Raf exists in a 
native heterocomplex with hsp90 and p50 that can be reconstituted in a cell-free 
system. J Biol Chern 268(29):21711-6, 1993. 
Steuart CD, Burke PJ. Cytidine deaminase and the development of resistance to 
arabinosyl cytosine. Nat New Biol233(38):109-10, 1971. 
Storey A, Banks L. Human papillomavirus type 16 E6 gene cooperates with EJ-ras to 
immortalize primary mouse cells. Oncogene 8(4):919-24, 1993. 
Storey A, Pim D, Murray A, Osborn K, Banks L, Crawford L. Comparison of the in vitro 
transforming activities of human papillomavirus types. EMBO J 7(6):1815-20, 
1988. 
Strasser A, Harris AW, Jacks T, Cory S. DNA damage can induce apoptosis in 
proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. 
Cell 79(2):329-39, 1994. 
Su IJ, Cheng AL, Tsai TF, Lay JD. Retinoic acid-induced apoptosis and regression of a 
refractory Epstein-Barr virus-containing T cell lymphoma expressing multidrug-
resistance phenotypes. Br J Haematol85(4):826-8, 1993. 
Sun Q, Tang SC, Pater !.\1M, Pater A. Different HPV16 E6/E7 oncogene expression 
patterns in epithelia reconstructed from HPV16-immortalized human endocervical 
cells and genital keratinocytes. Oncogene 15(20):2399-408, 1997. 
Sun Q, Tsutsumi K, Kelleher MB, Pater A, Pater MM. Squamous metaplasia of normal 
and carcinoma in situ of HPV 16-immortalized human endocervical cells. Cancer 
184 
Res 52(15):4254-60, 1992. 
Symonds H, Krall L, Remington L, Saenz RM, Lowe S, Jacks T, Van Dyke T. p53-
dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78: 703-
711, 1994. 
Takano YS, Harmon BV, Kerr JF. Apoptosis induced by mild hyperthermia in human 
and murine tumour cell lines: a study using electron microscopy and DNA gel 
electrophoresis. J Pathol163(4):329-36, 1991. 
Tak:aoka A, Adachi M, Okuda H, Sato S, Yawata A, Hinoda Y, Takayama S, Reed JC, 
Imai K. Anti-cell death activity promotes pulmonary metastasis of melanoma cells. 
Oncogene 14(24):2971-7, 1997. 
Takayama S, Bimston DN, Matsuzawa S, Freeman BC, Aime-Sempe C, Xie Z, 
Morimoto RI, Reed JC. BAG-1 modulates the chaperone activity ofHsp70/Hsc70. 
EMBO J 16(16):4887-96, 1997. 
Takayama S, Krajewski S, Krajewska M, Kitada S, Zapata JM, Kochel K, Knee D, 
Scudiero D, Tudor G, Miller GJ, Miyashita T, Yamada M, Reed JC. Expression and 
location of Hsp70/Hsc-binding anti-apoptotic protein BAG-1 and its variants in 
normal tissues and tumor cell lines. Cancer Res 58(14):3116-31, 1998. 
Takayama S, Sato T, Krajewski S, Kochel K, Irie S, Millan JA, Reed JC. Cloning and 
functional analysis of BAG-1: a novel Bcl-2-binding protein with anti-cell death 
activity. Cell 80(2):279-84, 1995. 
Takayama S, Xie Z, Reed JC. An evolutionarily conserved family of Hsp70/Hsc70 
molecular chaperone regulators. J Bioi Chern 274(2):781-6, 1999. 
185 
Taylor .TK, Zhang QQ, Monia BP, Marcusson EG, Dean NM. Inhibition of Bcl-xL 
expression sensitizes normal human keratinocytes and epithelial cells to apoptotic 
stimuli. Oncogene 18(31):4495-504, 1999. 
Thierry AR., Dritschilo A, Rahman A. Effect of liposomes on P-glycoprotein function in 
multidrug resistant cells. Biochem Biophys Res Commun 187(2):1098-105, 1992. 
Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 
267(5203):1456-62, 1995. 
Tsai CM, Chang KT, Pemg RP, Mitsudomi T, Chen MH, Kadoyama C, Gazdar AF. 
Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines 
with HER-2/neu gene expression but not with ras gene mutations. J Natl Cancer 
Inst 85(11):897-901, 1993. 
Tsai CM, Levitzki A, Wu LH, Chang KT, Cheng CC, Gazit A, Pemg RP. Enhancement 
of chemosensitivity by tyrphostin AG825 in high-p185(neu) expressing non-small 
cell lung cancer cells. Cancer Res 56(5): 1068-74, 1996. 
Tsai CM, Yu D, Chang KT, Wu LH, Pemg RP, Ibrahim NK, Hung MC. Enhanced 
chemoresistance by elevation of p185neu levels in HER-2/neu-transfected human 
lung cancer cells. J Natl Cancer Inst. 87(9): 682-4, 1995. 
Tsai MJ, O'Malley BW. Molecular mechanisms of action of steroid/thyroid receptor 
superfamily members. Annu Rev Biochem 63:451-86, 1994. 
Tsutsumi K, Belaguli N, Qi S, Michalak TI, Gulliver WP, Pater A, Pater MM. Human 
papillomavirus 16 DNA immortalizes two types of normal human epithelial cells of 
the uterine cervix. Am J Pathol140(2):255-61, 1992. 
186 
Turyk ME, Golub TR, Wood NB, Hawkins JL, Wilbanks GD. Growth and 
characterization of epithelial cells from normal human uterine ectocervix and 
endocervix. In vitro Cell Dev Biol25(6):544-56, 1989. 
Ucker DS, Obermiller PS, Eckhart W, Apgar JR., Berger NA, Meyers J. Genome 
digestion is a dispensable consequence of physiological cell death mediated by 
cytotoxic T lymphocytes. Mol Cell Biol12(7): 3060-9, 1992. 
Ucker DS. Death and dying in the immune system. Adv Pharmacal 41:179-218, 1997. 
KT21 
Ungermann C, Neupert W, Cyr DM. The role ofHsp70 in conferring unidirectionality on 
protein translocation into mitochondria. Sci~nce 266(5188):1250-3, 1994. 
van den Brule AJ, Cromme FV, Snijders PJ, Smit L, Oudejans CB, Baak JP, Meijer CJ, 
Walboomers JM. Nonradioactive RNA in situ hybridization detection of human 
papillomavirus 16-E7 transcripts in squamous cell carcinomas of the uterine cervix 
using confocal laser scan microscopy. Am J Pathol139(5):1037-45, 1991. 
Vargas-Roig LM, Gago FE, Tello 0, Aznar JC, Ciocca DR. Heat shock protein 
expression and drug resistance in breast cancer patients treated with induction 
chemotherapy. Int J Cancer 79(5):468-75, 1998. 
Vasey PA, Jones NA, Jenkins S, Dive C, Brown R. Cisplatin, camptothecin, and taxol 
sensitivities of cells with p53-associated multidrug resistance. Mol Pharmacal 
50(6):1536-40, 1996. 
Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and 
cooperates with c-myc to immortalize pre-B cells. Nature 335(6189):440-2, 1988. 
187 
Velculescu VE, El-Deiry WS. Biological and clinical importance of the p53 tumor 
suppressor gene. Clin Chern. 42(6 Pt 1):858-68, 1996. 
Vogt, C. Untersuchungen iiber die Entwicldungsgeschichte der Geburtshelferkroete 
(Alytes obstetricans), 1842. 
Vooijs GP. Benign proliferative reactions, intraepithelial neoplasia and invasive cancer 
of the uterine cervix. In: M. Bibbo (ed.), Comprehensive cytopathology, pp.153-
230, W.B. Saunders, Philadelphia, 1991. 
Vousden KH. Human papillomaviruses and cervical carcinoma Cancer Cells 1(2):43-50, 
1989. 
Wagner AJ, Kokontis JM, Hay N. Myc-mediated apoptosis requires wild-type p53 in a 
manner independent of cell cycle arrest and the ability of p53 to induce 
p21wafl/cipl. Genes Dev 8, 2817-2830. 1994. 
Waldman T, Lengauer C, Kinzler KW, Vogelstein B. Uncoupling ofS phase and mitosis 
induced by anticancer agents in cells lacking p2L Nature 381(6584):713-6, 1996. 
Walker PR, Smith C, Youdale T, Leblanc J, Whitfield JF, Sikorska M. Topoisomerase IT-
reactive chemotherapeutic drugs induce apoptosis in thymocytes. Cancer Res 
51(4):1078-85, 1991. 
Walker TL, White JD, Esdale WJ, Burton MA, DeCruz EE. Tumour cells surviving in 
vivo cisplatin chemotherapy display elevated c-myc expression. Br J Cancer. 73(5): 
610-4, 1996. 
Walton MI, Whysong D, O'Connor PM, Hockenbery D, Korsmeyer SJ, Kohn KW. 
Constitutive expression of human Bcl-2 modulates nitrogen mustard and 
188 
camptothecin induced apoptosis. Cancer Res 53(8):1853-61, 1993. 
Wang HG, Takayama S, Rapp UR, Reed JC. Bcl-2 interacting protein, BAG-1, binds to 
and activates the kinase Raf-1. Proc Natl Acad Sci USA 93(14):7063-8, 1996. 
Wang K, Gross A, Waksman G, Korsmeyer SJ. Mutagenesis of the BID domain ofBAX 
identifies residues critical for dimerization and killing. Mol Cell Biol 18(10):6083-
9, 1998. 
Wang QM, Luo X, Kheir A, Coffinan FD, Studzinski GP. Retinoblastoma protein-
overexpressing HL60 cells resistant to 1,25-dihydroxyvitamin D3 display increased 
CDK2 and CDK6 activity and shortened Gl phase. Oncogene 16(21):2729-37, 
1998. 
Webb A, Cunningham D, Cotter F, Clarke PA, di Stefano F, Ross P, Corbo M, 
Dziewanowska Z. BCL-2 antisense therapy in patients with non-Hodgkin 
lymphoma. Lancet 349(9059):1137-41, 1997. 
Welch WJ. Heat shock proteins functioning as molecular chaperones: their roles m 
normal and stressed cells. Philos Trans R Soc Lond B Bioi Sci 339(1289):327-33, 
1993. 
Wemess BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 
18 E6 proteins withp53. Science 248(4951):76-9, 1990. 
White AE, Livanos EM, Tlsty TD. Differential disruption of genomic integrity and cell 
cycle regulation of normal fibroblasts by the HPV oncoproteins. Genes Dev 8, 666-
677, 1994. 
White E. Life, death, and the pursuit ofapoptosis. Genes Dev 10(1):1-15, 1996. 
189 
Williams GT, Smith CA, Spooncer E, Dexter TM, Taylor DR. Haemopoietic colony 
stimulating factors promote cell survival by suppressing apoptosis. Nature 
343(6253):76-9, 1990. 
Woodworth CD, Bowden PE, Doniger J, Pirisi L, Barnes W, Lancaster WD, DiPaolo JA. 
Characterization of normal human exocervical epithelial cells immortalized in vitro 
by papillomavirus types 16 and 18 DNA. Cancer Res 48(16):4620-8, 1988. 
Woodworth CD, Doniger J, DiPaolo JA. Immortalization of human foreskin 
keratinocytes by various human papillomavirus DNAs corresponds to their 
association with cervical carcinoma J Virol63(1):159-64, 1989. 
Wyllie AH. Apoptosis: cell death in tissue regulation. J Pathol153(4):313-6. 1987. 
Xerri L, Pare P, Brousset P, Schlaifer D, Hassoun J, Reed JC, Krajewski S, Birnbaum D. 
Predominant expression of the long isoform of Bcl-x (Bcl-XL) in human 
lymphomas. Br JHaematol92(4):900-6, 1996. 
Yamamoto Y, Shimizu E, Masuda N, Takada M, Sone S. RB protein status and 
chemosensitivity in non-small cell lung cancers. Oneal Rep 5(2):447-51, 1998. 
Yamazaki H, Schneider E, Myers CE, Sinha BK. Oncogene overexpression and de novo 
drug-resistance in human prostate cancer cells. Biochim Biophys Acta 1226(1):89-
96, 1994. 
Yang X, Jin G, Nakao Y, Rahimtula M, Pater MM, Pater A. Malignant transformation of 
HPV 16-immortalized human endocervical cells by cigarette smoke condensate and 
characterization of multistage carcinogenesis. Int J Cancer 65(3):338-44, 1996a. 
Yang ~ Nakao Y, Pater lV!M:, Pater A. Identification of two novel cellular genes 
190 
associated with multistage carcinogenesis of human endocervical cells by mRNA 
differential display. Carcinogenesis 17(3):563-7, 1996b. 
Yang X, Chemenko G, Hao Y, Ding Z, Pater 1\.fM:, Pater A, Tang SC. Human BAG-
1/RAP46 protein is generated as four isoforms by alternative translation initiation 
and overexpressed in cancer cells. Oncogene 17(8):981-9, 1998a. 
Yang X, Hao Y, Pater MM, Tang SC, Pater A. Enhanced expression of anti-apoptotic 
proteins in human papillomavirus-immortalized and cigarette smoke condensate-
transformed human endocervical cells: correlation with resistance to apoptosis 
induced by DNA damage. Mol Carcinog 22(2):95-101, 1998b. 
Yang X, Hao Y, Ding Z, Pater A, Tang SC. Differential expression of anti-apoptotic 
gene BAG-1 in human breast normal and cancer cell lines and tissues. Clin. Cancer 
Res. 1999a(in press). 
Yang X, Hao Y, Ferenczy A, Tang SC, Pater A. Overexpression of anti-apoptotic gene 
BAG-1 in human cervical cancer. Exp Cell Res 247(1):200-7, 1999b. 
Yin C, Knudson CM, Korsmeyer SJ, Van Dyke T. Bax suppresses tumorigenesis and 
stimulates apoptosis in vivo. Nature 385(6617):637-40, 1997. 
Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM. Wild-type p53 restores cell 
cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 
70(6):937-48, 1992. 
Yonish-Rouach E, Deguin V, Zaitchouk T, Breugnot C, Mishal Z, Jenkins JR, May E. 
Transcriptional activation plays a role in the induction of apoptosis by transiently 
transfected wild-type p53. Oncogene 11(11):2197-205, 1995. 
191 
Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 
induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. 
Nature 352(6333):345-7, 1991. 
Yoo YD, Kang S, Kang YK. Cellular resistance to ad.riamycin conferred by enhanced Rb 
expression is associated with increased MDR1 expression. Biochem Biophys Res 
Commun 249(1):6-10, 1998. 
Zaman GJ, Flens MJ, van Leusden lVIR, de Haas M, Mulder HS, Lank:elma J, Pinedo 
Hlvf, Scheper RJ, Baas F, Broxterman HJ, et al. The human multidrug resistance-
associated protein :rv1RP is a plasma membrane drug-efflux pump. Proc Natl Acad 
Sci USA 91(19):8822-6, 1994. 
Zamzami N, Brenner C, Marzo I, Susin SA, Kraemer G. Subcellular and 
submitochondrial mode of action of Bcl-2-like oncoproteins. Oncogene 
16(17):2265-82, 1998. 
Zapata JM, Krajewska M, Krajewski S, Huang RP, Takayama S, Wang HG, Adamson E, 
Reed JC. Expression of multiple apoptosis-regulatory genes in human breast cancer 
cell lines and primary tumors. Breast Cancer Res Treat 47(2):129-40, 1998. 
Zeiner M, Gebauer M, Gehring U. Mammalian protein RAP46: an interaction partner and 
modulator of70 kDa heat shock proteins. El'ABO J 16(18):5483-90, 1997. 
Zeiner M, Gehring U. A protein that interacts with members of the nuclear hormone 
receptor family: identification and eDNA cloning. Proc Natl Acad Sci USA 
92(25):11465-9, 1995. 
Zha H, Reed JC. Heterodimerization-independent functions of cell death regulatory 
192 
proteins Bax and Bcl-2 in yeast and mammalian cells. J Biol Chern 272(50):31482-
8~ 1997. 
Zha J, Harada H, Yang E, Jockel J~ Korsmeyer SJ. Serine phosphorylation of death 
agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X. 
Cell 87(4):619-28, 1996. 
Zhan Q, Fan S, Bae I, Guillouf C, Liebermann DA, O'Connor PM, Fomace AI Jr. 
Induction of bax by genotoxic stress in human cells correlates with normal p53 
status and apoptosis. Oncogene 9(12):3743-51, 1994. 
Zhang L, Hung MC. Sensitization of HER-2/neu-overexpressing non-small cell lung 
cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin. 
Oncogene 12(3):571-6, 1996. 
Ziegler A, Luedke GH, Fabbro D, Altmann KH, Stahel RA, Zangemeister-Wittke U. 
Induction of apoptosis in small-cell lung cancer cells by an antisense 
oligodeoxynucleotide targeting the Bcl-2 coding sequence. J Natl Cancer Inst 
89(14):1027-36, 1997. 
Zou H, Henzel WJ, Liu X, Lutschg A, Wang X. Apaf-1, a human protein homologous to 
C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. 
Cell90(3):405-13, 1997. 
zur Hausen H, de Villers EM. Human papillomaviruses. Annu Rev Microbiol48:427-47, 
1994. 
zur Hausen H. Human papillomaviruses in the pathogenesis of anogenital cancer. 
Virology 184(1):9-13, 199la. 
193 
zur Hausen H. Viruses in human cancers. Science 254(5035):1167-73, 1991b. 
194 




